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ABSTRACT
To control outbreaks of norovirus infection and to understand better the importance of
norovirus in the developing world, appropriate diagnostic tests must be used. In an attempt to
improve norovirus diagnostics, two separate investigations were undertaken. Thefirst
investigated the use oforal samples for the diagnosis of norovirus infection in adult
hospitalised patients. The second investigated two recently developed immunologicaltests,
the RIDASCREEN ELISA and RIDAQUICK immunochromatographic (ICG)test, for their
detection of norovirus.
The first study was conductedat five hospitals in Merseyside, UK, in the winter of 2008/9. In
total, 66 paired oral and faecal samples werecollected from patients with symptoms
consistent with norovirus infection. Oral samples were mouthwashesofsterile water. Of the
66 mouthwashes, 59 (89%) had norovirus confirmed with the reference standard, RT-PCR of
faeces. Ofthese, 14 (24%: 95% C.I. 14-37%) had norovirus detected in mouthwashes by one
step real time RT-PCR.Thedetection of norovirus in mouthwashes wasassociated with the
presence of vomiting (p = 0.1). This study has demonstrated for thefirst time the detection of
norovirus in mouthwash samples. Thistest is not currently sensitive enough for routine
application in clinical diagnostics.
The second study was undertaken on faecal samples from children with diarrhoea in Brazil.
The study compared new immunological norovirustests, the RIDASCREEN ELISA and
RIDAQUICKICGtest, against an established norovirus ELISA (IDEIA ELISA). The
evaluation wascarried out on 96 positive and 116 negative samples for norovirus by PCR.
This showed the RIDASCREEN ELISA (R-Biopharm, Darmstadt, Germany) was more
sensitive (64%) than the IDEIA ELISA (Oxoid, Ely, UK), (49%), with RT-PCR as the
reference standard (p = <0.01). The sensitivity of the RIDASCREEN ELISAcould be
increased to 90% in hospitalised children by reducing the specificity of the test to 80%. The
RIDASCREENELISAis therefore a reasonable meansof testing samples for norovirus, prior
to molecular analysis, in molecular epidemiological surveys of children hospitalised with
gastroenteritis. The RIDASCREEN ELISA and RIDAQUICK ICG were 78% and 88%
sensitive respectively in detecting the GII.4 strain of norovirus. The GII.4 strain is
responsible for most outbreaks of infection in hospitals. Both the RISASCREENand
RIDAQUICKtests were 100% specific; therefore, multiple samples can be tested in an
outbreak to identify the presence of norovirus, leading to an increasein thetests sensitivity
without compromising test specificity. The RIDASCREEN and RIDAQUICKtests are
therefore likely to be useful in diagnosing nosocomial outbreaks of norovirus infection.
In addition to the diagnostic evaluations, the molecular epidemiology of noroviruses
collected in both studies (Liverpool, UK and Aracaju, Brazil) was investigated. In the
Merseyside hospitals, individual hospital trusts had distinct strains of GII.4 norovirus, despite
all 8 distinct strains detected being very similar. The Brazilian analysis demonstrated a
genetically stable GII.4 strain predominated. This strain was detected across a wide
geographic area throughoutthe study period (over 1 year). This requires further investigation
to define if this represents person to person transmission or semi-permanent environmental
sources of infection.
Continued improvementsin the diagnosis of noroviruswill allow an improved understanding
of the global burden and epidemiology of norovirus gastroenteritis. This may leadto
improved control strategies being developed for norovirus infection reducing the costs and
morbidity associated with norovirusinfection.
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CHAPTER1
Introduction and objectives
1.1 Viral gastroenteritis
Gastroenteritis is a ubiquitous clinical condition associated with substantial morbidity and
mortality, particularly in children living in developing countries. An estimation of paediatric
mortality concludedthat of ten million deaths in children underfive years of age globally
between 2000 and 2003, 18 % wererelated to gastrointestinal infection (Bryceet al. 2005).
While bacteria and parasites are significant causes of gastroenteritis, viruses are the major
cause (Kapikian 1993). Manyviruses are foundin the gastrointestinal tract, some are
confirmed agents of gastroenteritis, whereas the role of other virusesis less clear. In addition
to norovirus; rotavirus, astrovirus, adenovirus and sapovirusare the principal knownviral
aetiological agents of gastroenteritis. These are presented belowin brief, having been
presented in detailed reviews elsewhere (Matson and Szucs 2003; Wilhelmiet al. 2003; Clark
and McKendrick 2004).
Rotavirus has a genomeconsisting of segmental double stranded (ds) RNA. The virionis
70nm in diameter and nonenveloped with transmission via the faecal-oral route. Rotavirusis
the principal viral cause of paediatric diarrhoea and mainly causesillness in children aged six
months to two years. The incubation period is 1-2 days with fever and vomiting preceding the
onset of diarrhoea. Diarrhoealasts for 1-4 days and significant volume depletion can occur.
Diagnosis can be madebyelectron microscopy (EM),latex agglutination tests, enzyme
linked immunosorbant assay (ELISA) and polymerase chain reaction (PCR)testing.
Treatment is symptomatic including fluid replacement.
Astrovirus has a genomeconsisting of a single stranded RNA. Thevirion is 28-35nm in
diameter and nonenveloped with transmission by the faecal oral route. Astrovirus causes
infection mainly in children with an incubation period of 2-4 days. The infection results in an
illness whichis a mild version of rotavirus. Diagnosis can be made by EM, ELISA and PCR.
Treatment is symptomatic including fluid replacement.
Enteric adenovirus has a genomeconsisting of a dsDNA.Thevirion is 90—100nm in
diameter and nonenveloped. Enteric adenoviruses mainly affect children and the incubation
period is 8-10 days. Fever and vomiting occurin addition to diarrhoea whichlasts 3-11 days.
Diagnosis is by EM, ELISA and PCR.Treatment is symptomatic including fluid replacement.
Sapovirushasa single stranded RNA virus genome. Thevirion is 41-46nm in diameter and
is nonenveloped. Sapovirusis a cause ofacute gastroenteritis which is self limiting. Infection
with sapovirus is most commonlyreportedin institutional outbreaks affecting children.
Diagnosis is by EM, ELISA and PCR. Treatment is symptomatic including fluid replacement.
Viral gastroenteritis causes most morbidity and mortality in paediatric populations. Rotavirus
is the principal agent of paediatric gastroenteritis in developed and developing countries with
an estimated 444000 deaths per year (Parashar et al. 2006). Norovirus is the second most
commoncauseofpaediatric gastroenteritis and is also an important cause of outbreaks of
gastroenteritis in all ages.
1.1.1 Norovirus introduction
Norovirusis a cause ofgastroenteritis. It commonly causes outbreaks of infection becauseit
has a high secondaryattack rate (Lopmanet al. 2004). Norovirus gastroenteritis is normally
ofshort duration, approximately 48 hours, and has limited morbidity or mortality in healthy
adults. Its discovery in 1972 required the use of immuneelectron microscopy (Kapikian
2000) as it cannotbe grownin cell culture (Duizeret al. 2004). Since then it has been shown
to be oneofthe principal agents of infectious gastroenteritis worldwide (de Witet al. 2001;
Koopmans 2008). Today the medical implications of noroviruslie in two main areas. Firstly,
in the developed world it causes large institutional outbreaks with significant morbidity and
cost implications (Lopmanet al. 2004). Secondly,it is a cause of gastroenteritis in the
developing world whereit contributes to the burdenofintestinal disease in children.
1.1.2 Norovirus genome
Norovirusesconsist of small round virions of 27 to 35nm in diameter and possessa single-
stranded,positive sense, polyadenylated RNA genomeof7,400 to 7,700 nucleotides. The
genomeis divided into three open reading frames (ORFs) (Figure 1.1).
ORF1 ORF2 ORF3
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Figure 1.1: Division of the norovirus genomeinto three open reading frames (ORFs).
ORFI encodes a large polyprotein which undergoes proteolytic cleavage to produce viral
proteins that are homologous to proteins from other single-stranded RNA viruses. These
include a nucleosidetriphosphatase, a helicase enzyme which ensures uncoiling of dsRNA, a
3C-like protease and an RNA-dependent RNA polymerase (RdRp). ORF2 encodes the capsid
protein with an apparent molecular mass of 58kDa. The capsid protein has several domains,
including the N domain facing the interior of the capsid, the S domain involving the
formation of the icosahedral shell and the P domain forming the prominent protrusion
emanating from the shell. A component of the P domain, the P2 domain, formsthe antigenic
part of the virion. ORF3 encodes a small protein abundantin basic amino acids. Although the
precise role of the ORF3 protein is unknown,it is likely that it is a minor structural protein
that interacts with the genome RNA whenvirion formation occurs (Greenetal. 2001)
The norovirus genome, as an RNA genome, undergoes frequent genetic changes when
replication occurs. This allows rapid viral evolution which has been reported at rates of
4.3x10° nucleotide substitutions/site/year, similar to other RNA viruses (Bok et al. 2009).
This rapid rate of evolution allows antigenic change which has been suggested as a
mechanism ofescaping from population immunity. This antigenic change has been compared
to antigenic drift seen in influenza virus. A componentofinfluenzaviruses’ antigenic drift is
positive selection. Positively selected sites are those that have higher rates of
nonsynonymous than synonymous changes in protein coding sequences relative to other
regions of the genome. Positive selection indicates immune driven mechanisms of genetic
evolution are present. (Shih et al. 2007). Work by Bok e¢ a/ has investigated norovirus
genomesfor the presence of positive selection. This has been found in the capsid protein
(ORF2), mainly in the shell domain but at one site within the protruding P2 domain (Boket
al. 2009). Further study of ongoing norovirus genetic changes are needed to better understand
the process of norovirus evolution.
Investigation ofthe variation between norovirus genomeshasalso taken place. This has been
with the aim of determining where norovirus RNAis similar and divergent betweenstrains.
This has shown that norovirus isolates are most similar at the junction of ORF1/2 and most
dissimilar at the P2 region. This had led to the ORF1/2 junction being targeted for the
production ofbroadly reactive norovirus PCR primers (Katayamaetal. 2002).
1.1.3 Classification
The family Caliciviridae is composed of four genera of virus, Norovirus, Sapovirus,
Vesivirus, and Lagovirus. The Norovirus genusis split into genogroups based on
characterization of the capsid gene. Five genogroups have been described with genogroups|
and II, and rarely IV, being associated with humaninfection. These genogroups have been
classified into over 30 genotypes by RNA sequenceanalysis of the capsid sequence (Figure
1.2). Genogroup and genotypeclassifications have more recently been madeby structural
alignmentsof the capsid amino acid sequences (Table 1.1) (Zheng et al. 2006; Koopmans
2008). This alignment method demonstrated that genogroups havepairwise difference ranges
from 40-62%.
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Figure 1.2: Norovirus genogroup and genotypeclassification produced by genomic sequence
analysis of the capsid region. Figure reproduced from Zheng ef al. (Zheng etal. 2006).
Measurementbar represents nucleotide substitutions per base.
Table 1.1: Pairwise difference ranges between Norovirus genogroups(“%).
 
G1 G2 G3 G4 G5
G1 48.54-55.21 45.62-52.29 48.75-53.75 55.62-58.33
G2 50.20-57.06 50.21-54.79 41.88—48.33 55.21-58.54
G3 47.57-53.94 52.07-56.89 52.50-54.38 56.25-58.12
G4 52.11-56.11 44.91-51.61 54.88-56.58 56.04
G5 58.14-60.74 58.17-61.41 57.74-59.68 58.56-58.75      
Differences were calculated by using an uncorrected distance method with a 141 capsid
amino acid sequence alignment(top right portion) and with a 164 capsid aminoacid
sequencealignment(bottom left portion). Table reproduced from Zhengef al (Zhengetal.
2006).
1.1.4 Clinical and molecular epidemiology
Clinical epidemiology: Norovirusis global in its distribution, infecting people ofall ages.It
predominantly causes infection in the community: In a UK based prospective study 1562
community cases were predicted to occur for every one reportedto the national surveillance
scheme.It was also found that 6.3 cases of norovirus attended a general practitioner with
acute gastroenteritis for every person reported to the national surveillance scheme.A rate of
12.5 community cases per 1000 person years was demonstratedin this study, making
norovirus the most commoncauseof gastroenteritis identified (Wheeler et al. 1999). These
may have been underestimatesas electron microscopy wasused to detect norovirus whichis
recognised as aninsensitive test for the detection of norovirus. A Dutch study prospectively
investigated community gastroenteritis, also finding norovirus to be the most common cause
 
of gastroenteritis. It identified that in patients with gastroenteritis in the community, 16.1%
(10.9% adjusted for control group) of cases were infected with norovirus. This study analysed
norovirus infection in different age groups and showed norovirus wasdetected in patients
with gastroenteritis at prevalence’s of 14-18% in <18 year olds and =65 yearolds, but 7% in
18-64 year olds (de Witet al. 2001).
Norovirus, given its mild morbidity, commonly presents to the medical profession when an
outbreak occurs and large numbersofpeople are affected. A review ofthe location of these
outbreaks reported to the Center for Disease Control (CDC) in the USA showed 39% in
restaurants; 29% in nursing home/hospitals; 12% schools/day care centres; 10% in holiday
settings, including cruise ships; and 9% in othersettings (Parasharet al. 2001). In the UK
infection is mainly seen (80%) in health care institutions (Lopmanet al. 2003). These
numbersarelikely to differ due characteristics of a countries health care facilities e.g.
hospital isolation facilities. The impact of outbreaks in the developed world is greatest when
medicalinstitutions are affected as patients are already unwell and there are significant
associated cost implications (Lopmanet al. 2004).
Clinical studies have shownthat norovirus infection is most commonin the first two years
of life, and principally in the first year of life (de Wit et al. 2001). Seroepidemiological
studies have shownthat infection occurs worldwide, from a young age, and is more prevalent
in developing vs. developed countries with antibodies lowest in the first two yearsoflife
rising thereafter (Cubitt et al. 1987; Cubitt et al. 1998; Nakata et al. 1998; O'Ryan et al. 1998;
Peasey et al. 2004). The low seroprevalence in the first two yearsoflife may reflect that this
age group lack immunity to norovirus which may explain why they havea higherrate of
infection comparedto other age groups.It is also possible that serological assays are more
able to detect norovirus antibodies which developed in response to olderstrains of norovirus.
Older children may have antibodiesto older strains and younger children may have
9
antibodies to morerecent strains of norovirus which immunological assaysare less able to
detect.
In the developed world a numberof reports have investigated the rates of detection of
norovirus in the faeces. A wide range ofinfection rates are detected, as would be expected
with a virus with a high secondary attack rate leading to outbreaks of infection. Reported
rates range from 6-40% in children attending hospital with gastroenteritis with a mean rate of
15% (Koopmans2008). It is difficult to differentiate asymptomatic shedding from infection
in these studies as asymptomatic sheddingrates can be significant. Shedding rates have
varied from 1% to 30% (O'Ryanet al. 2000; Castilho et al. 2006) but are more commonly
seen at around 8-10% (Farkaset al. 2000; Monicaet al. 2007; Reither et al. 2007).
A seasonalpattern is often detected in norovirus epidemiological studies with norovirus
infection most commonly detected in winter. This is reported in studies from the USA,
Europe, Asia and Australasia (Mountset al. 2000; Iritani et al. 2003; Dey et al. 2007;
Siebengaet al. 2009). This winter pattern is not exclusive, summertime peaksof infection
have also been detected (Lopmanetal. 2003; Chhabraet al. 2009). In somestudies no
seasonal peak of norovirus infection is detected (O'Ryanet al. 2000; Kirkwoodet al. 2005).
Further work is needed to understand what drives the observed seasonality of norovirus
infections.
Molecular epidemiology: Currently there are global epidemics of norovirus GII.4 strains
which show genetic drift analogousto that seen in influenza A viruses,first reported by
Siebenga etal (Siebengaet al. 2007) (Figure 1.3). At any one time highly homogeneousvirus
is detected globally suggesting global spread. This wasfirst noted in 1999 (Noeletal. 1999).
Sincethat time a definitive answer has not emerged to explain the possible mechanism ofthis
global spread. Speculated mechanisms, in addition to person to person spread, include food
10
(Widdowsonet al. 2005) and water contamination (Lodder and de Roda Husman2005;
Maunulaet al. 2005).
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Figure 1.3: Neighbour-joining tree for capsid amino acid sequences of norovirus identified
from 1996-2006 (Netherlands). Figure reproduced from Siebengaet al (Siebengaet al. 2007).
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1.1.5 Clinical features
Theclinical features associated with norovirus infection can differ in specific cohorts,
principally: children, adults in the community, elderly adults in institutions and
immunosuppressedpatients.
Paediatric norovirus infection: An acute onset of vomiting is followed by diarrhoeaof short
duration (up to 48 hours). In children the illness is essentially not different from healthy
adults and consists of diarrhoea, vomiting, nausea, abdominal cramps, fever, and malaise.
Vomiting is though more commonin children/young adults comparedto elderly adults.
Infection with norovirus can be asymptomatic. One small study showed 11/14 children
infected with norovirus during a norovirus outbreak were asymptomatic (Matsonetal. 1990).
Asymptomatic shedding of norovirusin children has also been reported with rates of 6-30%
(Farkas et al. 2000; Akihara et al. 2005; Garcia et al. 2006; Amaret al. 2007). These studies
all used PCR to detect norovirus whichis a highly sensitive method of detecting norovirus.
Studies which used electron microscopyto detect norovirus had previously underestimated
the amount of asymptomatic norovirus shedding that occurs (Amaret al. 2007). Community
outbreaks have been reported where a point source has acted as an uncontrolled challenge to
allow documentation ofthe effect of norovirus infection. Symptoms in a community outbreak
associated with a water fountain in Holland were: abdominal pain 89%, vomiting 70%,
nausea 65%, headache 70% and diarrhoea 60%. A mean duration of illness of 2 days was
reported (Hoebeetal. 2004). The clinical features of children attending hospital with
norovirus detectable in faeces have been well reported. In a study of paediatric diarrhoea in
Vietnam symptoms/signs were: diarrhoea 100%, vomiting 66% and fever of >38.5°C in 33%
with a mean duration of diarrhoea and vomiting: 4.4 and 1.5 days respectively (Nguyenetal.
12
2008). In a study ofpaediatric gastroenteritis in Nicaragua symptoms/signswere: diarrhoea
46%, vomiting 54%, dehydration 43% and fever of >38°C in 29% (Bucardo et al. 2008)
(Bucardoet al. 2008; Nguyen et al. 2008). Therates of diarrhoea reported in these studies
vary because inclusioncriteria varied. Mortality from norovirus, excluding occasional case
reports (Thiele et al. 2005), is likely to be dueto its contribution to disease burdenin children
with malnutrition or other illness. Attributable mortality rates are unknownbut have the
potential to be significant in the developing world.
Adult norovirus infection in the community: An acute onset of vomiting and diarrhoea of up
to 48 hours duration, but not requiring medicalintervention,is typical. In a study of
community based norovirus infection in Spain symptoms/signs were: vomiting 64%,
diarrhoea 85% and fever 40% (Arias et al.). Community outbreaks of norovirus are
commonly caused by foodborne transmission of norovirus. Symptoms in foodborne
outbreaks havebeenreported in a Swedish study where symptoms/signswere: vomiting 64%,
diarrhoea 71% and fever in 44% (Gotz et al. 2001). Foodborne outbreaks have also been
reported in India where symptoms/signs were: vomiting 64%, diarrhoea 92% and feverin
43% andin Italy where symptoms/signs were: vomiting 85%, diarrhoea 58% and fever in
16%(Girish et al. 2002; Pratoet al. 2004).
Adult norovirus infection in institutions: Symptomologyis publishedfor elderly nursing
homeresidents, an example of symptomsare diarrhoea (73%), vomiting (40%), abdominal
pain (33%), malaise (30%) and fever (10%) (Grmek Kosniket al. 2007). Lopmanetal
comparedelderly (75-84 years old) nursing homeresidents with elderly hospital residents.It
was found hospitalised residents had a longer duration of diarrhoea, median duration 3 days
in hospitalised patients comparedto 2 days in nursing home residents (Figure 1.4) (Lopman
et al. 2004).
13
Comparingthe clinical features between infection in institutions and in the community by
foodborne outbreaks suggest vomiting is more common.It is difficult though to compare
these figures as the age of those affected differs and case detection will vary in the two
different settings.
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Figure 1.4: Duration of symptomsafter norovirus infection. A, all cases associated with
outbreaks of norovirus infection; B, microbiologically confirmed. Figure reproduced from
Lopmanet a/ (Lopmanetal. 2004).
The mortality from norovirus infection has been estimated to be approximately 70 deaths per
year in the UK in those 65 years old (Harriset al. 2008).
The complications of norovirus infection in hospitalised patients was assessed by Mattneret
al who showed dehydration confirmed by >10% increasein creatinine in 22/84 of patients as
well as 18/84 having detectable potassium loss of >10% (Mattneret al. 2006).
Immunosuppressed patients: The numbers of immunosuppressedpatients is increasing with
the spread of HIV infection and increased use of immunosuppressive agents associated with
transplants and chemotherapy treatments. Thesepatients are at risk of infection in the same
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wayas therest of the population butit is suggested theycan developpersistent gastroenteritis
of many months duration (Gallimoreet al. 2004; Lee et al. 2008; Ludwiget al. 2008).
1.1.6 Clinical management
Norovirus, being an acute gastroenteritis with minimal mortality in healthy adults, does not
routinely require specific therapy. In those patients severely affected, the young and the
elderly in particular, supportive therapy (fluid and electrolyte replacement, temperature
control and analgesia) may need to be moreintensive. The need for these supportive
measures was shownbyan assessmentof hospitalised patients which showed serum
potassium falls of 10% occurred in 21% of those affected and creatinine rises of 10%
occurred in 26% of patients. Risk factors for the development of potassium falls were
cardiovascular disease and renal transplantation. Immunosuppression wasa risk factor for
creatinine increases of >10%. In view of the common occurrence of vomiting the
managementof these complications may require intravenousinfusionsto replace fluids and
electrolytes (Mattneret al. 2006). In patients who are on immunosuppressive therapy a
reduction in the immunosuppression should be considered. The useofantivirals or
immunoglobulin has not been proven to have anyeffect in the patients though
immunoglobulin is occasionally used where diarrhoea has been prolonged (Florescuet al.
2008).
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1.1.7. Laboratory diagnosis
Norovirus wasinitially detected by immuneelectron microscopy (EM) whenthe virus was
first identified in 1972. This offered an opportunity to diagnose rapidly from faecal samples
(Kapikian 1993). A characteristic appearance of the 27nm virus by EM is shownin Figure
1.5. Its surface shows multiple cup shaped depressions, these cups (Latin=calix) have given
the Caliciviridae family its name. EM only detects virus when there are 10° particles per ml
of stool (Dolin et al. 1972). This givesit a sensitivity of approximately 30% andrestricts
diagnosis to the acute stage of infection.
 
Figure 1.5: Norovirusparticles by electron microscopy. Picture provided by Biichen-
Osmond,C.to the International Committee on Taxonomy of Viruses
(http://www.ncbi.nlm.nih.gov/ ICTVdb/WIntkey/Images/em_norwa.gif)
Routine laboratory diagnosis of norovirus can also be undertaken by ELISA. Thishas a
variable sensitivity and specificity when compared to PCR diagnosis but an approximate
sensitivity of 60% is reported (Vipondet al. 2000; Dimitriadis et al. 2006; Gray et al. 2007).
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Analternative to ELISA testing is immunochromatographic (ICG) testing. This allows small
numbers of samplesto be investigated quickly. Both ELISA and ICGtesting have continued
to be developed and new commercial products continue to be produced. Immunological
methods of diagnosing norovirus infection are optimal in the first 72 hours of infection as
viral load is reducedafter this time (Graham et al. 1994; Okhuysenet al. 1995). Antigen
detection methodsare presented in detail in Chapter Three (3.1.1).
Norovirus PCRis now the standard method used for the clinical detection of norovirus andis
described in detail in the literature (Atmar and Estes 2001; Vinje et al. 2003). It is highly
sensitive and specific but does have somelimitations in that the primers may notdetect all
strains of virus (Jiang et al. 1999). Two separate PCR primersets are commonly used to
detect norovirus genogroupI and II (Rolfe et al. 2007). Given norovirus is an RNAvirus, and
PCR requires DNA, the RNA mustfirst be reverse transcribed into cDNA from the RNA.
After reverse transcription (RT) the cDNAis replicated by PCR leading to the accumulation
of PRC product which can be detected by gel electrophoresis (called qualitative or end point
PCR). This method of detecting PCR productis being replaced by real time RT-PCR.Real
time RT-PCRis moresensitive than qualitative PCR (Panget al. 2004). Real time RT-PCR
uses two methodsfor detecting PCR product. Oneis the dye, SYBR Green, which binds non-
specifically to double stranded DNA (PCR product) and fluoresces. The other methodis to
use probes whichbind specifically to PCR products. These probes fluoresce when DNA
polymerase excises them following specific DNA binding. RT-PCR using probesis therefore
highly specific and it has also been found to be moresensitive than using SYBR Green
(Gunson and Carman 2005). The probe based method of norovirus PCR methodhasalso
been adapted so the RT and the PCRcanbecarried outin a single reaction tube, so called one
step real time RT-PCR (Rolfe et al. 2007).
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1.1.8 Modesof transmission.
Faecal oral transmission: Many foodborne outbreaks of norovirusare reported in the
literature. These outbreaks have been caused by food handlers (de Wit et al. 2007) and by
people eating food contaminated prior to preparation in a kitchen. This contaminationis
principally related to faecal contamination of food through the use of manure on crops
(Showell et al. 2007) and through bivalve shellfishes (filter feeders) e.g. oysters which are
taken from areas exposed to human sewage (Huppatz et al. 2008). Attack rates in bivalve
shellfish exposures and food handler outbreaks are high. The high attack rates are more
impressive when considering that 20% of the population are immuneto infection and
approximately 50% of those susceptible may have asymptomatic infection (Lindesmithetal.
2003): In 95 oyster-associated outbreaks 58% were symptomatically infected and in 195
food handler-associated outbreaks 47% were symptomatically infected (Nodaet al. 2008).
Outbreaks of norovirus are mainly caused by genogroupII viruses. Recent work has
suggested that GII virus is more prevalent than GI dueto a higherviral load being excreted
in the faeces (Chanetal. 2006); this higherviral load potentially increasing the number of
transmission events the GII viruses cause.
Airborne transmission: Norovirus is present in vomitus, with an estimated concentration of
30,000,000 norovirus particles per 30ml of vomit. It is a 27nm particle, a size that remains
airborne indefinitely (Morawska 2006). Given that the infectious dose of norovirusis 10-100
particles, it seems feasible that norovirus could be transmitted by the airborneroute.
Unfortunately, reports of airborne transmission in the literature have been unable to exclude
the role of fomite transmission (Sawyeret al. 1988; Markset al. 2000).
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Tracking transmission of virus: Transmission of outbreaks can be tracked through sequence
analysis of virus in affected patients. Accumulation of mutations is seen in virus transmitted
from person to person compared to a single source outbreak where limited virus mutation is
detected (Dingle 2004).
1.1.9 Prevention and control
Preventing norovirusinfection is difficult because vomiting and diarrhoea spread the virus in
the environmentand a low infectious dose is required to cause infection. The best way to
prevent infection is therefore to prevent exposure. This can be achieved by preventing
symptomatic people from cominginto contact with susceptible people. An example is
stopping admission of patients with gastroenteritis to hospitals. Once exposure has occurred
standard precautions are recommended e.g. hand washing. Thevirusis unculturableso it is
not knownwhatdisinfection procedures removethe viruses’ ability to infect cells/people. A
numberofsimilar viruses e.g. feline calicivirus, have been investigated as surrogates (Duizer
et al. 2004; Cannonet al. 2006; Bae and Schwab 2008). These suggest alcoholis ineffective
and high concentrations of bleach, >100ppm, are needed. Alternative disinfectants that may
be effective include Quaternary Ammonium Compounds and Hydrogen peroxide (Barker et
al. 2004; Duizeret al. 2004; Tree et al. 2005; Shin and Sobsey 2008). Givenit is difficult to
prevent infection in those exposed to norovirus it is important to cohort these patients for 48
hours after exposure as they maybe incubating infection during this time. Guidanceis
available from national bodies on howbestto control norovirus outbreaks e.g. Health
Protection Agency, UK (Chadwicket al. 2000). The only control measure documented to
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play a significant role in limiting spread of norovirusesin hospitals is ward closure (Lopman
et al. 2004).
1.1.10 Pathogenesis
The pathogenesis of norovirus infection has undergonelimited investigation due to the
difficulty in accessing the site of infection, the small bowel and pylorus of the stomach. In
the 1970s, two norovirus challenge studies did obtain gastrointestinal tissue via endoscopy.
Reported histological changes in duodenal-jejunal junction biopsies showed reduced crypt-
to-villous ratio, abnormal villous absorptive cells, increased cellularity of lamina propria and
polymorphonuclear leucocytes in the lamina propria (Schreiberet al. 1974). The second study
showed an intact mucosa, moderately blunted villi, and a moderate inflammatorycell
infiltrate in the lamina propria consisting of polymorphonuclear and mononuclear cells with
appearanceshaving returned to normalat 2-3 weeks (Dolin et al. 1975). A numberof animal
models are reported but the relevance of these to humaninfection is unclear (Cheetham etal.
2006; Ward et al. 2006; Mumphreyet al. 2007; Souzaet al. 2008).
1.1.11 Susceptibility and immuneresponsesto norovirus
In humansthe immuneresponsehasbeeninvestigated by completing challenge studies in
healthy adults. These studies have allowed collection of clinical samples (faeces, saliva and
serum)to investigate immuneresponses. Also, clinical outcomesof challenges, including
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repeat challenges, have been assessed. Challenge studies of healthy adults have shownthat
the clinical response to norovirus challenge is variable. Clinical responses include noclinical
illness to a range of mild to severe gastroenteritis. No clinical illness can be dueto the
absence ofa cell receptor in the gastrointestinal tract that the virus attaches to prior to causing
cell infection. This receptor is known as H antigen (H-type-1). Its formationis part of the
ABOblood group system which is expressed differently in the gastrointestinal tract to the
blood. The biosynthetic pathway is shownin detail in Figure 1.6. Non secretors do not have
an enzymefor the production of H-type-1, being homozygote recessive for the FUT2 gene
responsible for the production of a (1,2) fucosyltransferase which creates H-type-1. Jn vitro
studies have shownnorovirus binds to H-type-1 supporting the hypothesis this is the
gastrointestinal receptor for norovirus. Non secretors are therefore called this in view oftheir
lack of secreted H antigen onto the gastrointestinal epithelium (Lindesmith et al. 2003).
Approximately 20% of Caucasiansare nonsecretors of H antigen.
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Figure 1.6: Biosynthetic pathway for H antigen required by norovirus to cause human
infection, reproduced from Lindesmith ef a/ (Lindesmithet al. 2003).
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Subjects whoare secretors ofH antigen mayalso not becomeclinically unwell when
challenged with norovirus, as well as not becoming infected (infection defined as detection of
norovirus in faeces). This group of subjects have an early elevated level of salivary IgA,
compared to secretors who become infected with norovirus (Figure 1.7).
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Figure 1.7: Salivary IgA responses in patients challenged with norovirus on day 0. & —
susceptible patients who were infected, Ml - susceptible patients who were not infected
unsusceptible patients. Reproduced from Lindesmith et a/ (Lindesmith et al. 2003).
In those subjects who becomeinfected with norovirus, confirmed by detection of norovirus in
faeces, only half will become symptomatic. These findings were reported by Lindesmithef al
and are summarised in Figure 1.8 (Lindesmithet al. 2003).
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Figure 1.8: Clinical and immunological outcomesin norovirus challenge studies of healthy
adults. Figure reproduced from Lindesmith e¢ a/ (Lindesmith et al. 2003).
Immunity to norovirus has been investigated by a limited number of small studies. These
suggested that short term immunity to norovirus exists as subjects symptomatic after an
initial challenge remained asymptomatic after early, 6-14 weeks, re-challenge (Wyatt et al.
1974). Immunity wasseen in a study by Johnsonet a/ to last up to 6 months (Johnsonetal.
1990). Longer term immunity was shownto be limited as patients who were symptomatic on
initial challenge were also symptomatic on re-challenge 27-42 monthslater (Parrinoet al.
1977). Therefore, immunity to norovirus infectionis likely to last for between 6 months and 2
years. The duration acquired immunity protects against infection is complicated by the
evolution of norovirus, as described in section 1.1.4. This evolution leads to antigenic
variation which maylimit the protection offered by acquired immunity.
Immunological responses have been measured in faeces and serum.In faeces the immune
response detected has been shownto be associated withrises in interferon gammaand IL-2.
These are seen in T helper 1 cell responses which are associated with intracellular pathogens
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(Koet al. 2006). This results in macrophageactivation, B cell differentiation to IG1
synthesis and support for cytotoxic T lymphocytes. In addition faecal IgA responsesare also
elevated (Okhuysenet al. 1995). In studies of serum IgG responses > 4 fold increases are
seen in response to norovirus infection (Lindesmithet al. 2005). Their ability to offer
protection across the norovirus genogroups/genotypesis uncertain.It is likely some
protection may be offered across a genogroup of norovirus (Matsui and Greenberg 2000).
Morerecent studies have lookedspecifically at the GII.4 strain and the different variants
which have emerged overrecent years. These studies have shownthat genetic changes
associated with GII.4 strains produces variants which induce antibodies that bind poorly to
different GII.4 viral variants (Lindesmith et al. 2008).
1.2 THE CURRENT STUDY
1.2.1 Background
Norovirus diagnosis is based on testing faecal samples andinitially used electron microscopy
(EM)(Kapikian 2000). EM only has an approximately 30% sensitivity and can only be used
in centres with EM facilities, these are not commoneven in the more developed world. The
detection of norovirus improved with the use of PCR and ELISA tests (Kageyamaetal.
2003). PCR has becomethe gold standardtest as it is the most sensitive test. The limitations
of this method are based onits requirement for faecal samples, which in our experience can
be difficult to collect, and the requirement for specific equipment and technical expertise to
complete PCR. PCRis now a routinetest in manyclinical laboratories in the developed
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world. ELISA based testing offers a more low technology meansof diagnosing norovirus
infection. ELISAtesting is therefore suitable for laboratories without PCR basedtesting, but
has been limited by a lack of analytical sensitivity compared to PCR (Grayet al. 2007). Both
PCR and ELISAbasedtesting is commonly conducted on batches of samples to maketesting
more cost-effective. This can delay the timeit takes for a result to be obtained, important in
nosocomial outbreaks of infection given the short incubation time and high secondary attack
rate.
1.2.2 Objectives
This study investigates new diagnostic tests which may improvenorovirus testing with regard
the limitations of current testing, namely: The need for faecal samples, the sensitivity of
ELISAsandthe costs and time associated with testing small batches of samples for
norovirus. The process of investigating these new diagnostic tests also allows an assessment
of the molecular epidemiology of norovirus in two areas, Merseyside, UK and Aracaju,
Brazil. The specific aimsare:
1- To evaluate the diagnostic accuracy of one step real time RT-PCRoforal samples to
diagnose norovirusinfection.
Norovirustesting currently requires the use of faecal samples to be tested, which can be
difficult to collect. This is because faecesaretraditionally collected in pots. Collecting faecal
samples in pots in clinical environments can bedifficult as diarrhoeais intermittent, may only
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occurfor a short period of time and stool is produced without sufficient warning. Given
norovirus is commonlyassociated with vomiting, which may contaminatethe oralcavity,
investigating if an oral mouthwash could be a suitable specimen to support the diagnosis of
norovirus infection was conducted.
2- To investigate the sensitivity and specificity of a new ELISA, the RIDASCREEN
ELISA (R-Biopharm).
Currently, the norovirus ELISA with the best analytical sensitivity is approximately 60%
sensitive when compared to PCR(Grayet al. 2007). This hasrestricted the role of ELISA to
a cheap, quick and, in terms of analytic sensitivity, an insensitive method of screening
samples for norovirus infection. Given the low analytical sensitivity of the ELISAs, PCR
testing is used in preference in many diagnostic laboratories. If the analytical sensitivity of
ELISAs improvedthey could be used for testing individual patients and in molecular
epidemiological studies. Given manycentres are without the capacity for molecular
diagnosis of norovirusthere is a need for a moresensitive ELISAs. In those centres with PCR
testing available ELISAs mayoffer a cheaper and quicker way of testing samples for
norovirus infection prior to completing molecular testing. Therefore a newly developed
commercially available ELISA wasinvestigated for its sensitivity and specificity in
comparison to both PCR andanestablished ELISA, the IDEIA norovirus ELISA. The sample
set the ELISAis tested on is a cohort of children in Brazil with gastroenteritis.
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3- To investigate the sensitivity and specificity of a new immunochromatographictest
for norovirus, the RIDAQUICKnorovirustest (R-Biopharm).
In manyoutbreaks of norovirus infection only a small numberof samplesare collected for
testing. The use of PCR based testing can therefore be an inefficient means of reaching a
diagnosis. Immunochromatographic (ICG) testing allows testing to occur both rapidly, in
approximately 20 minutes, and on single samples. A new ICGtest for norovirus,
RIDAQUICKisinvestigated to allow consideration of this test as a rapid diagnostic test for
norovirus. The sample set the ICT test is tested on is derived from a cohort of Brazilian
children with gastroenteritis.
4- To investigate the molecular epidemiology of norovirus infection in Merseyside, UK,
and in Aracaju, Brazil.
Studies into the molecular epidemiology of infectious diseases are carried out to provide
information on the interaction of host/environment and the pathogene.g. transmission routes.
The intended outcome of understanding this interaction is to improve strategies which are
used to prevent infections by a pathogen e.g. by reducing transmissionrates. This study,
therefore, investigates the molecular epidemiology of norovirusin twosettings: hospitalised
adults in Merseyside, UK and children with gastroenteritis in Brazil. In both these settings,
improved norovirus prevention strategies would offer significant clinical benefits.
27
CHAPTER 2
An evaluation of the diagnostic accuracy of using oral samplesto test for
norovirus infection.
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2.1 Introduction
Norovirus comprises a genetically diverse genus within the Caliciviridae family. Two main
genogroupsofnorovirus(I and II), separated into over 30 genotypes, cause human infection
(Green et al. 2000). They are the predominant causative agent of acute viral gastroenteritis in
adults and one genotype, GII.4, is currently causing the majority of outbreaks of infection
globally (Bull et al. 2006). Diarrhoea and vomiting are the principal clinical features of
norovirus gastroenteritis (Lopmanet al. 2004) and cause widespread contamination ofthe
environment. This contamination, combined with the low infectious dose of norovirus (10-
100 particles), results in institutional outbreaks of gastroenteritis, including in hospitals.
These outbreaks are associated with a relatively mild morbidity and low mortality (Harris et
al. 2008), but the economic impacton healthcareinstitutions is significant (Lopmanetal.
2004). As norovirus has a short incubation period, approximately 24 hours, the prevention of
norovirus outbreaksrelies upon prompt diagnosis of infection. Whilst this can be carried out
by assessing clinical features, rapid laboratory confirmation (or exclusion) of norovirus
infectionis likely to help rationalise the use of infection control resources. The detection of
norovirus RNAin faeces byreverse transcriptase PCR (RT-PCR)is the current diagnostic
test of choice, though ELISA and immunochromatographictests are also available. These
diagnostic methodsrely on the collection of faecal samples. Collection of faeces can be
problematic and cause diagnostic delay. Given vomiting often precedes diarrhoea in
norovirus infection, leading to contamination ofthe oral cavity with norovirus, sampling from
the oral cavity mayallow the problem ofcollecting faecal samples to be negated. The
evidence which supports such a strategy comes from two observations. Firstly, the diagnosis
of norovirus using RT-PCR on vomit has been published (Dolin 2007). Secondly, an
outbreak of norovirus infection in the family of a research workerat the University of
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Liverpool, (to date unpublished), was used to complete a preliminary study into the oral
detection of norovirus. This family outbreak demonstrated that norovirus could be detected
for up to two weeks in mouthwash samples following infection. This family outbreak,
followed by a studyinto the oral diagnosis of norovirus infection, is now presented.
2.1.1 Preliminary studyinto the oral diagnosis of norovirus infection
An outbreak of norovirus infection within the family of a researcher provided the opportunity
to obtain faecal and oral samples (obtained by mouth washes and mouth swabs) during and
followingclinical illness. This allowed a preliminary study into the oral detection of
norovirus to be conducted.
The study
The index case wasa physiotherapist who workedat a hospital experiencing an outbreak of
norovirus infection, and who wasliving in a family household of six. The index case
returned homefrom work with diarrhoea, and the remainder of the household subsequently
developed symptomsof gastroenteritis over the next 24-48 hours.
Faecal samples werecollected into sterile universal containers (Sterilin, Stone, UK). Mouth
swabs were obtained by rubbing a swab (Virocult: Medical Wire, Corsham, UK) over buccal,
lingual and palatal surfaces. Mouthwashes were obtained by asking subjects to wash the
mouth with sterile distilled water (3mls), the fluid then collected in sterile containers.
Mouthwasheswerecollected from adults, and mouthswabsfrom the single infant in the
study. Samples werecollected in the morningprior to breakfast and were preparedfortesting
as follows: faecal samples by making a 10% suspension, mouth swabs by submersion in 1ml
of PBS and mouthwash samples weretaken directly for testing. Samples were vortexed
30
before centrifuging a 1mlaliquot for 10 minutes at 14000rpm. Supernatant (5001) from the
centrifuged oral samples then underwent RNAextraction using QIAGEN RNeasykits
(QIAGEN:Sussex, UK). Extract was eluted into 30] of RNAse free water and 3p] ofRNA
then subjected to RT-PCR using the method ofJiang et al (Jiang et al. 1999) in which a
319bp product is amplified from the RNA polymeraseregion. The product was detected by
electrophoresing in a 2% agarose gel with ethidium bromidestaining and viewed under
ultraviolet (UV) light. Amplicons were purified using the QIAGENgelpurification kit and
sequenced by Lark Technologies (Essex; UK). Negative controls were used in all RT-PCR
runs. Faecal samples were processed as described by Doveet al (Doveetal. 2005).
The index case (case 1) developed diarrhoea without vomiting. Four family members (cases
2-5) developed diarrhoea and vomiting, and one member(case 6) suffered abdominal
bloating without diarrhoea or vomiting. Four cases (2,3,5 and 6) had faecal samples collected
at the onsetofillness which underwent RT-PCR examination which wereall positive for the
presence of norovirus RNA. Norovirus RNA could be detected by RT-PCR oforal samples
from all six cases, including cases 1 and 6 who had not vomited. Examination ofserial oral
fluids demonstrated that norovirus RNA could be detected in each case for 10-15 days
following infection, after which it became undetectable (Figure 2.1). The nucleotide sequence
of RT-PCR products detected in oral samples were identical to that seen in the faeces [(cases
2 and 3) data not shown]. The nucleotide sequence of the RT-PCR products from case 2 was
a GII.3 norovirus (GenBank accession number AB236724). An asymptomatic staff member
provided oral samples which were used as negative control samples.
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Figure 2.1: Temporal relationships between symptomsand oral detection of norovirus RNA
following norovirus infection. For each case: top row = vomiting, middle row = diarrhoea,
bottom row= detection of norovirus RNA in samples from oral cavity). 8% = symptom not
present. ® = day on which norovirus RNA detected from oral sample, MJ = day on which
norovirus RNAnot detected from oral sample.
2.1.2 Standards for Reporting of Diagnostic Accuracycriteria
This chapter presents the results of a study whichis an evaluation of a diagnostic test.
Evaluating diagnostic tests and subsequently publishing the tests characteristics is undertaken
so others may makedecisions abouttheclinicalutility of that test. For others to make a
decision abouta test’s clinical utility, they need complete information about the evaluation
e.g. severity of disease and demographicsofpatients tested. A review in 1995 (Reidetal.
1995) of the reporting of evaluations of diagnostic tests found significant deficiencies. This
led to the developmentofcriteria for the evaluation of diagnostic tests, the Standards for
Reporting of Diagnostic Accuracy criteria (STARDcriteria), to be produced by the Cochrane
Diagnostic and Screening Test Methods Working Group (Bossuyt et al. 2003). The STARD
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criteria are a checklist that it is recommendedshould be usedin publishing the evaluation of
diagnostictests.
Presentation of the test evaluation according to the STARD criteria
The STARDcriteria allow an evaluation of a diagnostic test to be presented in a clear and
accessible format. Therefore, this chapter is presented in the format dictated by the STARD
criteria. The table with the STARTDcriteria (Table 2.1) allows the evaluation to be navigated
easily and presentation of the evaluation in accordance with the criteria ensuresall relevant
details of the study are presented.
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Table 2.1: STARD criteria reference table for the study: An evaluation of the diagnostic
accuracy ofreal time reverse transcriptase PCR for norovirus in oral samples.
 
 
 
     
Section and Topic Item Section
TITLE/ABSTRACT/ 1 Identify the article as a study of diagnostic accuracy (recommend MeSH heading'sensitivity 2.2
KEYWORDS and specificity’).
INTRODUCTION 2 State the research questions or study aims, such as estimating diagnostic accuracy or 2.2:1
comparing accuracy betweentests or across participant groups.
METHODS 2.3
Participants 3 The study population: The inclusion and exclusion criteria, setting and locations where data 2.3.1.1
werecollected.
4 Participant recruitment: Was recruitment based on presenting symptoms,results from 2.3.1.2
previoustests, or the fact that the participants had received the index tests or the reference
standard?
5 Participant sampling: Was the study population a consecutive series of participants defined 2.3.1.3
by the selection criteria in item 3 and 4?If not, specify how participants were further
selected.
6 Data collection: Was data collection planned before the index test and reference standard 2.3.1.4
were performed(prospective study)orafter (retrospective study)?
Test methods 7 The reference standardandits rationale. 23
8 Technical specifications of material and methodsinvolved including how and when 2.3.1-2.3.3.4
measurements were taken, and/orcite references for index tests and reference standard.
9 Definition of and rationale for the units, cut-offs and/or categories of the results of the 2.3.4
index tests and the reference standard.
10 The number,training and expertise of the persons executing and reading the index tests 2.3.5
and the reference standard.
11 Whetheror notthe readersof the index tests and reference standard wereblind (masked) 2.3.6
to the results of the other test and describe any other clinical information available to the
readers.
Statistical methods 12 Methodsforcalculating or comparing measuresof diagnostic accuracy, and the statistical 23.4
methodsused to quantify uncertainty (e.g. 95% confidenceintervals).
13 Methodsforcalculating test reproducibility, if done. Not done
RESULTS 2.4
Participants 14 Whenstudy wasperformed,including beginning and end datesof recruitment. 2.4.1.1
15 Clinical and demographic characteristics of the study population (at least information on 241.2
age, gender, spectrum of presenting symptoms).
16 The numberofparticipants satisfying the criteria for inclusion whodid or did not undergo 2.4.1.3
the index tests and/or the reference standard; describe whyparticipants failed to undergo
either test (a flow diagram is strongly recommended).
Test results 17 Treatment administered in between study and referencetest. 2.4.2.1
18 Distribution of severity of disease (define criteria) in those with the target condition; other 2.4.2.2
diagnosesin participants without the target condition.
19 A cross tabulation of the results of the index tests (including indeterminate and missing 2.4.2.3
results) by the results of the reference standard; for continuousresults, the distribution of
the test results by the results of the reference standard.
20 Any adverseevents from performing the index tests or the reference standard. 2.4.2.4
Estimates 21 Estimates of diagnostic accuracy and measuresofstatistical uncertainty (e.g. 95% 2.4.3.1
confidenceintervals).
22 Howindeterminate results, missing data and outliers of the index tests were handled. 2.4.3.2
23 Estimatesof variability of diagnostic accuracy between subgroupsofparticipants, readers or 2.4.3.3
centers, if done.
24 Estimatesof test reproducibility, if done. Not done
DISCUSSION 25 Discuss the clinical applicability of the study findings. 2.5
Table reproduced from Bossuyt et a/ (Bossuyt et al. 2003)
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2.2 Title /Abstract/Keywords
Title
Anevaluation of the diagnostic accuracy of using oral samplesto test for norovirusinfection.
Abstract
Rapid diagnosis of norovirus infection may help in the control of nosocomial outbreaks.
Laboratory diagnosis can be delayed while awaiting faecal samplesfor testing. An
investigation was conductedinto the use of oral samples to diagnose norovirusinfection as
these can be collected on demand.Real time reverse transcriptase PCR wascarried out on 66
paired faecal and oral samples. Norovirus infection was confirmed in 59 faecal samples. Of
these 59 patients, 14 (24% (95% C.I. 14-37%) were positive for norovirus in the oral
samples. Oral samplingis not currently suitable for routine diagnosis of nosocomial
norovirusinfection.
Keywords
Norovirus; Oral; Diagnosis; Test; Sensitivity; Specificity
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2.2.1 Aims
1- To evaluate the diagnostic accuracy of one step real time reverse transcriptase PCR of
oral samples to diagnose norovirusinfection.
2- To make an assessmentofclinical factors which affect the sensitivity of one step real
time reverse transcriptase PCR oforal samples to diagnose norovirusinfection.
2.3 METHODS
2.3.1 PARTICIPANTS
2.3.1.1 Study population
Participants were recruited for the study from November 2008 until February 2009
Inclusion Criteria
e Vomiting and/or diarrhoea.
e Diarrhoea within the preceding 72hours.
Diarrhoea was defined as | or more episodesofloosestools.
Exclusion Criteria
e Another obvious cause of diarrhoea and/or vomiting.
e No age/ sex prior disease / prior treatment exclusion criteria used.
e Severe / life threatening or terminalillness or unable to consent.
36
Settings
Patients were identified within hospital wards from four NHStrusts (five hospitals) in the
North West of England, UK.
e Royal Liverpool and Broadgreen University Hospital NHS Trust. Two study
hospitals: The Royal Liverpool University Hospital (RH) and Broadgreen Hospital
(BG), on separate sites. Liverpool, UK.
e Liverpool Heart and Chest Hospital NHS Trust. Liverpool Heart and Chest Hospital
(CT) on the samesite as Broadgreen Hospital. Liverpool, UK.
e Wirral University Teaching Hospital NHS Foundation Trust. Arrow Park Hospital
(AP), Upton, Wirral, UK
e St Helens & Knowsley NHSTrust, Whiston Hospital (WH), Prescot, UK.
Didelad Participant recruitment
Patients were recruited based ontheir clinical symptoms,see section 2.3.1.1.
Ethics: Ethics approval was gained from the Bolton Research Ethics committee: REC No.
08/H1009/12, for full details see Appendix.
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2.3.1.3 Participant sampling
Patients were identified for the study in two ways.
e Surveillance of laboratory requests for norovirus testing at RH bythe principal
investigator of the study, A Kirby.
e Reporting of suspected outbreaks of norovirus by medical and nursingstaff, involved
in hospital infection control, from each NHStrust, to the principal investigator of the
study (A Kirby). An outbreak wasnotstrictly defined. Local infection control staff
defined outbreaks according to local policy.
Patients wereclinically assessed bythe principal investigator of the study at the bedside.If
they metthe eligibility criteria they were consented and entered the study. The oral sample
would then be taken at the bedside by the principal investigator (A Kirby). The patient was
asked to provide a faecal sample when possible. Oral sampling consisted of asking a patient
to swill 3mls of sterile water around the mouth for 10 seconds with collection of the water in
a sterile container. Samples were stored at 4°C until extraction; this was carried out within 24
hours of sample collection.
2.3.1.4 Data collection
Data wascollected prospectively.
38
2.3.2 Test methods
The choice of PCR methodusedin this evaluation to detect norovirusis a onestep real time
RT-PCR method using faecal samples. This method was used becauseit is the method
routinely usedin the clinical laboratory at the Royal Liverpool Hospital. This methodis
established and undergoesexternal evaluation.
2.3.2.1 Test under evaluation: Onestep real time RT-PCR oforal/faecal samples
Onestep real time RT-PCR:Principle of test
One step real time RT-PCR consists of the following stages. RNA extraction: RNA is
extracted from the clinical samples to provide an RNA template for reverse transcription: RNA
is reverse transcribed using a reverse transcription enzyme providing complementary DNA
(cDNA) for the PCR step. PCR: cDNA is amplified using a DNA polymerase reaction to
provide a product of a specific size. In real time PCR a probe with the potential to fluoresceis
included in the PCR reaction mixture. This probe binds specifically to cDNA until cDNAis
replicated by DNA polymerase. DNA polymerase removes the probe which then fluoresces.
This fluorescence is detected and is proportional to the specific replication of the norovirus
derived cDNA. Onestep PCR combines the RT and PCR mixture in the same tube as opposed
to standard RT-PCR where RTand PCRarecarried out as separate reactions.
Onestep real time RT-PCR:Test procedure
Preparation: Oral samples: Samples were collected by swilling 3mls of sterile water in the
mouth. Samples were centrifuged at 14000rpm for 10 minutes and the supernatant used as
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described below. Faecal samples: Samples were prepared by diluting 1001 of liquid stool or
50-100mg of solid stool into 0.9ml of phosphate buffered saline (PBS). Samples were
homogenised by mixing with a vortex. Samples were then centrifuged at 14000rpm for 10
minutes. The supernatant wasused as described below.
The test: RNA extraction: This was undertaken using QIAGEN mini columns (QIAGEN,
West Sussex, UK). 500u1 of faecal/oral supernatant was mixed with 300ul of RLT buffer and
300u1 of 70% ethanol. This mixture was then added to QIAGEN mini columns and
centrifuged at 14000rpm. 700ul of RW1 wash buffer was then added to each column,
followed by centrifugation at 14000rpm for 15 seconds. Next, 500ul of RPE buffer was
added to the column, centrifuged at 14000rpm for 15 seconds before again adding S500u1 of
RPEbuffer to each columnandcentrifuging at 14000rpm for 2 minutes. The tubes were then
centrifuged without addition of any reagent to the columns for 2 minutes at 14000rpm.
Finally, 45u1 of high-performance liquid chromatography (HPLC) water was added directly
onto the silica membrane of the mini columns, incubated at room temperature for 1 minute
and centrifuged at 14000rpm for 1 minute. The flow though contained the extracted RNA and
wasstored at -70°C until used for the PCR reaction.
Onestep real time RT-PCR: The PCR mixture was prepared and included:
Supermix (Invitrogen, Paisley, UK) 10ul
Express mix (Invitrogen) 2ul
Primer mix (Metabion, Martinsried, Germany) lul
Probe mix (Applied Biosystems, Foster City USA) 0.5pl
HPLC water 1.5ul
RNAextract Sul
Total 20ul
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The primer and probe mixes were made at 10M concentrations.
Primers (Kageyamaet al. 2003; Pusch et al. 2005)
Cogl-F CGY TGG ATG CGN TTY CAT GA
GI_NV193as CGT CCT TAG ACG CCA TCA TCA
Cog2-F CAR GAR BCN ATG TTY AGR TGG ATG AG
Cog2-R TCG ACG CCA TCT TCA TTC ACA
Probes (Kageyamaet al. 2003)
GI_TM9-MGB-VIC VIC-TGG ACA GGA GAT CGC-NFQ
Ring2 FAM-TGG GAG GGC GAT CGC AAT CT-BHQ
The PCRreaction wascarried out in a thermocycler (Light cycler: Roche 480), cycling
conditions were 50°C for 15 minutes, 95°C for 2 minutes followed by 45 cycles of 95°C for
15 seconds, 56°C for 60 seconds and 72°Cfor 1 second. Fluorescence was detected on
channels FAM (GII) and HEX (GI).
Quality control: Test results were verified by the inclusion of positive and negative controls
in each batch of samples.
2.3.3 ADDITIONAL TEST METHODS
Dedede Qualitative RT-PCR
Qualitative RT-PCR:Principle of test
PCR product is formed by RT and PCRsteps as for one step PCR. PCR product formedis
detected by a different method, PCR product being stained with ethidium bromide. This
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stained product is then run on an electrophoresis gel to separate out products according to
their size. Products of the correct size, which vary according to the primers used, can be
identified by examining the gels under UV light.
Qualitative RT-PCR: Test procedure
Preparation: See onestep real time RT-PCR:test procedure.
The test: RNA extraction: See one step real time RT-PCR:test procedure.
Reverse transcription: 401 of the RNA wasdenatured by placingit in a thermocycler (2720
Thermal Cycler, Applied BioSystems, Foster City, USA) at 95°C for 5 minutes. The RT
reaction mixture was prepared which contained:
HPLC water I1ul
5x buffer (Invitrogen) 6ul
50mM MgCl(Invitrogen) Tul
20uM Random hexamers (6N Sigma, Dorset, UK) Iul
10mM dNTPs(Invitrogen) 2ul
RNaseinhibitor (Promega, Southampton, UK) 1ul
M-MLVreversetranscriptase (Invitrogen) 2ul
30ul of RT mix was added to the denatured sample, and then placed back into the
thermocycler at 37°C for 1 hour, followed by 95°C for 5 minutes.
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PCR: A 50pul PCR mixture was prepared for each sample and included:
HPLC H20
10X buffer (Invitrogen)
50mM MgCL2 (Invitrogen)
10mM dNTPs(Invitrogen)
10uM primers
Sunits/uL Taq polymerase (Invitrogen)
cDNA
Total
The PCRreaction was then undertaken in a 2720 Applied BioSystems Thermal Cycler under
the following conditions: 1 Cycle for 3 min at 94°C, 40 cycles for 1 min at 94°C, 1 min at
50°C and 2 min at 72°C,1 cycle for 15 min at 72°C. Once the PCRreaction finished the PCR
products were run on a 2% agarose gel (Bioline, London, UK) and stained with ethidium
bromide. Agarose gel was prepared with 0.5XTBE(Tris base, boric acid and EDTA). After
electrophoresis amplification products were visualized under UV light. Products co-migrating
with the positive control with a product size of 330bp for GI and 344bp for GII virus were
33.75 ul
5.0u1
1.5ul
1.0u1
3.0ul
0.75 ul
5.0u1
50ul
considered positive. The primers used were (Kojimaet al. 2002):
GISKF
GISKR
G2SKF
G2SKR
G2ALSKR
CTG CCC GAA TTY GTA AAT GA
CCA ACC CAR CCA TTR TAC A
CNT GGG AGG GCG ATC GCA A
CCR CCN GCA TRH CCR TTR TAC AT
CCA CCA GCA TAT GAA TTG TAC AT
43
Quality control: Test results were verified by the inclusion ofpositive and negative controls
in each batch of samples. In addition a 100bp lambda ladder (Invitrogen) was run on each
electrophoresisgel.
2.3.3.2 DNApurification
Sequencing of PCR products was conducted wheresufficient PCR product was produced. To
allow sequencing the products from the PCR needed purifying, two methods wereusedto
purify norovirus PCR product. Microspin columnswere usedif the 344bp product wasthe
predominantproducton the agarose gel. If multiple products were seen on the agarose gel the
QIAquick method was used.
Illustra Microspin Columns (GE Healthcare, Buckinghamshire, UK): Principleoftest
DNAis purified bythe use of a resin. The resin allowsgelfiltration of an applied sample.
Molecules larger than the largest pores in the resin e.g. DNA, donot penetrate the resin
matrix and are the first molecules to elute from the resin allowingtheir preferential
collection.
Illustra Microspin Columns (GE Healthcare): Test procedure
Preparation: Microspin columns were re-suspended by vortexing then centrifuging for one
minute at 3000rpm.
The test: PCR product waspipetted on to the spin column membrane and the column
centrifuged at 3000rpm for 2 minutes. Purified DNA wascollected in an eppendorftube.
Quality control: No specific quality control checks are in place for this procedure.
Confirmation it has been successful is derived from the sequence data produced.
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QIAquick Gel Extraction Kit (QIAGEN): Principle of test
The QIAquick columnscontain a size fractionated silica membrane. When a sample is
applied to the membrane impurities such as excess primers and agarose remain unbound. The
correct chaotropic (nucleic acid denaturing agent) salt concentration (high) and pH (<7.5)
ensure binding of DNA. Washbuffers are used to remove the chaotropic salts and DNA is
eluted from the membraneusing a nonacidic low salt concentration solution e.g. water.
QIAquick Gel Extraction Kit (QIAGEN): Test procedure
Preparation: The PCR product was visualized using UV light in a dark room and cut from
the agarosegel.
Thetest: The gel was weighed and 3 volumes of BufferQG were added to each | volume of
gel. Excised gel fragments were dissolved by incubating for 10 minutes at 50°C. 1 gel
volume of isopropanol wasadded to the sample mix which was added to the QIAquick
column and centrifuged for 1 minute at 13000rpm.After centrifugation 750ul of Buffer PE
wasaddedto the QIAquick columnandcentrifuged for | minute at 13000rpm. Flow through
was discarded and the column centrifuged (13000rpm)for an additional 1 minute. The DNA
wasthen eluted by adding 5Oul of distilled water to the centre of the membrane followed by
centrifugation at 13000rpm for 1 minute.
Quality control: No specific quality control checks are in place for this procedure.
Confirmation it has been successful is derived from the sequence data produced.
Zdeded Sequencing of PCR products
All of the purified PCR products were sequenced by Cogenics (Essex, UK). Methods were
requested from them which are now provided. DNA sequencing wasperformedusing the Big
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DyeTM Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City,
USA). Sequencing reactions are analyzed on a 3730xl automated DNA sequencer (Applied
Biosystems). The raw data is analyzed using ABI Prism® DNA Sequencing Analysis Software
Version 5.0.
2.3.3.4 Analysing sequence data
The norovirus genomeconsists of three open reading frames, ORF 1/2/3. The Primers used in
this study to generate sequence data were GISKF, GISKR, G2SKF, G2SKR and G2ALSKR
(Kojimaet al. 2002). These primers span the region at the 3 prime end of ORF1 andthe 5
prime end of ORF2. The sequenceswere aligned by removing the ORF1 section. This was
doneby finding the ATG start codon of ORF2. An approximately 278bp region of ORF2,
starting from the start codon, wasselected for phylogenetic analysis. The section of sequence
selected for analysis was based on quality of the sequence data. Software packages were used
to edit the sequence obtained (BioEdit and SeqMan), align the sequences (EditSeq and
Megalign) and produce phlyogenetic trees (CLUSTALW at Data Bank of Japan (DDBJ)
[http://clustalw.ddbj.nig.ac.jp]. DDBJ aligns sequences using the neighborjoining (NJ)
method. Sequencesused in the phylogenetic analysis included representatives from the
genotypes GI.1-14 and GII.1-19. Norovirus sequences were groupedasa distinct strain where
the sequence nucleotide data was 100% similar. Percent similarity between norovirus
sequenceswascalculated using Megalign computer software: sequence distances function.
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2.3.4 Categorisation of test results
Faecal/oral samples: Only GII virus wasdetected in this study. The cut off for detection was
a fluorescence over 3.7. The cut off was calculated with reference to the negative control
fluorescence values. The mean fluorescence was 0.5 (0.05-2.2), with a standard deviation of
0.5. The cut off was therefore set above this value at 3.7, equal to the highest negative value
plus 3 standard deviations.
2.3.5 Competenciesof staff completing laboratory work
Laboratory testing was carried out by personnel with experience of norovirus diagnostics (L
Ashton, Royal Liverpool University Hospital and A Kirby, Liverpool University).
2.3.6 Potential for result bias
Samples were processed and analysed without knowledgeofclinicaldetails.
2.3.7 Statistical methods
Statistical support was received from:
Stephen Taylor, Centre for Medical Statistics, Liverpool University; Steven Lane, Centre for
MedicalStatistics, Liverpool University; Brian Faragher, Liverpool School of Tropical
Medicine, Liverpool University.
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Dededoh Sample size calculation
Samples size wascalculated to see if the oral diagnosis of norovirus by PCR had a sensitivity
compared to faecal PCR of > 50%. This value was decided uponasnorovirusin hospitals
commonly causes outbreaks of infection which affect multiple patients at the same time. The
detection of norovirusin onepatient is routinely used as evidenceother patients with a
norovirus syndromic presentation also have norovirus infection. The diagnosis of norovirusin
a cohort of symptomatic patients can therefore be considered in terms of multiple tests on
different patients as opposedto a single test on a single patient. Figure 2.2 shows how joint
sensitivities can lead to an acceptable sensitivity of multiple tests despite a low sensitivity in
an individualtest.
Noroviruspresent (100%) Sensitivity
Patient 1 50% (TP) 50% (FN) 50%
a
Patient 2 50% (TP) 50% (FN) 75%
—“ ™
Patient 3 50% (TP) 50% (FN) 87.5%
Figure 2.2: The effect ofjoining sensitivities of an oral norovirustest with a sensitivity of
50% per sample.
A sample size with a sensitivity lower bound confidenceinterval of >50% was therefore
required (at a 95% confidenceinterval).
The formula for calculating sample size with a defined lower boundis given by:
n=1.96"x p(l—p)/(p—po)
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 where: n= sample size, p= sensitivity of the test under evaluation, po= accepted lower bound
of the confidenceinterval around this anticipated sensitivity value(p). If the test sensitivity is
estimated at 63% and the lower boundofthe tests C.I. is >50% the sample size can be
calculated as below:
p=63%
Po=52.42%
n= 1.96" x 0.63(1-0.63)/ (0.63-0.5242)
n=80
The samplesize is therefore 80 cases of norovirus infection.
Examining previous nosocomial outbreaks identified norovirus in 50%of samples submitted
to our laboratory (RH) for testing. Given this a sample of 160 is required to detect a
sensitivity with a lower bound 95% confidenceinterval of >50%.
2.01 Methodsfor interpretation of results
Reporting of diagnostic accuracy: Results will be presented in a cross tabulation table as
shownbelow (Table 2.2).
Table 2.2: Cross tabulation for presenting studyresults.
Reference standard
 
+ es
Test under + True positives False positives
evaluation - False negatives True negatives     
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True positive (TP): A sampletesting positive by the test under evaluation and the reference
standard.
False positive (FP): A sample testing positive by the test under evaluation and negative by the
reference standard.
False negative (FN): A sample testing negative by the test under evaluation and positive by
the reference standard.
True negative (TN): A sample testing negative by the test under evaluation and the reference
standard.
The reference standardin this study, faecal PCR,is used to define the presence of norovirus
disease.
The following characteristics of the test/statistical tests will be presented
1. Sensitivity= True positives / True positives + False negatives
2. Specificity= True negatives / True negative + False positives
These values will be presented with 95% confidenceinterval
3. Negative predictive value (NPV), based on a norovirus prevalence of 50%.
NPV=True negatives/True negatives + False negatives
4. Positive predictive value (PPV), based on a norovirus prevalence of 50%.
PPV=Truepositives/True positives + False positives
5. McNemar's test. To analysethe statistical significance in the differences in the
diagnostic accuracy of the oral norovirus test and the faecal norovirustest the
McNemar'’s test was used. This test was used as the data is categorical, summarised as
a percentage and paired.
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6. T-test: Unpaired. To analysethe statistical significance in the differences in the
clinical features in patients with/without norovirus detected by the oral norovirustest
the t-test was used (two sided). This test was used as the data is continuous and
independent.
7. Fishers exact test. To analyse thestatistical differences in the detection of norovirus
in oral samples in those with/without vomiting and diarrhoea Fishers exact test was
used (two sided). This test was used as the data is categorical, expressed as a
percentage and independent.
2.3.8 Test reproducibility
Test reproducibility was not assessed in this study.
2.4 RESULTS
2.4.1 PARTICIPANTS
2.4.1.1 Timing of participant recruitment
Participants were recruited for the study from November 2008 until February 2009.
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2.4.1.2 Clinical and demographic characteristics
Participants
e Total Number: 100.
e Mean age: 77 years (range 24-97).
e Sex: 35 male and 65 female.
Locations of participants: Hospital / Ward (numberofparticipants)
e Arrow Park Hospital (55): AMAU (2), Ward 23 (2), Ward 24 (6), Ward 25 (1), Ward
26 (5), Ward 27 (9), Ward 32 (2), Ward 33 (6), Ward 37 (10), Ward 38 (4), Ward 43 (8).
e Broadgreen Hospital (15): Ward 11 (5), Ward 5 (8), Ward 7 (2).
e Liverpool Heart and Lung Hospital (4): Ward A (4).
e Whiston Hospital (16): Ward B2 (3), Ward C3 (8), Ward F1 (5).
e Royal Liverpool Hospital (10), Ward 3A (1), Ward 3X (1), Ward 5B (1), Ward 8A
(2), Ward 8B (1), Ward 8MCU(1), Ward 9X (3).
2.4.1.3 Investigative strategy
All patients meeting the inclusion criteria and who gave consent underwentoral sampling
The laboratory investigations consisted of one step real time RT-PCR followed by (if
positive), qualitative PCR. If positive by qualitative PCR with sufficient PCR product, DNA
sequencing was then conducted. Ofthose patients who underwentoral sampling 66 provided
faecal samples which weretested by onestep real time RT-PCR.A representative selection,
with reference to study location, of these underwent qualitative PCR and sequencing.
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2.4.2 TEST RESULTS
2.4.2.1 Treatment administered in between study and referencetest.
Nospecific anti-norovirus treatment was administered between oral and faecal sampling.
2.4.2.2 Disease severity in participants
Disease severity can affect a tests sensitivity and specificity. The clinical factors most likely
to affect test sensitivity and specificity were considered to be duration of infection at testing
and timesince the last episode of diarrhoea/vomiting. Theseclinical factors were recordedat
the time of patient sampling. The clinical severity outside these factors was not analysed
given the heterogeneous co-morbidities in these hospitalised patients. Vomiting was present
in 58% ofparticipants, and the mean timesince onset of vomiting to sampling was 2.9 days
(0-23 days). Diarrhoea waspresent in 96% ofparticipants and the meantimesince onset of
diarrhoea to sampling was 2.3 days (0-23). Time since last vomit was a mean of 21 hours (0-
7days) and timesincelast diarrhoea was a mean of13 hours (0-3 days). Analysis of these
variables showed that they were associated with the detection of norovirusin the oral cavity
as follows. The detection of norovirus in the oral cavity was associated with shorter durations
of vomiting and diarrhoea and shorter times since the last episode of diarrhoea and vomiting,
at the time of oral sampling (Table 2.3).
53
Table 2.3: Impact ofclinical features associated with norovirus onthe results of the oral diagnostic
test for norovirus and associated p values.
 
Real Time PCR Qualitative PCR Norovirus sequence vatue
+ (14) - (45) + (6) - (53) + (4) - (55)
Vomiting present 12/14 26/45 5/6 33/53 4/4 34/55 0.1°
wetotontnetieetsoy (79 [3860)] | | |
Mean duration oftime since 0.8(1.1) 3.1(4.2) ; : 0.27onset of vomiting (days(S.D))
 
Mean durationof time since
onset of vomiting (days(S.D)) Le ed) os) on
Meantime since last vomit(days(S.D)) 0.4(0.6)
|
1.8(1.6) , 0.006
Mean timesince last vomit
(days (S.D)) 0.56(0.8) 1.5(1.6) . . 0.2
Meantime since last vomit(days (S.D)) 0.6 (0.9)
|
1.5(1.5) 0.30
 
Diarrhoea present 13/14 45/45 5/6 53/53 3/4 55/55 0.23'
Mean duration of time since
onsetof diarrhoea (days(S.D)) O70) 2:0(8:2) , : ; . 0.046
Mean duration of time since 0.8(1.1) 2.7(3.7) 0.27
onsetof diarrhoea (days(S.D))
Mean duration of time since
onset of diarrhoea (days(S.D)) LS t.2) 25(3<7) O56
Mean duration of time since
(days(S.D))
Mean durationof time since
last diarrhoeal episode ; : 0.2(0.2) 0.7(0.7) : , 0.18
(days (S.D))
 
Mean duration of time since
last diarrhoeal episode . 0.3(0.3)
|
0.6(0.7) 0.35
(days(S.D))        
' Denotes the p valuerelatesto real time PCRresults. Durations of symptomsarethoseat the
time of oral sampling. Vomiting/diarrhoea present = symptom having occurred by the time of
oral sampling.
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2.4.2.3 Cross-tabulation of results
In total 66 patients met the inclusion criteria and submitted faecal and oral samples for
norovirus testing. Within these patients 59 had norovirus detected in faeces. The sensitivity of
one-step real time RT-PCR, compared to faecal PCR,for the detection of norovirusin oral
samples was 24% at 100% specificity (Table 2.4).
Table 2.4: Sensitivity and specificity of the oral diagnosis of norovirus byreal time reverse
transcriptase PCR in comparisonto faecal diagnosis
 
    
Faeces one step real time RT-PCR
Oral one step real time PCR + -
+ 14 0)
- 45 7
59 7
Sensitivity 24% Specificity 100%
2.4.2.4 Adverse events from testing
No adverse events were noted from thetesting.
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2.4.3 ESTIMATES
2.4.3.1 Estimates of diagnostic accuracy and predictive values
The 95% confidenceintervals surrounding the sensitivity and specificity of the oral sampling
(section 2.4.2.3) for the detection of norovirus are 14-37% and 56-100% respectively. The
oral sampling results had a high positive predictive value (100%) but a low negative
predictive (56%) (Table 2.5).
Table 2.5: Estimates of the diagnostic accuracy associated with oral norovirustesting.
'PPV and NPVcalculated assuming a norovirus prevalence of 50%.
 
        
Test Sensitivity Sensitivity 95% C.I Specificity Specificity 95% C.1 PPV’ NPV"
oa! nn Rr 24% 14-37% 100% 56-100% 100% 56%
2.4.3.2 Handling of indeterminate results, missing results and outliers
Results were classified as positive/negative with no equivocal range. Faecal samples were not
collected from a numberofparticipants. These patients were excluded from the main analysis
but discussed in section 2.4.3.3.
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2.4.3.3 Estimatesof variability of diagnostic accuracy between subgroups of
participants
The sensitivity and specificity of norovirus testing was assessed where oral diagnosis was
based on oral qualitative PCR and on confirmation of norovirus sequence obtained from the
PCRproducts prepared from the samples obtained from the oral cavity (subsequently referred
to as oral sequencing samples). The sensitivity of these methods wasbelowthatofthe real
time RT-PCR at 11% (qualitative PCR) and 7% (norovirus sequence confirmation) (Table
2.6).
Table 2.6: The sensitivity and specificity of norovirus testing comparing oral qualitative RT-
PCRandoral sequencing vs. faecal real time RT-PCR.
 
Oral qualitative Oral sequencing
Sensitivity: True positives/All positives (%) 6/59 (11%) 4/59 (7%)
 Specificity: True negatives/All negatives (%) 7/7 (100%) 7/7 (100%)    
Contribution of sequencing data to the validity of the results
A total of 7 patients of the 100 sampled had norovirus sequence obtained from the PCR
products prepared from thesepatients oral samples. Within these 7, there were 5 where the
sequence wasidenticalto either the paired faecal sample, or to the strain of norovirus
detected within that study location at the same time. The sequence data from 2 samples could
be confirmed as norovirus but wasnotof sufficient quality to compareit to other norovirus
sequences. The sequencedata associated with this study are presented in detail in Chapter
Four.
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No faecal sample group
There were 34 patients who metthe study inclusion criteria, had samples from the oral cavity
collected but a faecal sample was not submitted to the study. Within this group 30 were from
outbreaks of gastroenteritis that were confirmed as being caused by norovirus. This group
waslikely to have a high incidence of norovirus infection. This is because of 62 patients who
did provide faecal samples and were from outbreaks of gastroenteritis confirmed as being
caused by norovirus; only 3 were negative for norovirus infection. The sensitivity of oral
PCRin patients without faecal samples but from within norovirus outbreaks was 27% (8/30).
Qualitative PCR waspositive in 3 of these 8 samples, with all 3 having norovirus sequence
obtained by sequencing the PCR product. Of these 3 sequences 2 wereidentical to faecal
samples from the corresponding outbreak and one was confirmedas norovirus but the
sequence quality wasnotofsufficient quality to compare to other sequences from the study.
2.4.3.4 Estimates of test reproducibility
Estimates of test reproducibility were not undertaken.
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2.5 Discussion
Thesensitivity of diagnosing norovirusinfection in oral samples by real time RT-PCR was
found to be 24%; by qualitative PCR 11% and by norovirus sequence confirmation 7%. The
differences in sensitivities may be to be dueto low levels of virus in the oral cavity and the
superiorsensitivity of real time RT-PCR comparedto qualitative PCR (Panget al. 2004;
Akiharaet al. 2005; Gunsonet al. 2006; Sun et al. 2008). Whilst recruitmentto this study
was not complete, the confidenceinterval around the estimate of the tests sensitivity is 14-
37%. This sensitivity is below whatis likely to be clinically useful for the detection of
nosocomial norovirusinfection. It may thoughstill be useful in situations where faecal
samplesare difficult to collect e.g. community outbreaks of gastroenteritis, or where samples
can be collected soon after vomiting. The findings of this study do not match the successful
detection of norovirus in the family outbreak described in section 2.11. The reasonsfor this
are unclear, but may include:
e Different study populations; in the hospital study participants were predominately
elderly, and all with other co-morbidities. This may have resulted in an impaired
ability to produce samples with an equivalent quantity of norovirus RNAto
participants in the family study.
e The samples in this study were collected at different times throughout the day. In the
family outbreak they were collected early in the morning. There may be human
characteristics which cause the oral cavity to collect norovirus RNAearly in the
morning. A possible cause could be nocturnal subclinical aspiration of gastric
contents. This would require further work to confirm.
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The virus wasdifferent, in this study it was a GII.4 virus, in the family outbreak study
it was a GII.3 virus. There is no obviousbiological process that supportsthis
affecting the detection of norovirusin the oral cavity.
Hospitalised patients were supplied with drinking water whenthey had gastroenteritis.
This regular provision of drinking of water may haveled to decontamination ofthe
oral cavity.
The detection of norovirus in faeces may haverepresented clinical false positives
(asymptomatic norovirus shedding). This may haveresulted in underestimating the
sensitivity of the oral detection of norovirus.
The detection of norovirus in this study wasinversely associated with the duration of
vomiting (p = 0.03) and diarrhoea (p = 0.046) at sampling. It was associated with the
presence of vomiting (p = 0.1) and inversely associated with the time since the last vomit (p =
0.006) and diarrhoea (p = 0.008).
2.6 Limitations
The sample size wasnot reached; this reduced the precision of the estimate of the
diagnostic accuracyofthe test.
The difference in the sensitivity of oral samples to diagnose norovirus infection
between the family outbreak and hospital study wasnot resolved.
It was not possibleto assign a duration of diarrhoea/vomiting in those patients without
these symptoms. This mayhaveaffected the estimates these symptomshad on the
sensitivity of the oral detection of norovirus.
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2.7 Further work
The current diagnosis of norovirus requires the use of a faecal sample. Further studies should
investigate diagnostic methods which do not require these samples which canbedifficult to
collect. Possible strategies could be to devise clinical criteria for the diagnosis of hospital
outbreaks of norovirus infection. These criteria would be analogousto the Kaplancriteria
used in community outbreaks of gastroenteritis (Kaplan et al. 1982). Another strategy could
be swabbing of vomit/faecal samples which were notcollectable in pots.
2.8 Conclusions
Oral samplingis unlikely to reliably allow a correct diagnosis of norovirus to be made in
nosocomial outbreaks of gastroenteritis. New approachesarestill required to improve the
rapid diagnosis of norovirus infection which do notrely on the collection of faecal samples.
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CHAPTER3
An evaluation of the diagnostic accuracy of the 3" generation
RIDASCREENnorovirus ELISA and the RIDAQUICK
immunochromatographic norovirustest, including a comparison of both to
the second generation IDEIA norovirus ELISA.
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3.1 Introduction
Gastroenteritis causes significant morbidity and mortality in children in the developing
world (Bryceet al. 2005). Viruses includingrotavirus, astrovirus, adenovirus 40/41,
sapovirus and norovirus accountfor a large proportion of this disease burden (Al-Mashhadani
et al. 2008; Bucardoet al. 2008; Koopmans 2008). Norovirus, as a cause of gastroenteritis,
was discovered in 1972, but its role in paediatric gastroenteritis has only recently begun to be
appreciated. To more fully understand the contribution of norovirus to childhood mortality
and morbidity requires detailed clinical and epidemiological studies. An integral component
of such studies is the diagnostic tests used, with the current gold standard diagnostic
technique for norovirus being PCR. Given norovirusis excreted for a prolonged period of
time, as detected by PCR, following symptomatic infection (approximately 4 weeks), some
investigators consider that PCR based diagnostics are too sensitive and unableto distinguish
current from past infection (Gallimoreet al. 2004; Atmaret al. 2008; Phillips et al. 2009).
This diagnostic challengeis also seen in rotavirus gastroenteritis, where ELISAbasedtesting
is used to diagnoseinfection (Phillips et al. 2009). Diagnosis of norovirusinfection is also
madedifficult by the high degree of genetic variation seen in norovirus. Norovirusis a single-
stranded RNAvirus and possesses two genogroups which are associated with human
infection, genogroup I and II (GI and GII). Within these genogroupsare over 30 genotypes
(Greenet al. 2000). This genetic variation makes diagnosis of norovirus difficult. ELISAs for
the diagnosis of norovirus, previously evaluated in the literature, have proven to have
moderate analytical sensitivity for the detection of norovirus GII.4 strain, the most common
genotype (approximately 66% (Grayet al. 2007)). Their sensitivity has been less for non
GII.4 strains (Grayet al. 2007). Two new immunological tests have recently become
available for the detection of norovirus. One is an ELISA-based assay, and another an
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immunochromatographic (ICG) test. These tests have been developed with the aim of being
more sensitive than current immunological norovirus tests. The ICG test should also allow
morerapid diagnosis of norovirus. This would be particularly useful as it may facilitate
studies which would rely on rapid diagnosis of norovirus, e.g. studies into the treatment of
norovirus infection in children attending hospital with gastroenteritis. An evaluation ofthe
new norovirus ELISA (RIDASCREEN®3" generation norovirus ELISA, R-Biopharm,
Darmstadt, Germany) and the new norovirus ICG test (RIDAQUICK®norovirus ICGtest,
R-Biopharm) was therefore undertaken. These two assays were compared to a PCRbasedtest
to estimate their diagnostic accuracy. In addition, the tests underwent a head to head
comparison to the ELISAtest that had the best sensitivity in published evaluations, the
IDEIA™ ELISA (Oxoid, Ely, United Kingdom). The results are used to assess how useful
the tests are, both for diagnosis of norovirus and for undertaking epidemiological surveys for
norovirus.
3.1.1 Backgroundto norovirus immunologicaltesting
Norovirus remains a non-culturable virus (Duizeret al. 2004). Despite one publication
reporting successful culture of norovirus using a physiologically relevant 3-dimensional,
organoid model of human small intestinal epithelium (Straubet al. 2007), this has not been
repeated in other laboratories (personal communication: Koopmans, M. Department of
Virology, Erasmus Medical Centre, Rotterdam, The Netherlands). ELISA based diagnostics
for norovirus were therefore difficult to produce until a Baculovirus expression system was
developedto allow the production of norovirus antigens (Jiang et al. 1992). The Baculovirus
expression system is based on the introduction of a foreign gene into a region ofthe viral
genomethat is nonessential for viral replication. This is carried out using a transfer vector
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containing the target gene. The resulting recombinant Baculovirus encoding the introduced
protein gene can be expressedin cultured insect cells. Using the noroviruslike particles that
were produced bythis system, which had antigenic properties similar to norovirus,
monoclonal antibodies (MAbs) and polyclonal antibodies were produced which could be
used in diagnostic ELISAs. Evaluationsofthe first norovirus ELISAswerefirst published in
2002. There were two ELISAsproducedat this time; the SRSV (II)-AD kit, (Denka Seiken
Co. Ltd. Tokyo, Japan), and the IDEIA NLVkit, (DakoCytomation Ltd. Ely, United
Kingdom)(Uchinoet al. 2002; Yamagamiet al. 2002; Richardset al. 2003). Both kits used
MAbswith the ability to bind to genogroup I and II noroviruses. The Denka kit was reported
to have a sensitivity and specificity of 68% and 76 % respectively (Uchinoetal. 2002;
Yamagamiet al. 2002). The Dako kit reported a sensitivity and specificity of 56% and 98%,
respectively (Richardset al. 2003). More recently, two different norovirus ELISAs became
commercially available: The second generation RIDASCREENELISAandthe second
generation IDEIA ELISA (Schmidet al. 2004). These ELISAs were repeatedly evaluated but
publications reported variable sensitivities and specificities (de Bruin et al. 2006; Okitsu-
Negishi et al. 2006; Castriciano et al. 2007; Wilhelmi de Cal et al. 2007). This may have been
attributable to either differing samples being tested or differing reference standards. This led
to a multicentre evaluation of the RIDASCREEN ELISAand the IDEIA ELISA in 2007
(Gray et al. 2007). This is the most definitive evaluation to date of norovirus ELISAsandis
therefore now presented in detail. The study consisted of six European centres’ that evaluated
the ELISAs in comparisonto eachinstitutions established PCRtest. The sensitivities and
specificities of the IDEIA ELISA were 58.9% and 93.9%, and for the RIDASCREEN ELISA
were 43.8% and 96.4% respectively (Table 3.01). This evaluation also carried out a further
analysis on a sub selection of samples which gave false positive samples by ELISA. This
further analysis was conducted on samples in which a non norovirus gastrointestinal pathogen
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wasidentified. Of the ten false positive reactions investigated seven were confirmed positive
for norovirus by a secondary PCR whichused a different primerset (Table 3.02). This
suggests the analytical specificities reported in the study by Grayetal, although already high
(88-97%), were underestimates. There wasalso variation betweenthe assays in termsof the
genotypes that were detected. Where there wasa statistical difference in the sensitivity for a
specific genotype, the IDEIA ELISA wasalways moresensitive. A statistical difference was
seen for genotypes GI.2/6 and GII.1/3/7 (Table 3.03).
Table 3.01: Sensitivities and specificities of the IDEIA norovirus and RIDASCREEN
norovirus ELISAs compared with RT-PCR in a European multicentre evaluation (Grayetal.
 
  
2007).
IDEIA Norovirus RIDASCREEN Norovirus
Country No.of Sensitivity 95% Cl Specificity 95% Cl Sensitivity 95% Cl Specificity 95% Cl
samples (%) (%) (%) (%)
France 320 61 55-68 94 87-97 40 34-47 95.96 90-98
Germany 97 67 54-77 90 75-97 37 26-49 83.33 66-93
Italy 461 47 41-53 88 83-92 42 36-48 96.90 94-98
The 414 67 62-73 93 87-96 36 31-42 92.00 87-95
Netherlands
Spain 425 76 69-82 98 95-99 70 62-76 99.20 97-100
United 474 45 39-51 97 93-98 40 34-46 97.61 95-99
Kingdom
All 2,191 59 56-62 94 92-95 44 41-47 96.37 95-97         
Table reproduced from Grayef al (Grayet al. 2007)
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TABLE3.02: Nonspecific reactivity detected with the norovirus EIAsand results of RT-PCR
tests to confirm the presence of norovirus from the norovirus ELISA evaluation by Grayef al
 
 
2007.
No. of samples
Organism = ; :
Positive for organism Positive by IDEIA EIA Positive by RIDASCREEN Confirmed positive by
EIA PCR
Astrovirus 28 1 0 1
C. difficile 18 1 0 0
Enteric adenovirus 22 2 0 1
Rotavirus 61 2 1 2
Sapovirus 15 3 0 3    
Table reproduced from Grayet al (Grayet al. 2007).
Table 3.03: Strain specific sensitivities of the IDEIA norovirus and RIDASCREENnorovirus
ELISAs compared with RT-PCRin a European multicentre evaluation (Gray et al. 2007).
 
  
Geno- No.of IDEIA Norovirus RIDASCREEN Norovirus P value
group positive
samples
No. (%) of samples in which 95% Cl No. (%) of samples in which 95% Cl
genotype wasdetected genotype wasdetected
Gl-1 5 4 (80.00) 37.55-96.36 3 (60.00) 23.1-88.24 0.49
Gl-2 13 11 (84.62) 57.77-95.67 2 (15.38) 4.33-42.23 0.0002
GI-3 28 12 (42.86) 26.51-60.93 9 (32.14) 17.9-50.66 0.4
GI-4 2 2 (100.00) 34.24-100.0 0 (0.00) 0.00-65.76 0.3
GI-5 8 3 (37.50) 13.68-69.43 0 (0.00) 0.00-32.44 0.2
GI-6 7 5 (71.43) 35.89-91.78 0 (0.00) 0.00-35.43 0.02
GI-7 1 0 (0.00) 0.00-79.35 0 (0.00) 0.00-79.35 >0.5
Gll-1 8 7 (87.50) 52.91-97.76 0 (0.00) 0.00-32.44 0.0024
Gil-2 16 8 (50.00) 28.00-72.00 4 (25.00) 10.2-49.50 0.2
GIl-3 52 30 (57.69) 44.19-70.13 11 (21.15) 12.2-34.03 0.0003
GIl-4 301 203 (67.44) 61.96-72.49 186 (61.79) 56.2-67.10 0.17
GII-5 6 2 (33.33) 9.68-70.00 1 (16.67) 3.01-56.35 >0.5
GIl-6 9 2 (22.22) 6.32-54.74 0 (0.00) 0.00-29.91 0.4
GIl-7 29 20 (68.97) 50.77-82.72 5 (17.24) 7.60-34.55 0.002
GIl-8 1 0 (0.00) 0.00-79.35 0 (0.00) 0.00-79.35 >0.5
GIV-1 4 0 (0.00) 0.00-48.99 0 (0.00) 0.00-48.99 >0.5       
Table reproduced from Grayet al (Gray et al. 2007)
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The RIDASCREENELISAhasbeen replaced by a third generation ELISA which is now
commercially available. No peer reviewed publications using this ELISA have been
identified, and available information on its performanceis provided by the manufacturer, R-
Biopharm, whoreport a sensitivity of 83% and a specificity of 100%. This is based on a
retrospective assessment of 183 samples collected during a norovirus season (2004/2005)
with 100 samples positive for norovirus by RT-PCRand 83 negative by RT-PCR.
immunochromatographictesting is an alternative to ELISA testing, and is based on similar
antigen-antibody interactions. Thefirst publication describing the development of an ICG test
for norovirus was in 2003 (Okameetal. 2003). The evaluations conducted since are shown
below (Table 3.04). These ICG tests were produced for the detection of GII.3/4 norovirus
(NV IC-1 Stick Kit and Takanashi Kit) and GI/GII norovirus (Quick Ex-Norovirus Kit).
Table 3.04: Comparison of rapid immunological tests for norovirus (Mutohet al. 2009).
 
 
Sensitivity (%) Specificity (%) Study/No. of samples
ICG kits
NV IC-1 Stick kit (Immuno-Probe, Saitama, Japan) 73.7 100 (Nguyenet al. 2007) /n=14
NV IC-1 Stick kit (Immuno-Probe, Saitama, Japan) 78.9 96.4 (Khamrin et al. 2008)/
n=100
Quick Ex-Norovirus kit (Denka Seiken, Tokyo, Japan) 73.6 98.9 Manufacturer
Quick Ex-Norovirus kit (Denka Seiken, Tokyo, Japan) 54.5 93 Mutoheta/ (Mutohet al.
2009)/ n=26
Kit by Takanashiet al. 69.8 93.7 Takanashi (Takanashi etal.
2008) /n=43     
Table reproduced from Mutoh et al (Mutohetal. 2009)
Morerecently the RIDAQUICKnorovirus ICG test has become commercially available. This
contains both G1 and G2 antibodies used as capture antibodies and are the same antibodies
used in the RIDASCREENnorovirus ELISA.Sensitivities and specificities reported by the
manufacturer of RIDAQUICKare 86% and 100% respectfully. This reported sensitivity is
comparable to, and in fact slightly higher than, the RIDASCREEN ELISA.
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3.1.2 Standards for Reporting of Diagnostic Accuracycriteria
The STARDcriteria (Chapter 2, 2.1.2) for the reporting of investigations into diagnostic
accuracy are followedin the reporting this study (Table 3.05).
3.1.3 ACCEcriteria for evaluating diagnostic tests
This study will assess how useful the tests are for diagnosis of norovirus and for undertaking
epidemiological surveys for norovirus. The diagnostic assessment should not be madesolely
on its diagnostic accuracy but should be madein termsof the tests clinicalutility. For
example, a diagnostic test with perfect analytical sensitivity and specificity but with no
clinical utility would be of limited clinical use. The importanceoftheclinical utility of a test
is being increasingly recognised and is now anarea targeted by a specific funding category
offered by the National Institute of Health Research in the UK (NIHR UK:Health
Technology Assessment programme: Diagnostic tests and test technologies). One structured
formatofassessing a test’s overall value is by following a framework called ACCE. This
assessestests in terms oftheir Analytic validity, Clinical Validity, Clinical Utility, and Ethical
aspects. Thesecriteria were developed by geneticists keen to rigorously evaluate new genetic
tests. As such they werenotspecific for microbiological tests. These criteria have therefore
been adaptedfor this dissertation (Table 3.06) to allow an evaluation of microbiologicaltests.
Thesecriteria are used to ensure the discussion covers the important points of the diagnostic
tests. The full ACCEreview ofthe evaluated tests is presented in the appendix.
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Table 3.06: ACCEcriteria for the evaluation of a diagnostictest.
Disorder/
Assay
Analytic
Validity
Clinical
Validity
Clinical
Utility
ELSI  
Is an infectious organism, or a specific condition caused by an unknowninfectious organism, being investigated?
Whatis the infectious organism or condition being studied?
Whatis the history,clinical findings and prognosesof this disease?
Whatis the clinical and molecular epidemiology of this disease? Are there public health/political implications?
Whattherapyis available? Is empirical therapy available? Whataretheside effects of therapy?
Whatis the clinical setting in which the testis to be performed?
Whatmicrobiological assays / non microbiological investigations are associated with this disorder? Which are you
evaluating?
Howlong doesthe assay take? How doesthis relate to the time courseof the infection and other diagnostic assays?
Whattime periodin relation toan illness is the test relevant to?
Are the assays used for screening/diagnostic purposes? Are the assays useful to rule in/rule out a condition?
Is the assay completed within the same assay as others? Is the assay completed at the sametime as other assays
(parallel) or on the basis of other results (series)? Doesthe result lead to further assays/investigations being
completed?
Whatis the laboratory setting in which the assay is to be performed?
Are there developmentsvisible in the future (diagnostic, therapeutic or preventativeO that will affect the durability of
the implications of the ACCE assessment? Is an ACCE analysis for this test a priority?
Using the information obtained by answering the above define the clinical care pathwaythis assayfits into.
Is the assay qualitative or quantitative?
Howoftenis the test positive/negative whentheinfectious organism is present (analytic sensitivity) / absent
(analytic specificity)?
Is an internal quality control program defined and externally monitored?
Have repeated measurements been madeonspecimens(e.g. positive/negative controls)?
Whatis the within- and between-laboratory precision?
If appropriate, how is confirmatory testing performedto resolvefalse positive results, how long doesthis take?
What range/quality of patient specimens has been tested?
Howoften doesthetestfail to give a useable result?
Howsimilar are results obtained in multiple laboratories using the same,or different technology?
How oftenis the test positive/negative whentheinfectious disease is present (clinical sensitivity) / absent(clinical
specificity)?
Whatis the prevalence of the disorderin this setting? Whatare the positive and negative predictive values?
Are there methodsto resolveclinical false positive results in a timely manner?
Has the test been adequately validated onall populations to which it may be offered?
Whatarethe relationship between presence of organism anddisease(e.g. colonisers/obligate pathogens)?
Whataffects the relationship between organism anddisease(e.g. immunosuppression, prosthetic material)?
Whatis the impactof a positive (or negative) test on patient care?
Whatis the impact on the prevention of spread of infection?
Is there an effective treatment or other measurable benefit? Is there general access to that treatmentor benefit?
Is the test being offered to a socially vulnerable population?
Whatquality assurance measuresarein place?
Whathealthrisks can be identified for the intervention?
Whatare the economiccosts associated with testing and whatare the economic benefits resulting from testing?
Whatare theresults of pilot trials?
Whatfacilities/personnelare available or easily put in place?
Are there informed consent requirements?
What methodsexist for long term monitoring?
Whatguidelines have been developedfor evaluating clinical care pathway performance?
Whatis known abouttransmission ofinfection, stigmatization, discrimination, confidentiality and personal/family
social issues?
Are there legal issues regarding consent, ownership of data and/or samples, patents, licensing, proprietarytesting,
obligationto disclose, or reporting requirements?
What safeguards have been described and are these safeguardsin place and effective?
Table adapted from Haddow JE and Palomaki GE (Haddow and Palomaki 2004).
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3.1.4 STARDcriteria reference table
This chapter presents the results of a study whichis an evaluation of a diagnostictest.
Evaluating diagnostic tests and subsequently publishing the tests characteristics is undertaken
so others may makedecisions aboutthe clinicalutility of that test. For others to make a
decision about test’s clinical utility, they need complete information about the evaluation
e.g. severity of disease and demographicsofpatients tested. A review in 1995 (Reid et al.
1995) of the reporting of evaluations of diagnostic tests found significant deficiencies. This
led to the developmentofcriteria for the evaluation of diagnostic tests, the Standards for
Reporting of Diagnostic Accuracy criteria (STARDcriteria), to be produced by the Cochrane
Diagnostic and Screening Test Methods Working Group (Bossuyt et al. 2003). The STARD
criteria are a checklist that it is recommended should be used in publishing the evaluation of
diagnostictests.
Presentation of the test evaluation according to the STARDcriteria
The STARDcriteria allow an evaluation of a diagnostic test to be presented in a clear and
accessible format. Therefore, this chapter is presented in the formatdictated by the STARD
criteria. The table with the STARTDcriteria (Table 3.05) allows the evaluation to be
navigated easily and presentation of the evaluation in accordance withthe criteria ensures
details of the study are comprehensively presented.
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Table 3.05: STARDcriteria reference: Evaluation ofthe diagnostic accuracy ofthe 3“
generation RIDASCREENand RIDAQUICKnorovirustests.
 
 
 
  
Section and Topic Item Section
TITLE/ABSTRACT/ 1 Identify the article as a study of diagnostic accuracy (recommend MeSH heading‘sensitivity 3.2
KEYWORDS and specificity’).
INTRODUCTION 2 State the research questions or study aims, such as estimating diagnostic accuracy or 3.2.1,
comparing accuracy betweentests or across participant groups.
METHODS 3.3
Participants 3 The study population: The inclusion and exclusion criteria, setting and locations where data 3.3.1.1
werecollected.
4 Participant recruitment: Was recruitment based on presenting symptoms, results from 3.3.11
previoustests, or the fact that the participants had received the index tests or the reference
standard?
5 Participant sampling: Wasthe study population a consecutiveseries of participants defined 3.3.1.1
by the selection criteria in item 3 and 4?If not, specify how participants were further
selected.
6 Data collection: Wasdata collection planned before the index test and reference standard 3.3.1.1
were performed (prospective study)or after (retrospective study)?
Test methods 7 The reference standard andits rationale. 3.3.2
8 Technical specifications of material and methodsinvolved including how and when 3.3.2.1/2/3
measurements weretaken, and/orcite referencesfor index tests and reference standard.
9 Definition of and rationale for the units, cut-offs and/or categories of the results of the 3.3.2.4
index tests and the reference standard.
10 The number,training and expertise of the persons executing and reading the index tests 3.3.2:5
and the reference standard.
11 Whetheror not the readersof the index tests and reference standard wereblind (masked) 3.3.2.6
to the results of the other test and describe any other clinical information available to the
readers.
Statistical methods 12 Methodsforcalculating or comparing measuresof diagnostic accuracy, and the statistical 3.3.3
methodsused to quantify uncertainty (e.g. 95% confidenceintervals).
13 Methodsforcalculating test reproducibility, if done. 3.3.3
RESULTS 3.4
Participants 14 Whenstudy wasperformed,including beginning and end datesof recruitment. 3.4.1.1
15 Clinical and demographic characteristics of the study population (at least information on 3.4.1.2
age, gender, spectrum of presenting symptoms).
16 The numberof participantssatisfying the criteria for inclusion who did or did not undergo 3.4.1.3
the index tests and/or the reference standard; describe whyparticipants failed to undergo
either test (a flow diagram is strongly recommended).
Test results 17 Timeinterval between samplescollected for testing 3.4.2.1
18 Distribution of severity of disease (define criteria) in those with the target condition; other 34.2.2
diagnosesin participants without the target condition.
19 A cross tabulation of the results of the indextests (including indeterminate and missing 3.4.2.3
results) by the results of the reference standard; for continuousresults, the distribution of
the test results by the results of the reference standard.
20 Any adverse events from performingthe indextests or the reference standard. 3.4.2.4
Estimates 21 Estimates of diagnostic accuracy and measuresofstatistical uncertainty (e.g. 95% 3.4.3.1
confidenceintervals).
22 How indeterminate results, missing data and outliers of the index tests were handled. 3.4.3.2
23 Estimates ofvariability of diagnostic accuracy between subgroupsof participants, readers or 3.4.3.3
centers, if done.
24 Estimates of test reproducibility, if done. 3.4.3.4
DISCUSSION 25 Discusstheclinical applicability of the study findings. 3.5   
Table reproduced from Bossuyt et a/ (Bossuyt et al. 2003)
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Den Title /Abstract/Keywords
Title
An evaluation of the diagnostic accuracy ofthe 3% generation RIDASCREENnorovirus
ELISA and the RIDAQUICK immunochromatographic norovirustest including a comparison
of both to the second generation IDEIA norovirus ELISA.
Abstract
The laboratory diagnosis of norovirus infection allows the appropriate managementof
norovirus outbreaks and norovirus infected patients.It also allows the undertaking of studies
into the clinical and molecular epidemiology of norovirus. Two new commercial diagnostic
tests have becomeavailable for the diagnosis of norovirus infection. These are the
RIDASCREENELISA and RIDAQUICK immunochromatographictest. These tests were
evaluated on a collection of samples from children with acute gastroenteritis in Brazil, 96
with norovirus and 116 without norovirusin their faeces by PCR. Of the 96 norovirus
positive samples, 66 were from children hospitalised with gastroenteritis and 30 from
community based cases of gastroenteritis. The RIDASCREEN ELISAwas found to have a
sensitivity of 90% at 80% specificity, in children admitted to hospital with gastroenteritis.
This makesit suitable for the testing of samples for norovirus in hospital based
epidemiological studies prior to molecular analysis. The RIDASCREEN ELISA and
RIDAQUICK immunochromatographic tests, compared to a PCRtest, are 70 and 79%
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sensitive respectively for the detection of norovirus in children hospitalised with
gastroenteritis, both with 100% specificity.
Keywords
Norovirus; ELISA; Chromogenic; Test; Sensitivity; Specificity
3.2.1 Aims
To estimate the diagnostic accuracy of the IDEIA norovirus 2 generation ELISA
(Oxoid), with PCR based norovirus detection as the gold standardtest.
To estimate the diagnostic accuracy of the RIDASCREEN 3" generation norovirus
ELISA (R-Biopharm), with PCR based norovirustesting as the gold standardtest.
To estimate the diagnostic accuracy of the RIDAQUICKnorovirus ICGtest (R-
Biopharm), with PCR based norovirustesting as the gold standardtest.
To comparethe diagnostic accuracy of the RIDASCREENand RIDAQUICKtests to
the ELISAtest that has the best sensitivity in published evaluations, the IDEIA
norovirus ELISA (Oxoid).
To consider theclinical utility and epidemiological surveyutility of the
RIDASCREEN3”generation norovirus ELISA, IDEIA ELISA and the RIDAQUICK
norovirus immunochromatographictest based on their analytical and diagnostic
accuracy.
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3.3 METHODS
Saul, PARTICIPANTS
3.3.1.1 Study population & 3.3.1.2 Participant recruitment & 3.3.1.3 Participant
sampling
Investigators at the Liverpool School of Tropical Medicine, UK (Dr L Cuevas) and the Federal
University of Sergipe, Brazil (Dr R Gurgel) undertook a study ofviral gastroenteritis in
Brazilian children. The aim ofthis study wasprincipally to monitor the epidemiology of
rotavirus infection following the introduction of rotavirus vaccination. The study ran from
October 2006 to September 2009, although only samples from October 2006 to December 2007
were used for the study presented in this chapter. This led to faecal samples being collected
from two paediatric cohorts. The cohorts were separated into children presenting to hospital
and children in the community. The hospital group comprised children with diarrhoea of <7
days duration, samples were collected consecutively over 4 days each week. The hospitals
attended were Jodo Alves Hospital and Hospital Municipal da Zona Norte, Aracaju, Brazil.
Data wascollected prospectively by medicalstaff at the time ofhospital admission. The
community based cohort consisted of children <5 years old in Santa Maria District, Aracaju, an
area with low cost houses and someadditional un-planned houses. Samples were collected by
parents andtakento a local health centre. Data was collected prospectively by community
based nursingstaff visiting the homes of symptomatic children on an ongoing basis.
Inclusion criteria: Meeting the description of the community or hospital criteria as described
above.
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Exclusion criteria: Children were excluded if they were non-permanent residents, homeless,
with major congenital anomalies or without a legal guardian orparent.
Ethics: Ethical approval was granted by the Liverpool School of Tropical Medicine Research
Ethics Committee, the Ethical Committee of the Federal University of Sergipe and Brazil's
National Ethics Committee (CONEP) (see Appendix).
3.3.1.4 Datacollection
Samples and data collected from study participants was collected prospectively.
3.3.2 Test methods
Processing pathwayof faecal samples
After samples were collected they were stored at -70°C in Brazil. They were sent to the UK
on ice where they werestored at -70°C. Samples were defrosted to make 10% faecal
suspensions in PBS which werestored at -70°C being defrosted once before testing by
norovirus PCR.A selection of the original samples, based on their PCR result, were then
defrosted and madeinto suspensionsin the recommendeddiluents, to allow ELISA/ICG
testing to be performed. ELISA/ICGtesting wascarried out on the same dayas the
ELISA/ICG suspensions were made.
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3.3.21 TESTS UNDER EVALUATION
3.3.2.1.1 IDEIA norovirus ELISA (Oxoid, ThermoFisher Scientific, Basingstoke,
UK).
IDEIA norovirus ELISA:Principle of test
Microwells in a microtitre plate are coated with antibodies against norovirus antigens. A
faecal suspension is mixed with monoclonal and polyclonal anti-norovirus antibodies which
are conjugated to horseradish peroxidase. These are added to the microwells and sandwich
the viral antigens to the surface of the microwells during an incubation step. After non
sandwiched sample/reagents are washed out from the well, a chromogenis added to the
microwells and incubated. The reaction is then stopped and the changein colouris detected
by a spectrometer and a result derived based on the value of the negative control.
IDEIA norovirus ELISA: Test procedure
Preparation: All reagents and the microwell plate were brought to room temperature (20—
25°C) before use, following storage at 2-8°C. The microwell strips were not removed from
their aluminium storage bag until they reached room temperature. The reagents were
thoroughly mixed immediately before use. Wash buffer was prepared to a working
concentration. Samples were prepared by diluting 100uI ofliquid stool or 50-100mg ofsolid
stool into 1ml ofsample dilution buffer. Samples were homogenised by mixing with a vortex,
then left to stand for 10 minutes and the supernatantused in the test described below.
The test: Samples were pipetted into the microwells as well as a negative control (sample
dilution buffer) and a positive control (100y1). 100y1 of peroxidase labeled monoclonal and
polyclonal antibodies were added to each well and mixed by gentle tappingofthe side of the
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microtitre plate. The microtitre plates were then left at 20-25°C for 1 hour. The wells were
then washed by emptying the wells with the plate being knocked onto absorbent paper to
removeresidual moisture. Five washes were then carried out for each microwell. This
involved adding 3501 of wash buffer to each well followed by knocking plates onto
absorbent paper to removeresidual moisture. After the wash 1001 of chromogen was added
to each well and incubation at 20-25°C for 30 minutes followed. After this, 100of stop
reagent was added to each well. The samples absorbance wasthen read with a microtitre plate
reader (FLUOstar Omega, BMG LABTECH,Aylesbury, UK) at 450nm with blank
correction.
Quality control: Positive and negative controls were used with each batch of samples. The
test results were accepted if the optical density (O.D.) for the negative control wasless than
0.15 at 450nm andthepositive control is greater than 0.5 at 450nm. The IDEIA noroviruskit
lot numbersusedin this study wereall lot no 773832.
3.3.2.1.2 RIDASCREENnorovirus ELISA (R-Biopharm, Darmstadt, Germany).
RIDASCREENnorovirus ELISA:Principle of test
Microwells in a microtitre plate are coated with antibodies against norovirus antigens. A
faecal suspension is mixed with a biotinylated monoclonalanti-norovirusantibody. These are
added to the microwells and sandwichthe viral antigens to the surface of the microwells
during an incubation step. After non sandwiched sample/reagents are washed out from the
well a conjugate, streptavidin peroxidase, is added to the microwell. Incubation,to allow
binding of the streptavidin peroxidase to the biotinylated monoclonal anti-norovirus
antibodies follows. Unattached streptavidin peroxidase conjugate is removed during a further
washing phase. A chromogenis then added which the streptavidin peroxidase acts upon. The
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reaction 1s then stopped after a further incubation using a stop solution. The change in colour
is then detected by a spectrometer anda result derived based on the value of the negative
control.
RIDASCREENnorovirus ELISA:Principle of test
Preparation:all reagents and the microwell plate were brought to room temperature
(20-25°C) before use, following storageat 2-8°C. The microwell strips were not removed
from their aluminium storage bag until they reached room temperature. The reagents were
thoroughly mixed immediately before use. Wash buffer was prepared to a working
concentration. Samples were prepared by diluting 100u1 of liquid stool or 50-100mgofsolid
stool into 1ml of sample dilution buffer. Samples were homogenised by mixing with a vortex.
Samples wereleft to stand for 10 minutes and the supernatant used in the test described
below.
Thetest: Samples, a negative control (sample dilution buffer) and a positive control (1001)
were pipetted into microwells. 100p1 of biotin-conjugated antibody was addedand the
resulting mixture mixed by gentle tapping ofthe side of the microtitre plate. Incubationat
room temperature (20 — 25 °C) for 60 minutes followed before the microwells were washed.
Firstly, the contents of the wells were emptied with the plates being knocked onto absorbent
paper to removeresidual moisture. Five washes were then carried out for each microwell
involving addition of 300ul of wash buffer. After the wash, 100y1 ofthe streptavidin-
peroxidase conjugate was added to the wells and incubated at room temperature (20 — 25 °C)
for 30 minutes. Five washes were again completed followed by 100yl of substrate being
added to each well. The plate was then incubated at room temperature (20 - 25 °C) for 15
minutesin the dark. After this, 501 of stop reagent was added to each well. The samples
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absorbancewasthen read with a FLUOstar Omegamicrotitre plate reader read at 450nm,
with blank correction.
Quality control: Positive and negative controls were used with each batch of samples. The
test results were accepted if the O.D. for the negative control wasless than 0.2 at 450nm and
the positive control greater than 0.5 at 450nm. The RIDASCREENnorovirus lot numbers
used in this study wereall lot no. 02069.
3.3.2.1. 3 RIDAQUICKnorovirus immunochromatographictest (R-Biopharm,
Darmstadt, Germany).
RIDAQUICKnorovirus immunochromatographictest: Principle of test
A membraneprovidesthe surface for the test to take place on, as opposed to a microwell in
an ELISA test. The membranehasa test section and control section, see Figure 3.1. The test
section has anti-norovirus antibodies and the control section contains anti-mouse IgG
antibodies. A sample supernatant is mixed with biotinylated antibodies against norovirus
antigens. This mixture is then added to the membrane which,if it contains norovirus antigens,
maybind to the immobilised anti-norovirus antibodies. The biotinylated antibodies, present
in excess, with no antigens boundwill bind to the controlline. Streptavidin with horseradish
peroxidise attached is then added whichwill bind to the biotinylated antibodies. The non-
bonded peroxidase is removed by adding Wash bufferto the reaction window. A chromogen
is then added to detect bound peroxidaseas an indicatorof the presence of norovirus antigen
in the sample.
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RIDAQUICKnorovirus immunochromatographic test: Test procedure
Preparation: All reagents, and the microwell plates, were brought to room temperature
(20-25 °C) before use, following storage at 2-8°C. The RIDAQUICKtest cartridges were not
removed from their aluminium storage bag until they reached room temperature. The
reagents were thoroughly mixed immediately before use. Samples were prepared by diluting
100y1 ofliquid stool or 50-100mgofsolid stool into I1ml of sample dilution buffer. Samples
were homogenised by mixing with a vortex andleft to stand for 2 minutes, with the
supernatant used in the test as described below.
Thetest: The test cassette was laid on flat surface. 250y1 of stool suspension supernatant
was mixed with 6 dropsofbiotinylated antibodies against norovirus antigens. The mixture
was addedto the sample test well, horizontal to T label (Figure 4.1), at 45° with the point of
the pipette used aimed towards the reaction window.After 10 minutes streptavidin with
horseradish peroxidise was addedto the reaction window. After 1 minute, 10 drops of wash
buffer were added followed by 6 drops of the chromogen. Thereaction result was read within
3 minutes.
Quality control: A blue line was required to be visible in the control section (C) ofthe test
for the test result to be valid. The blue control band confirmsthat the sample and the reagents
have been added correctly, the reagents were active when the test was carried out and the
sample has migrated properly through the test membrane. A colourless background in the
result zone (reaction window)acts as an internal negative control. The RIDAQUICK
norovirustest lot numbers used were lot no. 02408, 03049, 03448 and 05139.
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 Figure 3.1: The norovirus RIDAQUICKICGtest. Visual reading of the blue control (C) and
test (T) line givesa result.
3.3.2.2 Gold standardtests
Polymerase chain reaction (PCR)tests. Real time and qualitative reverse transcriptase PCR
(RT-PCR) were combinedto form the gold standard test, they are now described.
Principle of test: Qualitative RT-PCR consists of the following stages. RNA extraction: RNA
is extracted from the clinical samples to provide an RNA template for reverse transcription.
RNAis reverse transcribed using a reverse transcription enzyme providing cDNA for the PCR
step. PCR: cDNAis amplified using a DNA polymerase reaction to provide a product of a
specific size. The size of the product is dependent upon the primers used. Agarose gel
electrophoresis: The product produced by the PCR is stained with ethidium bromide and
separated on an agarose gel. The product is visualised andthe size of the product is confirmed
as being compatible with that expected by comparison to a positive control and a molecular
weight ladder. In real time RT-PCR a probe with the potential to fluoresce is included in the
PCR reaction mixture. This binds specifically to cDNA until cDNA is replicated by DNA
polymerase. DNA polymerase removes the probe which will then fluoresce. The fluorescence
detected is proportionalto the specific replication of the norovirus cDNA.
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3.3.2.2.1 Real time RT-PCR
Real time RT-PCR:Test procedure
Preparation: see section 2.3.2.1
The test: RNA extraction and reversetranscription: see section 2.3.2.1.
Real time PCR: the PCR mixture wasprepared containing:
Sensimix (Quantace, London, UK) 12.5ul
HPLC water 6.375 ul
10M primers ul
(Primers = COGIF and COGIR (GI), or COG2F and COG2R (GII) (Operon, Leeds, UK))
20uM Probe 0.125u1
(Probe = Ring 1AB/TP(GJ) or Ring 2 AB/TB (GII) (Operon))
cDNA 5uL was addedto this mix before PCR wascarried out underthe following
conditions: 50°C for 2 minutes, 95°C for 10 minutes, then 40 cycles of 95°C (denaturation)
for 15 seconds and 56°C (annealing) for 1 minute. GI PCR was undertaken on the Light
cycler (Roche 480) and the GII on the Rotagene 6200-HRM (QIAGEN). Different machines
were used to allow more rapid processing of samples.
All primers and probes have been previously published. They were purchased at 50nmole and
HPLCpurified, the sequences of which were (Kageyamaet al. 2003);
Primers:
COG1-F CGYTGGATGCGNTTYCATGA(forward primer)
COG1-R CTTAGACGCCATCATCATTYAC(reverse primer)
COG2-F CARGARBCNATGTTYAGRTGGATGAG(forward primer)
COG2-R TCGACGCCATCTTCATTCACA(reverse primer)
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Probes:
Ringl ABFAM [6-FAMJAGATYGCGRTCYCCTGTCCA[BHQ1a-6FAM]
Ring2TPFAM [6-FAM]TGGGAGGGCGATCGCAATCT[BHQ1a-6FAM]
Quality control: Test results were verified by the inclusion of positive and negative controls
in each batch of samples.
Diubeaid Qualitative RT-PCR:Seesection 2.3.3.1.
Sd ADDITIONAL TESTS: METHODS
3.3.2.3.1 DNApurification: See 2.3.3.2
3.3:2.3.2 Sequencing of PCR products: See 2.3.3.3
3.3.2.3.3 Processing sequencedata: See 2.3.3.4
3.3.2.4 Categorisation of test results
Categorisation of results by the gold standard.
Positive results by PCR
The gold standard usedin this study is defined by two PCRbasedtests carried out in series.
Firstly, real time RT-PCRwascarried out. Samples positive by this test were confirmed by
qualitative RT-PCR. Both tests were required to be positive for the sample to be considered
as positive for norovirus. Given excretion of norovirus in faeces whenclinical symptomsare
present, occursat high levels, both assays should detect infection causing clinical
gastroenteritis.
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Real time RT-PCR.A fluorescence level of over for >1 (Light cycler 480, Roche) for GI
testing and >10 (Rotagene 6200-HRM, QIAGEN)for GII testing was accepted as a positive
RT-PCRresult. In our experience real time RT-PCR can very occasionally give products
whichare not confirmedby qualitative PCR e.g. a productnot of this appropriate size is
produced by qualitative PCR.
Qualitative PCR. Qualitative PCR produces a product of a specific size which can be
visualised when the product is stained and run on an agarosegel.It is possible that non-
specific products are formed which produce a product of the same size as a norovirus product
(Zintz et al. 2005).
Given both real time PCR and qualitative PCR can givefalse positive results, both real time
RT-PCRandqualitative PCR were combined to improvethe specificity of the reference
standard.
Negative results by the gold standard
A sample negative by real RT-PCRis considered as negative.
Equivocalresults by the gold standard.
Results were only categorised as positive or negative, no equivocal category wasused.
Categorisation of results by the evaluated tests
IDEIAnorovirus ELISA
Categorising a samplestest result was carried out according to the manufacturer
interpretation of sample absorbance of 450nm wavelength light. Firstly cut off values were
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calculated. The cut-off is equal to the O.D. for the negative control + 0.1. A result is positive
if the results are >0.01 abovethe cut off. A result is negative if the results is <0.01 below the
cut off. An equivocal range exists and is + 0.01 of the cut-off. Equivocal results require
repeating.
RIDASCREENnorovirus ELISA
Categorising a samplestest result was undertaken according to the manufacturer’s
interpretation of sample absorbance of 450nm wavelength light. Firstly, cut off values were
calculated. The cut-off is equal to the O.D. for the negative control + 0.15. A result is positive
if the result is >10% abovethe cut off. A result is negative if the results is <10% below the
cut off. An equivocal range exists and is + 10 % ofthe cut-off. Equivocal results require
repeating.
RIDAQUICKnorovirus ICGtest
Categorising a samples test result was undertaken according to the manufacturerinstructions.
A positive result had any intensity blue line visible on the test strip of the test. A negative
result had no blueline visible on the test strip.
S.dided Competencies of staff completing laboratory work
The gold standardsof real time RT-PCR and qualitative PCR were conducted by three people
(A. Booth, W. Dove, A. Kirby; Liverpool University) with experience in completing PCR for
viral agents of gastroenteritis. The ELISA and ICGtests were undertaken by a single person
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(A. Kirby) with experience of undertaking immunological tests. ELISA results were obtained
by an automatic plate reader. Where visual readings werecarried out for the ICGtest, a
second person assessed the results. The second reader of the ICG test was blind, blinding of
the ELISAtest wasnot relevant as the result was read by a plate reader. Theresult of the
PCRtest wasavailable to the person completing the ELISAtests, but no clinical information
wasavailable to the persons completing the PCRtesting.
3.3.2.6 Potential for result bias
PCR:Noclinical information was available to allow bias to enter the PCRresults.
ELISA and ICG: The PCRresults were available when completing ELISA and ICGtesting
and had the potential to bias the ELISA and ICG results. The ELISA results were read by a
plate reader removing opportunity for bias. ICG tests were read in duplicate, one person
blinded to the PCR result with no disagreement occurring.
3.3.3 Statistical methods
Statistical support was provided by Brian Faragher, Liverpool School of Tropical Medicine,
Liverpool University.
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33.3%] Samplesize calculations
The samplesizes were calculated using the computer program, Epi-info (Version 3.5.1). Sample
sizes were calculated with reference to the aimsofthe study.
1- To estimate the diagnostic accuracy of the IDEIA norovirus ELISA (Oxoid) with PCR
based norovirustesting as the reference standard.
« Sample size to estimate the sensitivity of the IDEIA norovirustest, given:
e The population size was 728. This wasthe size of the cohort in this study.
e Thetest is 59% sensitive (Table 3.01).
e A lower boundto the tests sensitivity of 49%.
e The estimate should have a 95% C.I.
This gives a sample size of 82 to estimate the sensitivity of the IDEIA norovirus ELISA.
= Sample size calculation to estimate the specificity of the IDEIA norovirustest given:
e The population size was 728. This wasthe size of the cohort in this study.
e Thetest is 94% specific (Table 3.01).
e A lower boundto the tests specificity of 90%.
e The estimate should have a 95% C.I.
This gives a samplesize of 114 to estimate the specificity of the IDEIA norovirus ELISA.
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2- To estimate the diagnostic accuracy of the RIDASCREEN3” generation norovirus
ELISA, R-BIOPHARM,with PCRbasednorovirustesting as the gold standard.
Sample size to estimate the sensitivity of the RIDASCREENnorovirustest, given:
e The population size was 728. This wasthe size of the cohort in this study.
e Thetest is 83% sensitive, as reported by the manufacturer.
e A lower boundto the tests sensitivity of >75%.
e The estimate should have a 95% CI.
This gives a samplesize of 96 to estimate the sensitivity of the RIDASCREENnorovirustest
Sample size calculation to estimate the specificity of the RIDASCREENnorovirus
test given:
e The population size was 728. This wasthe size of the cohort in this study.
e Thetest is 90% specific, a conservative estimate given the claimed 100%
specificity, reported by the manufacturer.
e A lower boundto thetests specificity of 85%.
e The estimate should have a 95% C.I.
This gives a samplesize of 116 to investigate the specificity of the RIDASCREENnorovirus
test.
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3- To estimate the diagnostic accuracy of the RIDAQUICKnorovirus ICGtest, R-
BIOPHARM,with PCR based norovirustesting as the gold standard.
« Samplesize to estimate the sensitivity of the RIDAQUICKnorovirustest, given:
The population size was 728. This wasthe size of the cohort in this study.
Thetest is 83% sensitive, as reported by the manufacturer.
A lowerboundto thetests sensitivity of > 75%.
The estimate should have a 95% C.I.
This gives a sample size of 96 to estimate the sensitivity of the RIDAQUICKnorovirustest.
« Sample size calculation to estimate the specificity of the RIDAQUICKnorovirus
test given:
e The population size was 728. This wasthe size of the cohort in this study.
e Thetest is 95% specific, a conservative estimate given the claimed 100%
specificity.
e A lower boundto the tests specificity of 85%
e The estimate should have a 95% CI.
This gives a sample size of 18 to estimate the specificity of the RIDAQUICKnorovirustest.
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4- To compare the diagnostic accuracy of the RIDASCREEN and RIDAQUICKtests to
the ELISAtest that had the best sensitivity in published evaluations, the IDEIA
norovirus ELISA.
«Sample size calculation to comparethe sensitivity of the RIDASCREENand
RIDAQUICKnorovirustests to the IDEIA ELISA given:
e Thesensitivity of the RIDASCREEN and RIDAQUICKnorovirustests are
83% as reported by the manufacturer.
e Thesensitivity of the IDEIA norovirustest is 59% (Table 3.01).
e A 95% C.I. and 80% power.
This gives a sample size of 81 to compare the sensitivity of the RIDASCREENand
RIDAQUICKIDEIAnorovirustests.
Sample size calculation to compare the specificity of the RIDASCREEN and RIDAQUICK
IDEIA norovirustests. This was not carried out as both report specificities of 100%.
Sdodun Methodsfor interpretation of results
Reporting of diagnostic accuracy. Reporting of results is carried out by a crosstabulation
table as shown below (Table 3.07).
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Table 3.07: Cross tabulation for presenting study results.
 
 
PCR
Test under evaluation + :
+ True positives False positives
- False negatives True negatives     
True positive (TP): A sample testing positive by the test under evaluation and the reference
standard.
False positive (FP): A sample testing positive by the test under evaluation and negative by the
reference standard.
False negative (FN): A sampletesting negative by the test under evaluation and positive by
the reference standard.
True negative (TN): A sample testing negative by the test under evaluation and the reference
standard.
The reference standard in this study, norovirus PCR,is used to define the presence of
norovirus disease.
The following characteristics of the tests/statistical tests will be presented
1. Sensitivity= True positives / True positives + False negatives
2. Specificity= True negatives / True negative + False Positives
These values will be presented with 95% confidenceintervals.
3. Negative predictive value (NPV), based on the prevalence of norovirusin the
population.
NPV= True negatives/True negatives + False negatives
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4. Positive predictive value (PPV), based on the prevalence of norovirusin the
population.
PPV=True positives/Truepositives + False positives
Prevalence rates, as defined by PCR,are: overall 13.23%, hospital; 66/393= 16.8% and
community=30/335 = 9%.
5. Positive predictive value adjusted for detection of asymptomatic shedding
Positive predictive values will be calculated for PCR and the RIDASCREEN/ RIDAQUICK
ELISA for the hospital cohort, given this cohort is most likely to undergo diagnostictesting,
taking accountof clinical false positives. A clinical false positive is where the diagnostictest
detects a pathogen (norovirus) but that pathogenis not causing clinical disease. The clinical
false positive prevalence is estimated below, for PCR and ELISAtesting, and is considered
equal to the detection of asymptomatic shedding.
Calculating the detection of asymptomatic shedding by PCR/ELISA methods.
To calculate the detection of asymptomatic shedding of norovirusat any time point in a
random sampleofpatients the following information is needed:
e Thepercentage of the population susceptible to norovirus infection
e The frequency of norovirus infection within the susceptible population
e The duration of asymptomatic shedding
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Estimating the percentage of the population susceptible to norovirus infection
> 80% of the population are susceptible to norovirus infection (Marionneau
et al. 2002)
Estimating the frequency of infection
e Immunity to norovirus infection has been estimated as lasting 6-12 months
(Midpoint = 9 months)(Dolin et al. 1972; Wyatt et al. 1974; Parrinoet al.
1977).
e Infection in children is assumed to occur when immunity is absent.
> Infection can be estimated at occurring every 9 months
Estimating the duration of asymptomatic shedding
> Asymptomatic shedding has been estimated as lasting for an average of 28
days as detected by norovirus PCR (Murataet al. 2007; Atmaretal. 2008;
Kirkwood and Streitberg 2008).
> Asymptomatic shedding has been estimated as lasting for an average of 7
days after infection as detected by norovirus ELISA (Graham et al. 1994;
Okhuysenet al. 1995; Atmar and Estes 2001).
Calculation the prevalence of asymptomatic shedding of norovirusby:
PCR:Theproportion of time between norovirusinfections is 9 months, and PCR will detect
shedding for 28 days within this period. This will occur in 80% of the population. Therefore
asymptomatic excretion of norovirus will occur for | month in 80% of the population every 9
months ((28days /270 days) x0.8) = 8%
94
ELISA:The proportion of time between norovirusinfections is 9 months, and ELISA will
detect shedding for 7 days within this period. This will occur in 80% of the population.
Therefore asymptomatic excretion of norovirus will occur for 7 days in 80% ofthe
population every 9 months ((7 days /270 days) x0.8) = 2%
The decision to use these estimates ofclinical false positives to calculate norovirus tests
positive predictive values is supported by studies which have shown an approximately 10%
rate of asymptomatic shedding (Farkaset al. 2000; Monicaet al. 2007; Reither et al. 2007).
It is though evidentthere is a wide range of shedding seen studies of asymptomatic shedding;
from 1-30% (O'Ryanet al. 2000; Castilho et al. 2006). Further support for the use of these
| estimates is given by a recent Brazilian study which showed an asymptomatic shedding rate
as detected by PCR of 12%, a figure comparable to the estimate above.
6. McNemar's test. To compare the diagnostic accuracy of the RIDASCREENand
RIDAQUICKtests to the ELISAtest that had the bestsensitivity in published evaluations,
the IDEIA ELISA, the McNemar'’s test will be used. This will calculate if there 1s a statistical
difference in the results of the different norovirus tests as the data is categorical, summarised
as a percentage and paired.
7. Receiver operating characteristic curves. An evaluation of the ELISAstest cut off
will be made by producing receiver operating characteristic (ROC) curves. ROC curves show
graphically sensitivity against (1 - specificity). This allows consideration of what is an
appropriate cutoffpoint; different cut off points will give different sensitivity and specificity
characteristics to the ELISAs. The ELISA values will be normalised between the different
ELISAtest runs by dividing a samples optical density by that of its respective negative
control. E.g. an O.D. value of 0.64 where the negative control had an O.D of 0.32 would have
a normalised value of 2 (0.64/0.32). Sensitivity and specificity values will be calculated at
separations of the normalised values of 0.1 e.g. 0.1, 0.2, 0.3. The ROC analysis will
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specifically analyse the sensitivity of the ELISAsat 80% test specificity. This is a specificity
that may be acceptable if using the ELISA to screen a sample collection prior to completing
PCR.
3.3.3.3 Test reproducibility
Test reproducibility was assessed for the ELISA tests in terms of runto run variability with
new samples prepared. Runto run variability was measured by examiningthe variation in
O.D.values. This variation was examined in three categories, each containing eight samples.
The categories were: ELISA and PCR positive samples, ELISA and PCR negative samples
and samples with discordant ELISA and PCR samplesorvariation in the ELISAtest result
being observed during the evaluation e.g. equivocal results becomingpositive. The
reproducibility is expressed asa coefficient of variation (CV); this is calculated by dividing
the standard deviation by the mean optical density.
3.3.3.4 Impactof clinical features on test outcomes.
The usefulness of immunological testing for norovirusis likely to be affected by a number of
clinical characteristics. In the case of norovirus these are principally the time since diarrhoea
onset at the time oftesting and theclinical severity of the disease. Therefore, an analysis of
the impactof duration of diarrhoeaat the time the sample wastested and theclinical severity
of the disease on the RIDASCREEN/RIDAQUICKresults within the hospital cohort was
carried out.
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3.4 RESULTS
3.4.1 PARTICIPANTS
3.4.1.1 Timing of sample collection and study
The samples were collected between October 2006 and December 2007.
Testing wascarried out in May-June 2009.
3.4.1.2 Clinical and demographic characteristics
Hospital cohort
Age: 0 monthsold to 12 years old. Mean age (S.D): 21 (28) months.
Sex: Male 57%, Female 43%.
Mean (SD) duration of diarrhoea at presentation of 4.21 (3.1) days (range 0 — 15).
Community cohort.
Age: 0 months to 5 years old. Mean age (S.D) 18 (6) months
Sex: 50% Male, 50% Female.
Mean (SD) duration of diarrhoea of 4.27 (2.6) days (range 1-35).
Duration of diarrhoea in the community cohort was recorded at a separate time from
presentation so is not directly comparable to duration of diarrhoea in the hospital cohort.
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Duration wasassessed by a homevisit programme by community based nursing staff which
may or may not have beenrelated to the diarrhoeal episode.
3.4.1.3 Outcomes of included and excludedpatients
All patients whosatisfied the inclusion criteria underwentreal time RT-PCR for the detection
of norovirus. All patients with positive RT-PCR and qualitative PCR results with sufficient
sample underwent ELISAtesting. A collection of samples from patients who tested negative
by real time RT-PCR (systematically selected) were screened by ELISA.
3.4.2 TEST RESULTS
3.4.2.1 Timeinterval between samplescollected for testing
A single sample wascollected at a single time point to investigate a patient’s gastroenteritis.
Samples used for the study underwentboth the reference standard test and the immunological
norovirustests being evaluated.
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3.4.2.2 Disease severity in participants
Theseverity ofillness was assessed according to the modified Vesikari score (Table 3.08)
(Nakagomietal. 2005). This is used to assess the severity of rotavirus gastroenteritis butis
usedin this study as no clinical severity score exists for norovirusandthe clinical features of
the two conditions are similar. In the community cohort the modified Vesikari score was 8.8
and 10.05 in the hospital cohort.
Table 3.08: The 20 point modified Vesikari Severity Scoring System used to evaluate the
severity of rotavirus gastroenteritis (Nakagomiet al. 2005).
 
Clinical sign or symptom Point(s) assigned
Diarrhea
Duration, days
<2 1
2-4 2
>4 3
Maximumno. of diarrheal stools in 24 h
3 1
4-5 2
>5 3
Absence of vomiting oO
Vomiting
Duration, days
1-2 2
=3 3
Maximum no. of episodes in 24 h
1 1
2 2
=3 3
Dehydration
Absent 0
Clinically present
Fever®
<37.6°C 0
37.6°C-38.6°C
>38.6°C 3
General level of activity
Normal 0
Reduced 3
 
° Axillary temperature
Table reproduced from Nakagomiet a/ (Nakagomiet al. 2005)
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3.4.2.3 Cross-tabulation of results
Overall (community and hospital cohorts) results
Thesensitivities of the RIDASCREEN, RIDAQUICKand IDEIA norovirustests were 64%,
69% and 49% respectively. Their specificities were all 100%. These values are based on
faecal samples collected from the children in both the community and hospital cohorts (Table
3.09).
Table 3.09: Sensitivity and specificity of the RIDASCREEN/RIDAQUICKand IDEIA
norovirus tests compared to PCR for the hospital and community cohorts.
 RIDASCREEN RIDAQUICK IDEIA
Sensitivity
True positives/All positives (%)
Specificity (%)
True negatives/All negatives (%)
61/96 (64%) 66/96 (69%) 47/96 (49%)
    116/116 (100%) 20/20(100%) 116/116 (100%) 
3.4.2.4 Adverse events from testing
No adverse events from testing were recognised
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3.4.3 ESTIMATES
3.4.3.1 Estimates of diagnostic accuracy
The confidence intervals for the RIDASCREEN, RIDAQUICKand IDEIAtests sensitivities
were 54-72%, 58-78% and 39-59% respectively. All tests had similarly high positive and
negative predictive values (Table 3.10).The RIDASCREEN and RIDAQUICKtests were
both moresensitive than the IDEIA ELISA (p= <0.01) (Table 3.11).
Table 3.10: Overview ofthe sensitivity, specificity, negative and positive predictive values of
the RIDASCREENand IDEIA norovirus ELISA and RIDAQUICKICGtest compared to
PCRfor the hospital and community cohorts.
 
Test Sensitivity Sensitivity Specificity Specificity PPV" NPV"
95% C.l 95% C.l
RIDASCREEN 64% 54-72% 100% 96-100% 100% 95%
RIDAQUICK 69% 58-78% 100% 80-100% 100% 95%
IDEIA 49% 39-59% 100% 96-100% 100% 93%         
'Predictive values calculated using prevalence’s derived from norovirus PCRtesting.
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compared to the IDEIA norovirustest. P values calculated using McNemar’s test.
Table 3.11: Statistical difference in sensitivity of the RIDASCREEN and RIDAQUICKtests
 
  
RIDASCEEN RIDAQUICK IDEIA P value P value
RIDASCREEN RIDAQUICK
vs. IDEIA vs. IDEIA
Hospital and 64 (54-72) % 69 (58-78) % 49 (39-59) % 0.001 0.00002
community cohort      
3.4.3.2 Handling of indeterminate results, missing results and outliers
Noresults were indeterminate. No data were missing from the results of the norovirustesting
Nooutliers were recognised. ELISAs wererepeated if there was discrepancy between the
result of an ELISA and PCRandthere was a discrepancy between ELISAresults andif the
ELISA result was equivocal. If a repeat result was consistent with other results where
previously it was discrepant then the repeat result was accepted as that samples result. A
sample without a positiveresult after twotests, e.g. 2 equivocal results by ELISA, would also
be called negative. No repeat ICG tests were undertaken.In total, 11/96 RIDASCREEN
results were repeated. Three of these samples changedresult; two from negative to positive
and one from positive to negative. The IDEIAtest required 25 tests to be repeated,four of
these resulted in the result changing, three from negative to positive and one from equivocal
to positive. Within the negative by PCR samples four samples were positive by ELISA,
therefore qualitative PCR, as opposedto real time PCR, wascarried out on these samples. All
four were positive by qualitative PCR and the samples were removed from the evaluation of
test specificity.
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3.4.3.3 Estimates of variability of diagnostic accuracy between subgroups of
participants.
Subgroup analysis of the results in different patient groups is shown below.
Hospital cohort
Thesensitivities of the RIDASCREEN, RIDAQUICKand IDEIA norovirus tests were 70%,
79% and 62% respectively. Their specificities were all 100%. These values are based on
faecal samples collected from the children in the hospital cohort (Table 3.12).
Table 3.12: Sensitivity and specificity of the RIDASCREEN, RIDAQUICKand IDEIA
norovirus tests compared to PCR for the hospital cohort.
 
     
RIDASCREEN RIDAQUICK IDEIA
Sensitivity ° 3 4 2%True positives/All positives (%) 46/66 (70%) 52/66 (79%) 1/66 (62%)
Specificity (%) % 4 9 58/58 YTrue negatives/All negatives (%) 58/58 (100%) ap (LOe) P58 (200%)
Community cohort
Thesensitivities of the RIDASCREEN, RIDAQUICKand IDEIAnorovirustests were 50%,
47% and 20% respectively. Their specificities were all 100%. These values are based on
faecal samples collected from the children in the community cohort (Table 3.13).
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Table 3.13: Sensitivity and specificity of the RIDASCREEN, RIDAQUICKand IDEIA
norovirus tests compared to PCR for the community cohort.
 
RIDASCREEN RIDAQUICK IDEIA
Sensitivity
True positives/All positives (%)
Specificity (%)
True negatives/All negatives (%)
15/30 (50%) 14/30 (47%) 6/30 (20%)
58/58 (100%) 16/16 (100%) 58/58 (100%)     
Genogroupanalysis
Thesensitivity of the RIDASCREEN, RIDAQUICKand IDEIA for detecting genogroup II
norovirus was higher than for genogroup I norovirus. Their sensitivities were 67%, 76% and
55% for genogroup II and 13%, 0% and 0% for genogroupI respectively (Table 3.14)
Table 3.14: Sensitivity of the RIDASCREEN, RIDAQUICK ANDIDEIAnorovirustests by
genogroup,I orII.
 
 
RIDASCREEN RIDAQUICK IDEIA
Gl Gll Gl Gll Gl Gl
Sensitivity 1/8 (13%) 58/86 (67%) 0/8 (0%) 65/86 (76%) 0/8 (0%) 47/86 (55%)      
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GenogroupII and hospital cohort
Thesensitivity of the RIDASCREEN, RIDAQUICKand IDEIAfor detecting genogroup II
norovirusin the hospital cohort alone washigher than for the hospital and community cohort.
Their sensitivities were 75%, 68% and 87% respectively (Table 3.15)
Table 3.15: Sensitivity of the RIDASCREENand IDEIA norovirus ELISA and RIDAQUICK
ICGtest within the genogroup II hospital subgroup.
 
   
RIDASCREEN IDEIA RIDAQUICK
+ - + - +
PCR
+ 45 15 41 19 52 |8
Sensitivity 75% 68% 87%      
Summaryof subgroup analyses
Thetests sensitivities varied greatly between subgroups but were foundto be highest in the
hospital cohort as opposed to the community cohort and genogroup IJ norovirus as opposed
to genogroup I norovirus. The RIDASCREEN and RIDAQUICKtests were moresensitive
than or as sensitive as the IDEIA ELISAin all subgroups analysed (3.16).
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Table 3.16: Sensitivity, specificity, negative and positive predictive values for the subgroup
analysis of the IDEIA and RIDASCREENnorovirus ELISA and the RIDAQUICKICGtest.
 
  
Test Sensitivity Sensitivity 95% C.l Specificity Specificity 95% C.l ppv’ NPV’
RIDASCREEN hospital 70 58-80 100% 92-100 1 94
RIDASCREEN community 50 33-67 100% 92-100 1 95
RIDASCREEN G1 12.5 2-47
RIDASCREEN G2 67 57-76
RIDASCREEN G2 & 75 63-84
Hospital
RIDAQUICK hospital 79 67-88 100% 51-100 1 96
RIDAQUICK community 47 30-64 100% 81-100 1 95
RIDAQUICK G1 0 0-40
RIDAQUICK G2 76 65-84
RIDAQUICK G2 and 87 75-94
hospital
IDEIA Hospital 62 50-73 100% 92-100 1 93
IDEIA Community 20 10-37 100% 92-100 1 93
IDEIA G1 0 0-32
IDEIA G2 55 44-65
IDEIA G2 & hospital 68 55-79      
'Predictive values calculated using prevalence’s derived from norovirus PCRtesting.
Norovirus genotype analysis.
The RIDASCREEN, RIDAQUICKand IDEIAtests were 77.6%, 88% and 70.7% sensitive,
respectively, at detecting genotype II.4 norovirus. Only small numbers of other genotypes
were detected and thetests sensitivity at detecting them was poor(Table 3.17).
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Table 3.17: Detection of specific genotypes for the IDEIA and RIDASCREENnorovirus
ELISA and the RIDAQUICKICGtest. Two samples with genogroupI and II detected
excluded from the analysis.
 
 
RIDASCREEN RIDAQUICK IDEIA
GI.3 0/2 0/2 0/2
GI.7 0/1 0/1 0/1
GI.12 0/1 0/1 0/1
GI.14 1/3 0/3 0/3
GIl.2 1/4 2/4 1/4
GIl.4 45/58 (77.6%) 51/58(88%) 41/58 (70.7%)
GII.6 1/1 1/1 0/1
GIl.13 5/7 5/7 1/7
Total 53/77 58/77 43/77     
Statistical analysis of variations in sensitivity between the RIDASCREEN,
RIDAQUICKand IDEIA norovirustests.
Wherestatistical significance (p=<0.01) was detected between tests the IDEIA test was found
to be less sensitive than the RIDASCREENand RIDAQUICKtests. This wastrue of the
hospital cohort (RIDAQUICK), community cohort (RIDASCREEN and RIDAQUICK),
genogroupII norovirus (RIDASCREEN and RIDAQUICK)(Table 3.18).
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Table 3.18: Statistical difference in sensitivity of the RIDASCREEN and RIDAQUICKtest
compared to the IDEIA norovirustest. P values calculated using McNemar’s test. Analysis
conducted on subcategories within the main study.
 
      
RIDASCEEN RIDAQUICK IDEIA P value P value
RIDASCREEN RIDAQUICK
vs. IDEIA vs. IDEIA
Hospital 70 (58-80)% 79 ( 67-88)% 62 (50-73)% 0.18 0.003
Community 50 (33-67)% 47 (30-64)% 20 (10-37)% 0.004 0.008
Gl 12 (2-47)% O (0-40)% 0 (0-32)% 1.0 1.0
Gll 68 (58-77)% 76 (65-84)% 55 (44-65)% 0.007 0.00004
GIl and Hospital 75 (63-84)% 87 (75-94)% 68 (55-79)% 0.29 0.003
3.4.3.4 Estimates of predictive values
PPVs of PCR and the RIDASCREENELISAbased onfixed prevalence’s of asymptomatic
shedding: The detection of asymptomatic shedding (clinical false positives) by PCRis
estimated at 8% and by ELISAat 2%, (see 3.3.3.2). In hospitalised patients the prevalence of
norovirus infection by PCR is 16.8% and by ELISAis 70% ofthat value, 11.76%. Using
these estimates the PPV of PCR and the RIDASCREEN ELISAcan becalculated (Tables
3.19/3.20). These calculations demonstrate how, based these estimates, PCR for norovirus
has a PPV of 52% compared to 83% for the RIDASCREENtest.
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Table 3.19: The sensitivity, specificity and PPV of PCRin detecting norovirus in this study
against a gold standard which defines PCR ashavinga clinical false positive rate of 8%.
 
Estimated gold standard
PCR + . PPV
 + 8.8 8 8.8/16.8=52% - 83.2  
Table 3.20: Thesensitivity, specificity and PPV of the RIDASCREENin detecting norovirus
in this study against a gold standard which defines ELISA as havinga clinical false positive
 
    
rate of 2%.
Estimated gold standard
RIDASCREEN + - PPV
+ 9.76 2 9.76/11.76=83%
- 88.24
3.4.3.5 ROCanalysis
The Receiver Operating Characteristic curves shown below (Figure 3.2-3.7) demonstrate that
the RIDASCREENELISA,in hospitalised patients, had a sensitivity of 90% at an 80%
specificity. Reducing the specificity in other situations e.g. IDEIA ELISAand the
community cohort, did not usefully improvetest specificity.
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Figure 3.2: Receiver operating characteristics of the IDEIA ELISA: Communityand hospital
cohort.
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Figure 3.3: Receiver operating characteristics of the IDEIA ELISA: Community cohort.
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Figure 3.4: Receiver operating characteristics of the IDEIA ELISA: Hospital cohort.
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Figure 3.5: Receiver operating characteristics of the RIDASCREEN ELISA:Hospital and
community cohort.
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Figure 3.6: Receiver operating characteristics of the RIDASCREEN ELISA: Community
cohort.
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Figure 3.7: Receiver operating characteristics of the RIDASCREEN ELISA:Hospital cohort.
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3.4.3.6 Estimates of test reproducibility
Both the RIDASCREEN and IDEIA ELISAshadcoefficients of variation of < 25% in
samples from the positive and negative groups. The coefficient of variation was >25% in
samples from the variable group (see section 3.3.3.3 for definition of groups) (Table 3.21).
Table 3.21: Estimates of test reproducibility for the IDEIA and RIDASCREENnorovirus
ELISAbased on samples with positive, negative and discordant/variable ELISA/PCRresults.
 
Positives Negatives Variable results
Mean ° Mean ° Mean °OD S.D CV% OD S.D CV % OD S.D CV %
IDEIA 1.3 0.24 18% 0.082 0.0047 5.7% 0.196 0.1 51%
RIDASCREEN 1.7 0.41 24% 0.058 0.011 18% 0.16 0.052 33%            
CV= coefficient of variation, S.D = standard deviation, O.D = optical density.
3.4.3.7 RIDASCREENand RIDAQUICKresults in a clinical context.
Amonghospitalised children the severity of disease was higher in children with both positive
PCR and immunological tests compared with children with a positive PCR test alone. The
meanseverity scores were, for the immunological test positive/negative children, 10.6/8.1
(p=0.03) for the RIDAQUICKand 10.6/8.8 (p=0.08) for the RIDASCREEN. Among
hospitalised children the detection of norovirus by immunologicaltests was not affected by
the timing of sample collection. The mean duration of diarrhoea at time of sample collection
in those with norovirus detected by PCR were, for the immunological test positive/negative
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children, 4.2/3.4 days (p=0.18) for the RIDAQUICKand 3.8/4.6 days (p=0.27) for the
RIDASCREEN(Table 3.22/3.23). Both the RIDASCREEN and RIDAQUICKtests detected
norovirus for up to 13 days following the onset of diarrhoea (Figure 3.8).
Table 3.22: Relationships between RIDASCREENELISAresult, disease severity (modified
Vesikari score) and duration of diarrhoea within hospital samples positive for norovirus by
PCR.
 
 Timesince diarrhoea onset (S.D)    
RIDASCREEN RIDASCREEN P value
Positive (n=46) Negative (n=20)
Disease severity (S.D) 10.6 (3.9) 8.8 (3.6) 0.08
3.8 days (2.7) 4.6 days (2.7) 0.27  
Table 3.23: Relationships between RIDAQUICKICGresult, disease severity (modified
Vesikari score) and duration of diarrhoea within hospital samples positive for norovirus by
 
PCR.
RIDAQUICK RIDAQUICK P value
Positive (n=52) Negative (n=14)
Disease severity (S.D) 10.6 (3.8) 8.1 (3.5) 0.03
Timesince diarrhoea onset (S.D) 4.2 days (2.8) 3.4 days (2.1) 0.39    
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Figure 3.8: Sensitivity of the RIDASCREEN and RIDAQUICKtests with respect to the
duration of diarrhoeaat the time samples were collected within the hospital cohort.
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3.4.3.8 Summary ofresults
IDEIA ELISA
Sensitivity = 49%
Specificity was 100%,in the entire cohort as well as all subgroups analysed.
Sensitivity subgroups: 62% in the hospital cohort
20% in the community cohort
0% in the genogroup I subgroup
55% in the genogroupII subgroup
Sensitivity at 80% specificity (ROC analysis) 67% in the entire cohort
58% in the community cohort
75% in the hospital cohort
Coefficient of variation positive samples: 18%
negative samples: 5.7%
variable samples: 52%
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RIDASCREEN ELISA
Sensitivity = 64%, significantly higher than the IDEIA ELISA (p = 0.0013).
Specificity was 100%, in the entire cohort as well as all subgroups analysed.
Sensitivity in the subgroups: 70% in the hospital cohort
50% in the community cohort
12.5% in the GI subgroup
67% in the GII subgroup
The RIDASCREENELISAwassignificantly moresensitive than the IDEIA ELISA in the
community (p = 0.0039) and genogroupII subgroups (p = 0.0073).
Sensitivity at 80% specificity (ROC analysis) 78% in the entire cohort
56% in the community cohort
91% in the hospital cohort
Coefficient of variation positive samples: 24%
negative samples: 18%
variable samples: 33%
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RIDAQUICK ELISA
Sensitivity = 69%, significantly higher than the IDEIA ELISA (p = 0.00002)
Specificity was 100%, in the entire cohort as well as all subgroups analysed.
Sensitivity in the subgroups: 79% in the hospital cohort
47% in the community cohort
0% in the GI subgroup
76% in the GII subgroup
The RIDAQUICKELISAwassignificantly moresensitive (significance at p =<0.05) than
the IDEIA ELISAin the hospital, community and genogroupII subgroups.
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3.5 Discussion
Tests for norovirus infection have utility in two principal areas, for the completion of
molecular epidemiological studies and the diagnosis of infection. The requirements oftests in
these areas are different, therefore the discussion below assessthe tests usefulness in these
two areas separately.
3.5.1 Molecular epidemiological studies.
Studies of the molecular epidemiology of norovirus require processing of DNA products
from PCRreactions. Obtaining these products by completing PCR onall samples under
evaluation is time consuming and expensive. Given the low prevalence of norovirus in most
studies, about 15% (Koopmans2008), the costs and time involved maybe reduced if samples
are first tested using a simpler, cheaper method. ELISA mayoffer a relatively low cost/low
technology test to analyse samples for norovirus infection. For an ELISAtest to be suitable
for pre-PCRtesting it must be sufficiently sensitive. Of the two commercially available
ELISAs the RIDASCREENELISA,in this study, was significantly more sensitive than the
IDEIA ELISA. The RIDASCREEN ELISAshould be the ELISA ofchoice if this methodis
to be used to test samples for norovirus. The sensitivity of the RIDASCEENELISA,at 70%
in the hospital cohort,is still a lot less sensitive than PCR detection of norovirus. It was found
that if the specificity of the RIDASCREENtest was adjusted to 80%, then the sensitivity in
the hospital cohort increased to 90%. This may be an acceptable sensitivity and specificity for
the test to be used prior to PCR in molecular epidemiological studies of norovirus.
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3.5.2 Diagnostic use of norovirustests
A diagnosis of norovirus infection allows completion ofclinical epidemiological studies and
a diagnosis to be given to an individual patient. Making a diagnosis of norovirusinfection is
difficult as there are many causesof gastroenteritis. The similarity of norovirus
gastroenteritis, outside an outbreak, to other causes of gastroenteritis e.g. rotavirus, is likely
to prevent a high pretest probability of norovirus infection from favourably effecting the post
test probability of norovirus infection (a high pre test probability can raise the positive
predictive value ofa test). Also, the presence of norovirusin faecesis not clearly correlated
with current illness as norovirus maybepresentin faeces for a prolonged period following
infection. That is, a test for norovirus may havea good analytical accuracy but poor
clinical/diagnostic accuracy. Analytical accuracy in this contestis the ability to detect
norovirusin a clinical sample when norovirusis truly present in the sample. It does not give
information on whether norovirusis causing disease. Clinical/diagnostic accuracyis the
ability to detect norovirus which is causing disease. Measurementsofanalytical/clinical
accuracy can be limited by an imperfect reference standard, the reference standard providing
the information as to whether an organism/diseaseis truly present. In view of the knowledge
that PCR provides an imperfect reference standard for the detection of norovirus disease, as
it detects asymptomatic shedding of norovirus, an attempt improvethe reference standard
was made. An improvedreference standard would allow better estimationsofthe tests
predictive values and therefore a better understanding of their usefulness. An attemptto
improvethe reference standard, norovirus PCR,wascarried out by estimating the detection
of asymptomatic norovirus shedding. Estimates were that PCR detected asymptomatic
shedding at 8% by PCR and 2% by ELISA(section 3.3.3.2). Based on these figures the PPV
of PCR and ELISAfornorovirustesting in this study was estimated. PCR on these
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assumptions had a PPV of 52% compared to a PPV of 83% by the RIDASCREEN ELISA.If
the assumptions madein reachingthis value are valid, PCR haslimited value for norovirus
infection in this study setting and RIDASCREEN ELISAbased testing mayoffer a better
diagnostic test than PCR. These estimates of PPVsare though,just estimates. There are
clearly limitations of these estimates and this highlights the importance ofincluding control
groups in designing evaluations of diagnostic tests. In addition, the false negative results by
the RIDASCREEN/RIDAQUICKtests were associated with a less severe disease. This
supports ELISA/ICG based norovirus testing because missing a diagnosis of norovirus where
the gastroenteritis is less severe may have morelimited clinical implications.
The reproducibility of the ELISAs was good whenthetests were positive/negative by PCR
and ELISAoninitial testing. Where discordant results were seen a repeated result had up to a
50% variation in the O.D value. These discordant results gave O.D readingscloseto thetests
cut off values. Therefore, if a result is important and the O.D value is within 50% ofthetest
cut off, the test result should be confirmed by a moleculartest.
The specificity ofthe tests, 100%, is consistent with the manufacturer’s findings. This
appears a high sensitivity but consideration should be givento the reporting algorithm ofthis
study. This study did not report a negative sample by PCR positive by ELISA unless repeat
PCRtesting was negative. Previous evaluations of ELISAs which report specificities below
100% have found most apparent false positives by ELISA are positive by PCR whenretesting
by an alternative PCRis carried out (Grayet al. 2007).
Theclinical utility of making a diagnosis of norovirusis reduced by the lack of a specific
therapy for norovirus. However, therapy and investigations for gastroenteritis may be reduced
if a specific diagnosis is made. There mayalso beutility when investigating an outbreak of
infection, as identifying the aetiological cause of an outbreak will direct the management of
that outbreak. These benefits maybe increasedif the diagnosis can be made morerapidly.
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This study shows the RIDAQUICKtestto be sufficiently sensitive and specific as to be
clinically useful in making rapid diagnoses of norovirus infection. This may beparticularly
valuable in the investigation of an outbreak as early responses to norovirus outbreaks have
been associated with a reduction in the size of the outbreak (Lopmanetal. 2004). Both
RIDASCREENand RIDAQUICKtests have the advantage that they can be used in
laboratories without the facility for PCR, thus expanding the locations norovirus can be
diagnosed.
Whilst immunological tests should be used within the first 72 hours of infection, this study
demonstrated the RIDASCREEN and RIDAQUICKtests were able to detect norovirus for up
to 13 days following infection. Although the numbers tested beyond seven days waslow,
these results demonstrate in patients with prolonged diarrhoea, these tests maystill be used as
a first line test to investigate for norovirusinfection.
3.6 Limitations
e PCRdiagnosis was used as an imperfect reference standard in this study.
e No control group wasavailable to accurately define the prevalence of norovirus
infection in the study group which would allow accurate calculation ofthe tests
predictive values.
e The normalised values used to define the ROC curves were based on single negative
control per ELISA run.
e The data collected from the community cohort differed from the hospital cohort
preventing direct comparisons. The duration of diarrhoea at the time of sample
collection was not calculable from the data for the community cohort.
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e The severity score used was developed for rotavirus and not specific for norovirus.
e A small number of Genogroup I samples were detected in the study makingit difficult
to commenton the tests usefulness to detect GenogroupI infections.
3.7 Further work
Improving the ELISA assay
To improvethe assay for use as a screening tool prior to molecular testing it would be good
to increase the sensitivity of the assay. The assays sensitivity could be increasedif it could
differentiate false negatives and true negatives with high negative O.D. values. There are a
numberof factors which affect the sensitivity and specificity of ELISAsincluding:
concentration of capture antibody, duration of incubation, concentration of sample assayed
and temperature of incubation. Investigating variations in these conditions may improve
assay characteristics.
Improving the ICG assay
The RIDAQUICKICGassayis marketed as a rapid diagnostic test, suggesting a 15 minute
test time. This excludesthe timeit takes for reagents to achieve room temperature. In this
study the reagents took at least 1 hour to reach room temperature. Wherethearrival of
samples cannotinto a laboratory cannotbe predicted this mayresult in a less rapid test or a
test used outside the recommended experimental protocol. It will therefore be of benefit to
know what impact completing the test with reagents below room temperature has andif there
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are methods which can speed the warming of reagents to room temperature without adversely
affecting test performance.
Differentiating symptomatic infection from asymptomatic shedding.
To better understand the diagnostic value of the norovirustests a reliable gold standardtest is
required. Recently, a PCR cycle threshold has been suggested for genogroupII norovirus by
RT-PCR.This requires an individual laboratory to complete a ROC analysis of cases and
controls, not possible for most laboratories (Phillips et al. 2009). In addition the viral load
excreted between viruses is different with GII.4 excreting 100x morevirus than other GII
viruses and GII viruses excreting 100x more virus than GI viruses (Chanet al. 2006). An
alternative methodis to use the immunological responseto differentiate acute infection from
non acute infection. A rise in salivary IgA has been shownto develop in norovirusinfection
(Lindesmith et al. 2003). This would require acute and convalescent samples to be taken,
whichis not practical for many diagnostic studies. An alternative would be to measure IgA
using an absenceto indicate acute infection. This could bedifficult as people may have
antibody detectable from past infections or recent unsuccessful viral challenge. Diagnosing
norovirus infection will therefore continueto be difficult until there is a greater understanding
of norovirus shedding, sufficient to be able to differentiate it from symptomatic infection. In
the first instance, ELISAs should be used on series of symptomatic and asymptomatic
patients to see if the asymptomatic infected patients are detected by commercial ELISA
testing. This maynotbethe case given asymptomatic infection is associated with reduced
levels of antigen excretion (Okhuysenet al. 1995).
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Multicentre evaluation. The ELISA/ICG norovirustests require evaluation in multiple
centres and in different patient cohorts to establish test characteristics under different
situations.
3.8 Conclusions
The RIDASCREENnorovirus ELISA offers a good preliminary screening tool for molecular
epidemiological studies into norovirus in hospitalised children. They are also suitable to
inform surveillance systems of the prevalence of norovirus in low and middle income
countries. Both the RIDASCREENand the RIDAQUICKnorovirustests offer a sensitive and
specific diagnostic test for norovirus infection in hospitalised children. These tests may have
a better positive predictive value than PCR when usedasa diagnostic test.
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CHAPTER4
Molecular epidemiology of norovirus in Merseyside, UK and Aracaju,
Brazil.
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4.1 Introduction: Molecular epidemiology of norovirus
Norovirusis separated into five genogroups, of these genogroupsI, II and occasionally
genogroup IV causeinfection in humans (Greenet al. 2000). Within these genogroupsare
over 30 genotypes.Initial analysis of the molecular epidemiology of norovirus outbreaks
showed genetic diversity in norovirus isolated from epidemiologically unrelated outbreaks
(Andoet al. 1995). More recently the genogroup II, genotype 4 (GII.4) norovirus has been
recognised as the cause of most cases of norovirus globally. Whilst there is heterogeneity
within GII.4 in unrelated outbreaks of norovirus it has also been shownthat highly similar
strains of norovirus can be detected in epidemiologically unrelated outbreaks. A study by
Noel ef a/ on samplescollected from 1993-1997 showedthat multiple epidemiologically
unrelated outbreaks from across the United States of America showed 100% nucleotide(nt)
identity (Figure 4.1(Noelet al. 1999)) when a 277 bp sequence from the 5 prime end of
ORF2 from norovirus wasanalysed. Further analysis in this study of the entire capsid
sequence (1620 nt) of ten isolates showed half had below 10 base pair mutations different
betweenstrains. Given the mutation rate in norovirus has been estimated at 0.0043 nucleotide
substitutions/site/year by BoKetal, over a year, 7 mutations might be expected to occur in
this 1620bp region. This suggests many outbreakstrains identified were related to each other
by a recent ancestor. Since then, studies have repeatedly shown genetically similar GII.4
norovirus causing outbreaks intra/inter nationally (Vainio and Myrmel 2006; Tuet al. 2008;
Ramirezet al. 2009; Sdiri-Loulizi et al. 2009; Siebengaet al. 2009). It has also been
suggested GII.4 norovirus undergoes genetic drift over time (Gallimoreet al. 2007; Siebenga
et al. 2007). Antigenic drift results in new norovirus whichare antigenically distinct from
previous norovirus strains making the human population susceptible to infection by these new
strains. This high degree of genetic variability seen within norovirus allows information on
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the epidemiology of norovirus to be obtained by analysis of its genetic sequence. Therefore,
to understand this molecular epidemiology more, we havecarried out an analysis of the
genetic sequences from the studies into norovirusin hospitalised adult patients in the UK
(section 4.2) and in community onset gastroenteritis in Brazilian children (section 4.3).
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Figure 4.1: Phylogenetic analysis of norovirus isolates from across the United States, 1993-
1997. Analysis based on the 277-base nucleotide sequences from the partial capsid region.
Table reproduced from Noel et a/ (Noel et al. 1999).
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4.2.1 Background: Molecular epidemiology of norovirus infection in hospitals
Most UK outbreaks of norovirus occurin health care settings, approximately 80%, and these
health care related outbreaks occur mainly in the winter (Lopmanetal. 2003). Research into
the molecular epidemiology of health care associated norovirus has demonstrated that a
single genotype (GII.4) is responsible for most outbreaks of infection. A numberofstudies
have examined the molecular epidemiology of GII.4, principally within hospitalised patients.
A study by Maguire et al sequenced a 270bp polymerase sequence of norovirus from
outbreaks in East Anglia, UK (1996-7). This showed that mostly, distinct viral strains were
identified in specific geographic locations with nearby geographical locations having
genetically similar but distinct strains. The mutations which were associated with a particular
location were often point mutations and infrequently associated with alterations in the amino
acid functional group (Maguireet al. 1999). Similar results were found by Schreieret a/
(Schreier et al. 2000). Dingle et a/ investigated norovirus molecular epidemiology in
nosocomial outbreaks of norovirus in Oxford, UK (2002-3) by sequencing a 3225 nucleotide
section of norovirus. They found that a norovirus outbreak with clinical evidence of person to
person transmission had accumulation of multiple mutations where outbreaks with evidence
of a point source of infection were associated with single mutations (Dingle 2004). Evidence
of intra-outbreak sequence homology, without reference to the suspected type of
transmission, was shown byXerryet al (Xerry et al. 2008; Xerry et al. 2009).
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4.2.2 Introduction: Molecular epidemiology of norovirus in Merseyside, UK
The control of norovirus infection within health care institutions requires an understanding of
its molecular epidemiology. To studythis, norovirus isolates from the study into the oral
diagnosis of norovirus, Chapter Two, were sequenced. The study wasbasedin five hospitals
in Merseyside, UK. The hospitals locations are shown in Figure 4.2. Patients in hospital with
gastroenteritis were entered into the study. Full details of the participants are presented in
section 2.3.1. An investigation of the molecular epidemiology of norovirus was a secondary
research objective of the study into the oral diagnosis of norovirus, detailed in Chapter Two.
Therefore there are limitations on the epidemiological data collected including the complete
history of patient’s locations within hospitals and probable transmission routes between
patients not being collected.
 
Figure 4.2: Location ofthe studysites for the oral diagnosis of norovirus study. Left to right,
with distances from Arrow Park,the study sites are: Arrow Park, Royal Liverpool (9.8km),
Broadgreen and Liverpool Heart and Chest (14.2km) and Whiston Hospital (21.3km).
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4.2.3 Aims
To define the molecular epidemiology of norovirus infection in Merseyside hospitals, UK,
during the winter of 2008/9: in particular:
e To define if there is evidence for inter-hospital transmission of norovirus in
Merseyside hospitals, UK, during the winter of 2008/9.
e To define if introduction of norovirus into Merseyside hospitals is a single or
recurrent event.
e To define if there is evidence specific geographical areas within Merseyside have
distinct strains of norovirus.
4.2.4 TEST METHODS
Qualitative reverse transcriptase PCR:See 2.3.3.1.
DNApurification: See 2.3.3.2.
Sequencing of PCR products: See 2.3.3.3.
Processing and aligning sequence data: See 2.3.3.4.
4.2.5 Results
A total of 100 people were consented for this study with all providing oral samples and 66
providing faecal samples. A total of 22 oral samples and 59 faecal samples had norovirus
sequence detected byreal time RT-PCR.All oral samples and a representative selection of
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these faecal samples underwent qualitative PCR to obtain PCR product for sequencing. A
total of 7 oral and 44 faecal samples were successfully sequenced. Within these norovirus
sequences were8 distinct strains, A-H, with a numberofstrains identified in multiple
patients, Figure 4.3 and Table 4.1. The strains, based on a 278bp region of norovirus
sequence, mainly varied by only 1-3 base pairs, Figure 4.4.
There were 3/100 patients in this study who were admitted to hospital with gastroenteritis, all
other patients acquired the disease nosocomially. Of these 3 patients, only 1 (RH8B-
12/08(16) (see Table 4.1) provided a faecal sample for testing. This patient's (RH8B-
12/08(16)) strain (Strain H) of norovirus wasdistinct from all other sequences identified in
the study.
~— GI/1_M87661Norwalk/68/us
; StrainG: Whiston Hospital
StrainA: Arrow Park
) StrainE Whiston Hospital
| StrainC Royal Liverpool/Broadgreen/Heart and Chest
; StrainF: Arrow Park
StrainB: Arrow Park
StrainD: Arrow Park
 
| | StrainH Royal Liverpool
|. GII/4_X86557Lordsdale/93/UK
GII/13_AY130761M7/99/US
2 — GIV/8_AB067543SaitamaU25/98/JP
~~ GI/9_AY054299IdahoFalls/378/9
| |
|
Figure 4.3: Phylogenetic alignmentofthe strains identified in the oral diagnosis of norovirus
study, A-H,and the hospitals each strain was identified in. Analysis based on 278bp region of
ORF2(starting from ORF2start codon). Phylogenetic analysis conducted using neighbour
joining method. Thecalibration represents nucleotide substitutions perbase.
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Table 4.1: The patients in the study into the oral diagnosis of noroviruslisted alongside the
strains of norovirusidentified in this study, A-H.
 
 
Strain Patient identifying label
Strain A AP33-17/12/08(31), AP43-09/01/09(52), AP43-08/01/09(53), AP24-11/01/09(56), AP24-
(n=14) 11/01/09(57), AP24(MW)-12/01/09(60), AP24-10/01/09(63), AP43-15/01/09(74), AP27-
14/01/09(79), AP26-20/01/09(103), AP27-19/01/09(105), AP27(MW)-19/01/09(106), AP27-
21/01/09(109), AP38-21/01/09(110)
Strain B AP33-14/12/08(30), AP43-08/01/09(50), AP23-13/01/09(65), AP23(MW)-13/01/09(65), AP43-
(n=9) 13/01/09(75), APAMAU-14/01/09(76), AP37-17/01/09(85), AP38-17/01/09(87), AP38-
14/01/09(88), AP38-21/01/09(110)
Strain C BG5-25/12/08(38), BG5(MW)-25/12/08(38), RH9X-27/12/08(41), RH9X-28/12/08(42), RH3X-
(n=12) 24/12/08(46), BG5-28/12/08(47), BG5-08/01/09(54), BG5-10/01/09(55), BG5(MW)-
10/01/09(55), BG5-12/01/09(71), BG11-17/01/09(94), BG11-17/01/09(96), CTA-
30/01/09(121), CTA-31/01/09(122)
Strain D (n=4) AP37-23/11/08(3), AP37-22/11/08(4), AP37-22/11/08(10), AP37-18/11/08(11)
   Strain E (n=3) WHF1-08/12/08(22), WHF1-26/11/08(23), WHB2-0912/08(28)Strain F AP33-17/12/08(33)Strain G WHC3-22/11/08(6)Strain H RH8B-10/11/08(16)No strain AP26(MW)-20/01/09(102), BG11(MW)-17/01/09(94), AP37-25/11/08(9)designation
Patient’s identification: location, date of onset of symptomsand study numberi.e. Hospital
and Ward-DD/MM/YY(study number)). AP= Arrow Park; BG = Broadgreen Hospital;
RH=Royal Liverpool Hospital; CT=Liverpool Heart and Chest Hospital and WH= Whiston
Hospital. Mouthwashesare identified by MW (mouthwash) Where sequenceinformation
was incomplete no strain designation wasassigned.
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5 15 25 35 45 55StrainA ATGAAGATGG CGTCGAATGA CGCCAACCCA TCTGATGGGT CCGCAGCCAA CCTCGTCCCAStrainB ATGAAGATGG CGTCGAATGA CGCCAACCCA TCTGATGGGT CCGCAGCCAA CCTCGTCCCAStrainc ATGAAGATGG CGTCGAATGA CGCCAACCCA TCTGATGGGT CCGCAGCCAA CCTCGTCCCAStrainD ATGAAGATGG CGTCGAATGA CGCCAACCCA TCTGATGGGT CCGCAGCCAA CCTCGTCCCAStrainE ATGAAGATGG CGTCGAATGA CGCCAACCCA TCTGATGGGT CCGCAGCCAA CCTCGTCCCAStrainF ATGAAGATGG CGTCGAATGA CGCCAACCCA TCTGATGGGT CCGCAGCCAA [CTCGTCCCAStrainG ATGAAGATGG CGTCGAATGA CGCCAACCCA TCTGATGGGT CCGCAGCCAA CCTCGTCCCAStrainH ATGAAGATGG CGTCGAJJTGA CGCCAACCCA TCTGATGGGT CCJCAGCCAA CCTCGTCCCA
weleeeel | celeeeel elewas| waas lesan] saws | aes |65 75 85 95 105 115StrainA GAGGTCAACA ATGAGGTTAT GGCTTTGGAG CCCGTTGTCG GTGCCGCTAT TGCGGCGCCTStrainB GAGGTCAACA ATGAGGTTAT GGCTTTGGAG CCCGTTGTCG GTGCCGCTAT TGCGGCGCCTStrainc GAGGTCAACA ATGAGGTTAT GGCTTTGGAG CCCGTTGTCG GTGCCGCTAT TGCGGCGCCTStrainD GAGGTCAACA ATGAGGTTAT GGCTTTGGAG CCCGTTGT§JG GTGCCGCTAT TGCGGCGCCTStrainE GAGGTCAACA ATGAGGTTAT GGCTTTGGAG CCCGTTGTCG GTGCCGCTAT TGCGGCGCCTStrainF GAGGTCAACA ATGAGGTTAT GGCTTTGGAG CCCGTTGTCG GTGCCGCTAT TGCGGCGCCTStrainG GAGGTCAACA ATGAGGTTAT GGCTTTGGAG CCCGTTGTCG GTGCCGCTAT TGCGGCGCCTStrainH GAGGTCAACA ATGAGGTTAT GGCTTTGGAG CCCGTTGT§Jc GTGcccc§AT TGccGcfcct
seelmaes( omselmece! wersfeues| amsslenes! cosa lmae: | oes boos |125 135 145 155 165 175StrainA GTAGCGGGCC AACAAAATGT AATTGACCCC TGGATTAGAA ATAATTTTGT ACAAGCCCCTStrainB GTAGCGGGCC AACAAAATGT AATTGACCCC TGGATTAGAA AMJAATTTTGT ACAAGCCCCTStrainc GTAGCGGGCC AACAAAATGT AATTGACCCC TGGATTAGAA ATAATTTTGT ACAAGCCCCTStrainD GTAGCGGGCC AACAAAATGT AATTGACCCC TGGATTAGAA ATAATTTTGT ACAAGCCCCTStrainE GTAGCGGGCC AACAAAATGT AATIJGACCCC TGGATTAGAA ATAATTTTGT ACAAGCCCCTStrainF GTAGCGGGCC AACAAAATGT AATTGACCCC TGGATTAGAA AJAATTTTGT ACAAGCCCCTStrainG GTAGCGGGCC AACAAAATGT JJATTGACCCC TGGATTAGAA ATAATTTTGT ACAAGCCCCTStrainH GTAGCGGGCC AACAAAATGT AATTGACCCC TGGATTAGAA AMJAATTTTGT ACAAGCCCCT
wom [woes] saoe[wase [seca fmass | asealeesa| earatowse! wave bomns |185 195 205 215 225 235StrainA GGTGGAGAGT TCACAGTATC CCCTAGAAAC GCTCCAGGTG AAATACTATG GAGCGCGCCCStrainB GGTGGAGAGT TCACAGTATC CCCTAGAAAC GCTCCAGGTG AAATACTATG GAGCGCGCCCStrainc GGTGGAGAGT TCACAGTATC CCCTAGAAAC GCTCCAGGTG AAATACTIfTG GAGCGCGCCCStrainD GGTGGAGAGT TCACAGTATC CCCTAGAAAC GCTCCAGGTG AAATACTATG GAGCGCGCCCStrainE GGTGGAGAGT TCACAGTATC CCCTAGAAAC GCTCCAGGTG AAATACTATG GAGCGCGCCCStrainF GGTGGAGAGT TCACAGTATC CCCTAGAAAC GCTCCAGGTG AAATACTATG GAGCGCGCCCStrainG GGTGGAGAGT TCACAGTATC CCCTAGAAAC GCTCCAGGTG AAATACTATG GAGCGCfjCccStrainH GGTGGAGAGT TJACAGTATC CCCTAGAAAC GCTCCAGGTG AAATACTATG GAGCGCGCCC
wemlfawne | nem femme e | omen lames | amet ands | meee [ins245 255 265 275 285StrainA TTAGGCCCTG ATCTGAATCC CTACCTATCT CATTTGGCCA GAATGTAStrainB TTAGGCCCTG ATCTGAATCC CTACYTATCT CATTTGGCCA GAATGTAStrainCc TTAGGCCCTG ATCTGAA[CC CTACCTATCT CATTTGGCCA GAATGTAStrainD TTAGGCCCTG ATCTGAATCC CTACCTATCT CATTTGGCCA GAATGTAStrainE TTAGGCCCTG ATCTGAATCC CTACCTATCT CATTTGGCCA GAATGTAStrainF TTAGGCCCTG ATCTGAATCC CTACCTATCT CATTTGGCCA GAATGTAStrainG TTAGGI[CCTG ATCTGAATCC CTACCTATCT CATTTGGCCA GAATGTAStrainH TTAGGCCCTG ATITGAATCC CTACCT§[Tcl] CATTTGGCCA GAATGTA
Figure 4.4: Sequence data from ORF2ofnorovirusforstrains, (A-H), identified in the oral
diagnosis of norovirus study. The referencestrain is Strain A and where sequencediffers
from Strain A the baseis highlighted.
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4.2.6 Discussion
Norovirus infection in Merseyside hospitals in the winter of 2008/9 was caused by GII.4
norovirus, GII.4 being recognised as the principal cause of nosocomial norovirusglobally.
The 8 distinct strains detected in this study were associated with specific geographical areas.
Strains A, B, D and F wereseen only in Arrow Park Hospital, Upton, Wirral. Strains E andG
were seen in only Whiston Hospital, Prescot. Strain C was seen in morethan onehospital:
Royal Liverpool, Broadgreen and Liverpool Heart and Lung hospital. The hospitals with
strain C serve a population living in the samelocation, transfer patients frequently between
themselves and are geographically close to each other, approximately 4kmsapart. It is
therefore possible Strain C was present in the community whichthese hospitals serve or
spread between these hospitals. These findings are consistent with those of Maguire et al
(Maguireet al. 1999) who also found a predominanceofdistinct viral strains in specific but
closely located geographical areas. The detection of distinct strains within specific locations
mayrepresent either each location has its owndistinct strains of norovirus, or, that there is
such a large degree of variation within norovirus in the community thatit is unlikely the same
strain of norovirus would be detected in two different locations.
The detection of a single strain on multiple wards over a period of a month is difficult to
interpret. It initially suggests environmental contamination but a similar finding, distinct
strains in multiple outbreaks, was noted by Dingle et a/, after analysing a 285nt RNA
polymerase region in multiple outbreaks (Dingle 2004). Further analysis, of a 3225nt section
of norovirus sequence, allowed the investigators to subsequently definethatdistinct strains
were responsible for single outbreaks. By resolving that the outbreaks were caused by
different strains Dingle et al concluded the outbreaks resulted from multiple viral
introductions from the community. The data at Arrow Park hospital, though not asdetailed, is
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consistent with this conclusion as three different strains were found to cause outbreaks,
Strains A, B and D. Further genetic analysis of our isolates is needed before making more
detailed conclusions on the associations of outbreaks defined in this study as having the same
strain. In addition, information onstrainscirculating in the community would help to confirm
if the local community wasthe sourceofthe strains of norovirus identified in the study.
Strain H had the most mutations present compared to the other strains. This strain was found
in the eldest person in the study, 97 years old, who had also had the longest duration of
symptomsat sampling, 23 days. This patient was admitted to the hospital with gastroenteritis
therefore it is possible the virus was acquired with the genetic sequence we obtained.It is
also possible that in vivo mutation occurred, as previously described (Nilssonet al. 2003).
The environmental sites where mutations occur are important to understand as these
mutations representviral evolution. In theory, controlling the sites of this evolution would
prevent the developmentof new viral strains for which humanshave no immunity.
4.2.7 Limitations
e Epidemiological and sequence data was incomplete preventing more detailed analysis
of closely related, in time and place, outbreaks of norovirus.
e The molecular analysis ofthe norovirusstrains within these hospitals is limited by an
absence of information on thestrains circulating in the community in Merseyside. For
example, why wasonly the GII.4 strain of norovirus detected in this study? Is the
GIL.4 strain of norovirus biologically adapted to transmission in hospitals oris it
predominant in the community?
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4.2.8 Further work
e Further sequenceanalysis of distinct strains is needed to increase confidencein the
study findings
e Analysis of the clinical and molecular epidemiology of community acquired norovirus
infection is needed to define the source/s of community acquired norovirusinfection.
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4.3.1 Background: Molecular epidemiology of community acquired paediatric
norovirus infection
The molecular epidemiology of paediatric norovirus infection has been investigated globally
and both genogroup I and genogroup IJ norovirus commonly cause infection. One genotype,
GII.4, is the predominant cause of norovirus infection. Other genotypes that are more
commoninclude GII.2/3/5/7 (Doveet al. 2005; Kirkwoodet al. 2005; Sdiri-Louliziet al.
2009). Whilst GII.4 is the predominant genotypeit does not usually dominate the
epidemiology of paediatric diarrhoea in the waythat it does in nosocomial infection. Some
studies show that GI and GII infections are detected equally as often, with the detection of
multiple genotypes being common (Colombaet al. 2007; Monicaet al. 2007; Soaresetal.
2007; Victoria et al. 2007; Lee et al. 2008; Malasaoet al. 2008; Rachakondaet al. 2008;
Chhabraet al. 2009; Guoet al. 2009; Xavieret al. 2009).
4.3.2 Introduction: Molecular epidemiology of norovirus in Aracaju, Brazil.
Children are the age cohort mainly infected by norovirus. Given no vaccineis available to
prevent norovirus infection, preventing transmission of norovirusis the main strategy
available to prevent children becoming infected. An understanding of the molecular
epidemiology ofnorovirus in this cohort may allow an improved understanding of
transmission of norovirus. This may lead to prevention strategies being better informed and
further research into norovirus transmission being appropriately designed. Therefore, a study
into the molecular epidemiology ofthe norovirus isolates derived from the study into
norovirus diagnostics, Chapter Three, on Brazilian paediatric faecal samples, was undertaken.
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The study used faecal samples collected from children with acute gastroenteritis, Aracaju,
Brazil. The population was made oftwo cohorts of children with gastroenteritis: Children
presenting to hospital with gastroenteritis and children in the community with gastroenteritis
whowerepart of a longitudinal study of investigating paediatric gastroenteritis. Full details
of the participants are presented in section 3.3.1.
4.3.3 Aims
e To define the molecular epidemiology of community acquired norovirus infection in
children in Aracaju, Brazil, in 2006/7 including:
e Defining the tempora-spatial distribution of distinct norovirusstrains in Aracaju,
Brazil, over the study period, October 2006-December 2007.
4.3.4 Methods:Seesection 4.2.4
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4.3.5 Results
A total of 96 faecal samples had norovirus infection confirmed byreal time and qualitative
PCR.Of these, 79 samples produced sufficient PCR product to obtain sequence data. The
phylogenetic profile of these isolates is shown in Figure 4.5. Most isolates were detected in
genogroupII and most f these were GII.4. The molecular epidemiology of norovirus infection
detected in the community and hospital cohorts did not obviously differ.
In addition a sequenceof uncertain strain classification (genotype) was detected in patients
89/93. These unclassified sequences are shown in moredetail in Figure 4.6. A numberof
sequences were identified in multiple patients, Table 4.2.
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Figure 4.6: Phylogenetic analysis (NJ method) of GII norovirus and undetermined genogroup
norovirusisolates from children with gastroenteritis, Aracaju, Brazil. Analysis carried out on
an approximately 278bp region of ORF2. This study patients are labelled as H, hospital, C,
community, MonthYearofisolation and study numbere.g. H0607-43. Where multiple
isolates with sameposition on the tree are presentjust the study numberis given e.g. 10-25-
44 (Table 4.2). Genbank accession No’s: EU007803.1, GQ166516, FJ88291 and FJ788291.1
are the isolates most closely related to Study No.isolates 83 and 89.
Table 4.2: Dates, sources and study numbersfor isolates grouping at the same terminal
 
  
branch in Figure 4.4.
Strain . . Time betweenfirst and last
designation Patientdetails (study No.) detection (months)
H10/06(1), H11/06(3), H11/06(2), H11/06(4), H12/06(7),
H12/06(11), ) HO3/07(16), HO4/07(19), HO5/07(23),
1 H05/07(24), HOS/07(25), HO6/07(30), C06/07(73), CO6/07(84), 12
C09/07(90)
H04/07(17), HO4/07(18),HO4/07(20),HO4/07(21),HO4/07(22),
5 H05/07(27), HO5/07(26), HO6/07(28),HO6/07(29), 3
H06/07(30),HO6/07(35)
, H07/07(44), H10/07(51), H10/07(54), H10/07(56), 5
H10/07(57), C10/07(94), H12/07(66)
4 H09/07(47), HO9/07(48), HO9/07(49), H10/07(53), 2
H10/07(58), H10/07(60)
5 HO7/07(42), CO8/07(69), CO5/07(70), CO5/07(72), C01/07(75), 7
C08/07(80)
6 H06/07(33), HO6/07(36), HO6/07(37), HO7/07(38) HO7/07(39) 2
7 C09/07(83), C10/07(89) 2
8 H06/07(34), H10/07(55) 4
9 C11/07(92), CO1/07(75) 2
10 H12/06(8), NK(67) nk  
Patients label: community (C) or hospital location (H); date sample collected
month/year(study number).
4.3.6 Discussion
The norovirusesidentified in this study included both genogroupsI and II. They were mainly
genogroupII (91%: 70/77) and the main genotype was GII.4 (75%: 58/77). Two patients had
mixed genogroupI andII infections. These data are consistent with other published studies
that have shown GII, and principally GII.4 being the main genogroups/genotypes of
norovirus detected (Soares et al. 2007; Victoria et al. 2007; Lee et al. 2008; Malasao etal.
2008; Rachakondaet al. 2008; Chhabraet al. 2009; Guoet al. 2009; Nayaket al. 2009;
Ramirezet al. 2009; Xavieret al. 2009). In addition, a putative new genotype of norovirus
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only previously described four times was detected in this study. This was Strain 7, detected in
two samples, C09/07(83), C10/07(89). The phylogenetic analysis of strain 7 showed the
sequence distance betweenit andits closets reference genotype, GII.4, was similar to
distances seen recognised genotypes (Figure 4.5). A nucleotide BLASTanalysis ofthe
sequence registered three human (Genbank accession No’s: EU007803.1, GQ166516,
FJ88291) and one surface water derived (FJ788291.1|) matching sequences (=98% maximal
identity) (Figure 4.6). The humanisolates were detected in Sweden 2002-6; Bulgaria 2007
and Botswana 2006. The surface water sample was from Singapore in 2006. The next most
similar sequence was 93% similar (EU373815). This strain is widely dispersed, now detected
in four continents and may be a newly emerging strain. Continued molecular surveillance will
be needed to investigate this possibility. It may also represent a new genotype but more
genetic sequence data is needed to makethat conclusion.
A numberofdistinct sequences(strains) were detected in multiple patients (Table 4.2). Of
note, several strains were identified over prolonged timeperiods. Strain 1, 3 and 5 were
detected over a period of 12, 5 and 7 monthsrespectfully. The patients with these strains were
resident over a wide area within Sergipe State and Bahia State in Brazil (Personnel
communication: R Gurgel, Sergipe University, Brazil). With a short duration of infection,if
person to person transmission maintained the virus overthis time period then multiple
transmission events(viral replications) would have been expected to occur over these time
periods. Mutations associated with viral replication has been showninthree studies. In two
cases of prolonged excretion mutation rates of 0.03 nucleotide substitutions per site per year
were detected (Nilsson et al. 2003; Dingle 2004) and in one personto person outbreak a rate
of 0.04 was detected (Dingle 2004). These mutation rates should result in 8 mutations in a
277bp region overa one year period (0.03x277). Given onestrain was detected over a one
year period without any mutations in the 277bp region, it is tempting to concludethis
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provides evidencethat person to person transmission wasnot how norovirusspread in this
community, and therefore transmission was based on environmental sources of norovirus.
This conclusion cannot though be madeas the 277bp region studied in these patients (5 prime
end of ORF2) has a lowerrate of mutation than other regions of the norovirus genome, and
the mutation rate of this section of genome has not been reported (Boket al. 2009). More
detailed sequence analysis and epidemiological information is needed to understand how the
GII.4 strains spread in this population. The recognition of the global distribution of similar
strains of norovirus over prolonged periods has also been noted previously (Noelet al. 1999;
Siebengaet al. 2009). Since that time a definitive answer has not emerged to explain how
norovirus spreads globally. Speculated transmission routes include person to person and
environmental sources including food (Widdowsonet al. 2005) and water contamination
(Lodder and de Roda Husman 2005; Maunulaet al. 2005). Future epidemiological research
may better define how norovirus spreads globally and this may allow the implementation of
effective controlstrategies.
4.3.7 Limitations
e Only norovirus isolates with sufficient PCR product to sequence after a single
qualitative PCR reaction were sequenced. This provided representatives from all
outbreak locations in the oral diagnosis study and the majority (79/96) of samples
from the Brazilian study. Therefore all norovirus infected patients from the studies did
not havetheir isolates sequenced. This may have introduced somebiasinto the
phylogenetic analysis of these two norovirus infected cohorts.
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e Data on exposure history (to gastroenteritis) was not collected limiting ability to
epidemiologically link subjects with molecularly related norovirus.
e Sequence data collected waslimited to the shell domain of ORF2.
4.3.8 Further work
e Descriptive epidemiological studies are needed to describe environmental sources of
norovirus infection and person to person transmission in this community.
e Further sequenceanalysis of Strain 7 is needed to investigate if it is a new genotype of
norovirus.
4.4 Conclusions
This study has provided a preliminary assessment of the molecular epidemiology of norovirus
infection in two very different settings. One setting a paediatric cohort of community
acquired infection in Brazil, and the other setting a predominantly elderly cohort with
nosocomially acquired infection. It is difficult therefore to bring these data sets together to
providea joint conclusion about the molecular epidemiology of norovirus infection, which
mayin fact be very different within these two cohorts.It is though clearthat in bothsettings
GII.4 norovirusis the main strain causing norovirus infection. Globally, spread of GII.4
norovirus has been shownto occur by manyroutes, from foodborne sourcese.g. shellfish and
salads, to water sources, with large outbreaks caused by municipal water supplies and from
person to person. In the future it maybe of benefit to the prevention of norovirusinfection to
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understand if one of these methodsaloneis responsible for maintaining GII.4 transmission
within populations, or if transmission is maintained by a combination ofdifferent
transmission routes.
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Conclusions
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Conclusions
Evaluating diagnostictests is a difficult process (Scott et al. 2008). Ideally any evaluation
would haveat its centre a gold standard which was 100% accurate. Thisis rarely the case in
practise, and evaluations must proceedin their absence. This study evaluated novel
approachesto the diagnosis of norovirus.
In Chapter Two,results from an investigation into the sensitivity of the oral diagnosis of
norovirus infection were reported. The sensitivity was found to be 24% compared to
diagnosis using faecal samples. The detection of norovirus was associated with vomiting and
inversely associated with the duration of diarrhoea and vomiting. This chapter concludes,
given the low sensitivity of oral samples, faecal samples should continue to be used to
diagnose norovirus infection. It may though be ofbenefit to investigate swab samples of
faeces and vomit as samples to diagnose norovirusinfection, and this is ongoing.
In Chapter Three, the results of an investigation into new immunological norovirustests, the
RIDASCREENELISA and RIDAQUICK immunochromatographictests, were reported. This
showed the RIDASCREEN ELISA and the RIDAQUICKICGhada sensitivity of 70% and
79% respectively in hospitalised children in Aracaju, Brazil. Both tests had a specificity of
100%. This was based on a comparison to PCR diagnosis of faecal samples. Given these
findings, how should a laboratory decide on whichtest is best for them to use to diagnose
norovirus infection? This may becarried out by considering practical factors. Practical
factors include the laboratory situation testing is to be undertakenin. For instance, some
laboratories may have no molecular diagnostic tests available and the choice will therefore
depend on how manysamplesthe laboratory anticipates testing. Thus, the RIDAQUICKtest
would be appropriate if low numbersare to be examined, the RIDASCREENiflarger
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numbers were being tested. In those laboratories with molecular testing available the number
of tests being carried out should dictate whichtest to use. If small numbersare beingtested,
given the high specificity of immunological testing, samples could befirst tested
immunologically followed by PCRtesting if needed. If laboratories are routinely testing
many samplesit may be preferable to use PCR. Samples positive by PCR could be
categorised astrue positives by either defining a cut off PCR value or confirming by the
RIDASCREEN/RIDAQUICK,given the lower probability of a false positive by antigen
detection. Another meansof deciding betweentests is to considertheir clinical utility. Given
there is no specific treatment for norovirus gastroenteritis there are many situations where a
diagnosis will have no benefit to the patient. Without consideration ofa test’s clinicalutility
these tests will drift into becoming routine diagnostic tests without an understanding on the
impact they have on patientcare. In particular, the role norovirus diagnostics have in
outbreaks of norovirus gastroenteritis needs further consideration before deciding how to
confirm a norovirus outbreak. To decide uponthe role norovirus diagnostics have in
outbreaks of gastroenteritis two questions need answering. Thefirst questionis if there is
actually a need for laboratory testing of norovirus. Clinical assessmentof an outbreak of
norovirus, in the experience of the Infection Control team at the Royal Liverpool University
Hospital (RH) (personnel communication: G. Smith, RH), is an accurate meansof diagnosing
norovirusinfection. This is also supported by the use of simple inclusion and exclusion
criteria for the oral diagnosis study. This resulted in 89% ofparticipants entered for this study
having norovirus infection. Secondly, consideration should be given to the impact of
laboratory testing in controlling norovirus outbreaks. Given these outbreaks require prompt
instigation of infection control practices there is a risk that these actions are delayed whilst
waiting for a norovirustest result. Therefore whether norovirus diagnostics contribute
positively to the control of norovirus outbreaks should be confirmed.
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In Chapter Four, the phylogenetic analysis conducted highlighted important issues regarding
the transmission of norovirus. Theprincipal issue raised was how norovirus transmission
occurs andtheresults raised the possibility that environmental sources maybe the cause of
norovirus infection over a wide area in Brazil. In a globalised world it is easy to see how this
may occur, with for example, food exported globally. Water and food are likely
environmentalreservoirs of infection. Contamination of water and food offers challenges
and opportunities. The challenge results from the failure of established processes for cleaning
water/food. The opportunity arises when norovirusis considered alongside other viral agents
which cause infection via drinking water/food (Leclerc et al. 2002). Other agents include
enteroviruses, astrovirus, rotavirus and hepatitis A and E. All these agents are RNA viruses,
all are non enveloped andall are between 20-70nm in diameter. Therefore, there is the
potential that devising/implementing methods stopping the transmission of any one ofthese
viruses may prevent transmissionofall of these viruses.
In conclusion, the analytical sensitivity of norovirus immunological diagnostics has
increased with the introduction of the RIDASCREEN and RIDAQUICKnorovirus diagnostic
tests. The clinical accuracy though, of both tests, remains uncertain. Establishing these
relationships offers challenges for future researches of immunological norovirus diagnostics.
Given the lack of preventative strategies for norovirus infection globally, further work into
understanding the global transmission of epidemicstrains of norovirus is needed.
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WHF1-12/08(23)
WHB2-12/08(26)
WHF1-12/08(24)
WHB2-11/08(27)
WHF1-12/08(21)
WHF1-12/08(20)
WHF1-12/08(22)
WHB2-12/08(28)
AP33-12/08(33)
AP33-12/08(32)
AP33-12/08(35)
AP33-12/08(34)
AP33-12/08(30)
AP33-12/08(31)
BG5-12/08(39)
BG5-12/08(38)
BG5-12/08(37)
BG5-12/08(40)
RH9X-12/08(41)
RH9X-12/08(42)
RH9X-10/08(43)
RH8A-12/08(34)
RH3X-12/08(46)
RH8A-12/08(45)
BG7-12/08(48)
BG5-11/08(47)
Age Ward
AP 37
AP 37
AP 37
WHC3
AP 37
WHC3
AP 37
WHC3
WHC3
AP 37
WHC3
WH C3
WH C3
WH C3
RH 8B
WH F1
WH B2
WH F1
WHB2
WH F1
WH F1
WH F1
WH B2
AP 33
AP 33
AP 33
AP 33
AP 33
AP 33
BG5
BG5
BG5
BG5
RH 9X
RH 9X
RH 9X
RH 8A
RH 3X
RH 8A
BG7
BG5
Date Of
admission
18/11/2008
20/11/2008
20/11/2008
20/11/2008
15/11/2008
18/11/2008
17/11/2008
16/11/2008
10/10/2008
21/11/2008
02/10/2008
23/11/2008
21/11/2008
22/11/2008
20/11/2008
26/11/2008
03/12/2008
04/12/2008
24/11/2008
28/11/2008
03/12/2008
18/10/2008
28/11/2008
12/12/2008
10/12/2008
08/12/2008
10/10/2008
08/12/2008
16/11/2008
14/12/2008
14/12/2008
02/12/2008
06/12/2008
22/12/2008
22/12/2008
05/10/2008
26/11/2008
17/12/2008
25/11/2008
07/12/2008
26/11/2008
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Dateof oral
sampling/data
collection
24/11/2008
24/11/2008
24/11/2008
25/11/2008
25/11/2008
25/11/2008
25/11/2008
25/11/2008
25/11/2008
25/11/2008
26/11/2008
26/11/2008
26/11/2008
26/11/2008
03/12/2008
11/12/2008
11/12/2008
11/12/2008
11/12/2008
11/12/2008
11/12/2008
11/12/2008
11/12/2008
18/12/2008
18/12/2008
18/12/2008
18/12/2008
18/12/2008
18/12/2008
27/12/2008
27/12/2008
27/12/2008
27/12/2008
29/12/2008
29/12/2008
29/12/2008
30/12/2008
30/12/2008
30/12/2008
31/12/2008
31/12/2008
Duration of
admissionat oral
sampling: Days
6
4
4
10
46
55
13
15
17
13
54
13
10
69
10
32
13
13
25
21
85
34
13
35
24
35
Date of Onset:
Vomiting
23/11/2008
22/11/2008
19/11/2008
22/11/2008
18/11/2008
No vomiting
No vomiting
No vomiting
No vomiting
No vomiting
23/11/2008
23/11/2008
25/11/2008
26/11/2008
10/11/2008
26/11/2008
05/12/2008
09/12/2008
07/12/2008
08/12/2008
No vomiting
No vomiting
No vomiting
17/12/2008
17/12/2008
15/12/2008
15/12/2008
14/12/2008
No vomiting
27/12/2008
25/12/2008
24/12/2008
No vomiting
27/12/2008
25/12/2008
No vomiting
27/12/2008
24/12/2008
No vomiting
24/12/2008
No vomiting
Study ID (Number)
BG7-12/08(49)
AP43-01/09(52)
AP43-01/09(50)
AP43-01/09(51)
AP43-01/09(53)
BG5-01/09(55)
BG5-01/09(54)
AP24-01/09(60)
AP23-01/09(65)
AP24-01/09(57)
AP24-01/09(61)
AP24-01/09(58)
AP24-01/09(63)
AP24-01/09(56)
AP25-01/09(68)
AP32-01/09(69)
AP32-01/09(70)
AP27-01/09(78)
AP43-01/09(72)
APAMAU-
01/09(77)
AP43-01/09(74)
AP27-01/09(81)
AP27-01/09(79)
AP23-01/09(80)
AP43-01/09(75)
APAMAU-
01/09(76)
BG5-01/09(71)
AP27-01/09(82)
AP43-01/09(73)
AP38-01/09(86)
AP38-01/09(87)
AP38-01/09(88)
AP37-01/09(85)
AP27-01/09(84)
BG11-01/09(70)
BG11-01/09(96)
BG11-01/09(94)
AP37-01/09(90)
AP27-01/09(91)
AP26-01/09(101)
Age
92
64
91
87
76
66
86
94
89
91
85
85
83
88
64
71
75
83
86
80
76
78
84
85
89
93
75
66
87
77
64
82
61
89
93
91
94
70
88
91
Sex
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eE
em
nm
nm
Zz
Fm
re
sa
Tm
Mr
TF
TMF
TF
TM
TH
Z
F
m
4m
Tm
T
T
n
o
n
7
F<
f
e
z
m
S
78
5
£5
8
F7
17
F
m
oT
n
n
=
m
Ward
BG7
AP 43
AP 43
AP 43
AP 43
BGS
BGS5
AP 24
AP 23
AP 24
AP 24
AP 24
AP 24
AP 24
AP 25
AP 32
AP 32
AP 27
AP 43
AP
AMAU
AP 43
AP 27
AP 27
AP 23
AP 43
AP
AMAU
BGS
AP 27
AP 43
AP 38
AP 38
AP 38
AP 37
AP 27
BG 11
BG 11
BG 11
AP 37
AP 27
AP 26
Date Of
admission
16/12/2008
05/01/2009
13/12/2008
05/01/2009
06/01/2009
09/12/2008
05/01/2009
30/12/2008
08/01/2009
06/01/2009
31/12/2008
07/01/2009
26/12/2008
29/12/2008
27/11/2008
10/01/2009
08/01/2009
15/12/2008
14/01/2009
12/01/2009
09/01/2009
10/01/2009
17/12/2008
18/12/2008
09/01/2009
07/01/2009
16/12/2008
24/12/2008
02/01/2009
02/01/2009
08/01/2009
09/01/2009
09/01/2009
05/12/2008
10/11/2008
03/01/2009
03/01/2009
13/01/2009
13/01/2009
30/12/2008
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Dateoforal
sampling/data
collection
31/12/2008
09/01/2009
09/01/2009
09/01/2009
09/01/2009
10/01/2009
10/01/2009
13/01/2009
13/01/2009
13/01/2009
13/01/2009
13/01/2009
13/01/2009
13/01/2009
14/01/2009
15/01/2009
15/01/2009
16/01/2009
16/01/2009
16/01/2009
16/01/2009
16/01/2009
16/01/2009
16/01/2009
16/01/2009
16/01/2009
16/01/2009
16/01/2009
16/01/2009
18/01/2009
18/01/2009
18/01/2009
18/01/2009
18/01/2009
19/01/2009
19/01/2009
19/01/2009
19/01/2009
19/01/2009
20/01/2009
Duration of
admission at
oral sampling:
Days
15
4
27
4
32
5
30
29
31
23
14
16
10
44
70
16
16
21
Date of Onset:
Vomiting
No vomiting
09/01/2009
08/01/2009
08/01/2009
No vomiting
10/01/2009
No vomiting
12/01/2009
13/01/2009
11/01/2009
10/01/2009
10/01/2009
No vomiting
No vomiting
14/01/2009
13/01/2009
No vomiting
15/01/2009
16/01/2009
11/01/2009
15/01/2009
14/01/2009
14/01/2009
14/01/2009
14/01/2009
14/01/2009
12/01/2009
No vomiting
No vomiting
18/01/2009
17/01/2009
No vomiting
No vomiting
No vomiting
19/01/2009
17/01/2009
17/01/2009
No vomiting
No vomiting
20/01/2009
Study ID (Number)
AP27-01/09(106)
AP27-01/09(105)
AP26-01/09(102)
BG11-01/09(100)
AP37-01/09(107)
AP26-01/09(103)
AP26-01/09(104)
AP27-01/09(109)
AP38-01/09(110)
BG11-01/09(108)
AP37-01/09(111)
RH8MCU-
01/09(112)
AP26-01/09(113)
RH3A-01/09(115)
RH5B-01/09(117)
CTA-02/09(120)
CTA-02/09(121)
CTA-02/09(122)
CTA-02/09(123)
Age
79
95
61
74
74
53
84
77
80
55
55
76
66
88
70
57
78
56
86
Sex
=<
=
€©€
€
€
7
<
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<€
€&
Ward
AP 27
AP 27
AP 26
BG 11
AP 37
AP 26
AP 26
AP 27
AP 38
BG 11
AP 37
RH
8MCU
AP 26
RH 3A
RH 5B
CTA
CTA
CTA
CTA
Date Of
admission
08/01/2009
03/01/2009
16/01/2009
07/11/2008
17/01/2009
16/01/2009
14/01/2009
06/01/2009
16/01/2009
16/01/2009
17/01/2009
17/12/2008
11/01/2009
23/01/2009
16/09/2008
28/01/2009
28/01/2009
29/01/2009
30/01/2009
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Dateof oral
sampling/data
collection
20/01/2009
20/01/2009
20/01/2009
20/01/2009
20/01/2009
20/01/2009
20/01/2009
21/01/2009
21/01/2009
21/01/2009
22/01/2009
22/01/2009
23/01/2009
27/01/2009
30/01/2009
03/02/2009
03/02/2009
03/02/2009
03/02/2009
Duration of
admission at
oral sampling:
Days
12
17
74
36
12
136
Fr
UN
D
BD
Date of Onset:
Vomiting
19/01/2009
19/01/2009
20/01/2009
19/01/2009
19/01/2009
No vomiting
No vomiting
21/01/2009
21/01/2009
No vomiting
21/01/2009
22/01/2009
21/01/2009
No vomiting
29/01/2009
02/02/2009
01/02/2009
No vomiting
No vomiting
Study ID (Number)
AP37-11/08(3)
AP37-11/08(4)
AP37-11/08(2)
WHC3-11/08(7)
AP37-11/08(11)
WHC3-11/08(5)
AP37-11/08(10)
WHC3-11/08(8)
WHC3-11/08(6)
AP37-11/08(9)
WHC3-11/08(13)
WHC3-11/08(14)
WHC3-11/08(12)
WHC3-11/08(15)
RH8B-12/08(16)
WHF1-12/08(23)
WHB2-12/08(26)
WHF1-12/08(24)
WHB2-11/08(27)
WHF1-12/08(21)
WHF1-12/08(20)
WHF1-12/08(22)
WHB2-12/08(28)
AP33-12/08(33)
AP33-12/08(32)
AP33-12/08(35)
AP33-12/08(34)
AP33-12/08(30)
AP33-12/08(31)
BG5-12/08(39)
BG5-12/08(38)
BG5-12/08(37)
BG5-12/08(40)
RH9X-12/08(41)
RH9X-12/08(42)
RH9X-10/08(43)
RH8A-12/08(34)
RH3X-12/08(46)
RH8A-12/08(45)
BG7-12/08(48)
BG5-11/08(47)
No. of days
since vomiting
began
1
2
5
3
7
N/A
N/A
N/A
N/A
N/A
23
15
N/A
N/A
N/A
PP
W
W
RP
PR
N/A
Dateof onset:
Diarrhoea
23/11/2008
22/11/2008
19/11/2008
23/11/2008
18/11/2008
24/11/2008
22/11/2008
25/11/2008
22/11/2008
25/11/2008
23/11/2008
23/11/2008
26/11/2008
26/11/2008
10/11/2008
26/11/2008
05/12/2008
09/12/2008
07/12/2008
08/12/2008
08/12/2008
08/12/2008
09/12/2008
17/12/2008
17/12/2008
15/12/2008
15/12/2008
14/12/2008
16/12/2008
27/12/2008
25/12/2008
24/12/2008
26/12/2008
27/12/2008
28/12/2008
27/12/2008
27/12/2008
24/12/2008
27/12/2008
24/12/2008
28/12/2008
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No. of days
since
diarrhoea
began
1
SD
oO
W
W
O
W
OC
W
r
R
NY
NY
WN
DN
P
N
nm
Ww
W
D
W
N
P
NY
RP
W
n
DO
NY
F
W
W
P
PRP
NY
W
W
wo
B
N
OD
N
Last
Vomit:
Days
0.75
1.00
4.00
0.00
3.00
N/A
N/A
N/A
N/A
N/A
0.00
0.13
0.25
0.25
N/K
0.33
1.00
1.00
3.00
3.50
N/A
N/A
N/A
0.75
1.17
2.00
2.00
4.00
N/A
0.33
0:33
3.00
N/A
1.50
2.00
N/A
3.50
4.00
N/A
7.00
N/A
Last diarrhoea:
Days
0.75
2.00
0.00
0.17
1.00
0.00
0.00
0.16
0.75
0.00
0.00
0.00
0.00
0.16
1.00
0.20
1.00
1.00
3.00
2.00
2.00
2.00
0.00
0.25
0.50
0.00
0.00
1.50
1.00
0.16
0.07
0.00
1.00
1.15
0.13
0.00
2.50
2.50
1.00
1.00
0.25
Oral real
time PCR
result
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
POS
NEG
NEG
NEG
NEG
POS
POS
NEG
NEG
POS
NEG
NEG
NEG
POS
NEG
POS
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
No.of days
No.of days since Last Oral real
since vomiting Date of onset: diarrhoea Vomit: Last diarrhoea: time PCR
Study ID (Number) began Diarrhoea began Days Days result
BG7-12/08(49) N/A 29/12/2008 2 N/A 0.50 NEG
AP43-01/09(52) 0 09/01/2009 0 0.25 0.16 POS
AP43-01/09(50) 1 08/01/2009 1 0.77 0.75 POS
AP43-01/09(51) 1 No Diarrhoea N/A 1.50 0.00 POS
AP43-01/09(53) N/A 08/01/2009 1 N/A 0.00 NEG
BG5-01/09(55) 0 No Diarrhoea N/A 0.00 0.00 POS
BG5-01/09(54) N/A 08/01/2009 2 N/A 0.00 NEG
AP24-01/09(60) 1 12/01/2009 1 0.13 0.50 POS
AP23-01/09(65) 0 13/01/2009 0 0.20 0.15 POS
AP24-01/09(57) 2 11/01/2009 2 0.33 0.15 NEG
AP24-01/09(61) 3 10/01/2009 3 2.50 0.15 NEG
AP24-01/09(58) 3 10/01/2009 3 3.00 0.50 NEG
AP24-01/09(63) N/A 10/01/2009 3 N/A 2.00 NEG
AP24-01/09(56) N/A 11/01/2009 2 N/A 0,25 NEG
AP25-01/09(68) 0 14/01/2009 0 0.00 0.00 NEG
AP32-01/09(69) y 13/01/2009 2 2.00 0.00 NEG
AP32-01/09(70) N/A 14/01/2009 © 1 N/A 0.15 NEG
AP27-01/09(78) 1 15/01/2009 1 0.00 0.25 NEG
AP43-01/09(72) 0 16/01/2009 0 0.13 0.00 NEG
APAMAU-01/09(77) 5 11/01/2009 5 0.20 0.75 NEG
AP43-01/09(74) 1 15/01/2009 1 0.75 0.43 NEG
AP27-01/09(81) 2 14/01/2009 2 0.85 0.80 NEG
AP27-01/09(79) 2 14/01/2009 2 117 1.15 NEG
AP23-01/09(80) 2 14/01/2009 2 1.33 0.75 NEG
AP43-01/09(75) 2 13/01/2009 3 2.00 1.75 NEG
APAMAU-01/09(76) 2 14/01/2009 2 2.00 0,25 NEG
BG5-01/09(71) 4 12/01/2009 4 3.00 2.00 NEG
AP27-01/09(82) N/A 16/01/2009 0 N/A 0.00 NEG
AP43-01/09(73) N/A 14/01/2009 2 N/A 2.00 NEG
AP38-01/09(86) 0 18/01/2009 0 0.30 0.16 NEG
AP38-01/09(87) 1 17/01/2009 1 1.00 1.57 NEG
AP38-01/09(88) N/A 14/01/2009 4 N/A 0.00 NEG
AP37-01/09(85) N/A 17/01/2009 1 N/A 0.13 NEG
AP27-01/09(84) N/A 17/01/2009 1 N/A 1.00 NEG
BG11-01/09(70) 0 19/01/2009 0 0.20 0.00 POS
BG11-01/09(96) 2 17/01/2009 2 2.00 0.60 NEG
BG11-01/09(94) 2 17/01/2009 2 2.00 0.60 POS
AP37-01/09(90) N/A 19/01/2009 0 N/A 0.10 NEG
AP27-01/09(91) N/A 19/01/2009 0 N/A 0.13 NEG
AP26-01/09(101) 0 No Diarrhoea N/A 0.00 0.00 NEG
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Study ID (Number)
AP27-01/09(106)
AP27-01/09(105)
AP26-01/09(102)
BG11-01/09(100)
AP37-01/09(107)
AP26-01/09(103)
AP26-01/09(104)
AP27-01/09(109)
AP38-01/09(110)
BG11-01/09(108)
AP37-01/09(111)
RH8MCU-
01/09(112)
AP26-01/09(113)
RH3A-01/09(115)
RH5B-01/09(117)
CTA-02/09(120)
CTA-02/09(121)
CTA-02/09(122)
CTA-02/09(123)
No.of days
No. of days Date of since Last
since vomiting onset: diarrhoea Vomit:
began Diarrhoea began Days
1 19/01/2009 1 0.00
1 19/01/2009 1 0.00
0 No Diarrhoea N/A 0.00
1 19/01/2009 1 0.25
1 19/01/2009 1 0.25
N/A 20/01/2009 0 N/A
N/A 20/01/2009 0 N/A
0 21/01/2009 0 0.00
0 21/01/2009 0 0.40
N/A 19/01/2009 2 N/A
1 21/01/2009 1 0.13
0 22/01/2009 0 0.18
2 21/01/2009 2 0.85
N/A 27/01/2009 0 N/A
1 29/01/2009 1 0.50
1 02/02/2009 1 0.85
2 30/01/2009 4 3.00
N/A 31/01/2009 3 N/A
N/A 31/01/2009 3 N/A
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Last
diarrhoea:
Days
0.00
0.00
0.00
0.00
0.33
0.13
0.00
0.00
0.50
0.75
0.00
0.33
0.15
0.13
0.57
0.80
0.13
0.20
1.00
Oral real
time PCR
result
POS
POS
POS
POS
POS
NEG
POS
POS
POS
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
Study ID (Number)
AP37-11/08(3)
AP37-11/08(4)
AP37-11/08(2)
WHC3-11/08(7)
AP37-11/08(11)
WHC3-11/08(5)
AP37-11/08(10)
WHC3-11/08(8)
WHC3-11/08(6)
AP37-11/08(9)
WHC3-11/08(13)
WHC3-11/08(14)
WHC3-11/08(12)
WHC3-11/08(15)
RH8B-12/08(16)
WHF1-12/08(23)
WHB2-12/08(26)
WHF1-12/08(24)
WHB2-11/08(27)
WHF1-12/08(21)
WHF1-12/08(20)
WHF1-12/08(22)
WHB2-12/08(28)
AP33-12/08(33)
AP33-12/08(32)
AP33-12/08(35)
AP33-12/08(34)
AP33-12/08(30)
AP33-12/08(31)
BG5-12/08(39)
BG5-12/08(38)
BG5-12/08(37)
BG5-12/08(40)
RH9X-12/08(41)
RH9X-12/08(42)
RH9X-10/08(43)
RH8A-12/08(34)
RH3X-12/08(46)
RH8A-12/08(45)
BG7-12/08(48)
BG5-11/08(47)
Oral
qualitative
PCR result
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
NEG
N/A
N/A
N/A
N/A
NEG
NEG
N/A
N/A
NEG
N/A
N/A
N/A
POS
N/A
NEG
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Faecesoral
PCR result
POS
POS
NEG
POS
POS
NO SAMPLE
POS
NEG
POS
POS
NO SAMPLE
NO SAMPLE
NO SAMPLE
POS
POS
POS
NO SAMPLE
NO SAMPLE
NO SAMPLE
NO SAMPLE
NO SAMPLE
POS
POS
POS
POS
NEG
NO SAMPLE
POS
POS
NO SAMPLE
POS
NO SAMPLE
NO SAMPLE
POS
POS
NO SAMPLE
POS
POS
NO SAMPLE
POS
POS
Norovirus
sequence
obtained from
faecal sample
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YES
YES
N/A
NO
YES
N/A
YES
N/A
YES
YES
N/A
N/A
N/A
NO
YES
YES
N/A
N/A
N/A
N/A
N/A
YES
YES
YES
NO
N/A
N/A
YES
YES
N/A
YES
N/A
N/A
YES
YES
N/A
NO
YES
N/A
NO
YES
Patient in
laboratory
confirmed
outbreak
Y
Z~
<~
<~
«<
_~
«<
«-
~<
«<
«~
«<
«~
««
«
~«
~«
~«
~«
«~«
~«
~«
~«
~«
~«
~«
~
~
«~«
«~«
«
«
«
«
~«
«
«
«
«~«
<«
«
<«
<«
«
~<
Norovirus Patient in
Oral sequence laboratory
qualitative Faecesoral obtained from confirmed
Study ID (Number) PCR result PCR result faecal sample outbreak
BG7-12/08(49) N/A POS NO Y
AP43-01/09(52) POS POS YES Y
AP43-01/09(50) NEG POS YES Y
AP43-01/09(51) NEG NO SAMPLE N/A Y
AP43-01/09(53) N/A POS YES Y
BG5-01/09(55) POS POS YES Y
BG5-01/09(54) N/A POS YES Y
AP24-01/09(60) POS NO SAMPLE N/A Y
AP23-01/09(65) POS POS YES Y
AP24-01/09(57) N/A POS YES Y
AP24-01/09(61) N/A NO SAMPLE N/A Y
AP24-01/09(58) N/A NO SAMPLE N/A Y
AP24-01/09(63) N/A POS YES Y
AP24-01/09(56) N/A POS YES Y
AP25-01/09(68) N/A NO SAMPLE N/A N
AP32-01/09(69) N/A NO SAMPLE N/A N
AP32-01/09(70) N/A NEG N/A N
AP27-01/09(78) N/A NO SAMPLE N/A Y
AP43-01/09(72) N/A NO SAMPLE N/A ¥
APAMAU-01/09(77) N/A NEG N/A N
AP43-01/09(74) N/A POS YES Y
AP27-01/09(81) N/A POS NOT TESTED Y
AP27-01/09(79) N/A POS YES Y
AP23-01/09(80) N/A NO SAMPLE N/A Y
AP43-01/09(75) N/A POS YES Y
APAMAU-01/09(76) N/A POS YES Y
BG5-01/09(71) N/A POS YES Y
AP27-01/09(82) N/A POS NO Y
AP43-01/09(73) N/A NO SAMPLE N/A Y
AP38-01/09(86) N/A POS NO Y
AP38-01/09(87) N/A POS YES Y
AP38-01/09(88) N/A POS YES Y
AP37-01/09(85) N/A POS YES Y
AP27-01/09(84) N/A POS NOT TESTED Y
BG11-01/09(70) NEG POS NO Y
BG11-01/09(96) N/A POS YES Y
BG11-01/09(94) POS POS YES Y
AP37-01/09(90) N/A NO SAMPLE N/A Y
AP27-01/09(91) N/A NO SAMPLE N/A Y
AP26-01/09(101) N/A NO SAMPLE N/A Y
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AP27-01/09(106) POS NO SAMPLE N/A Y
AP27-01/09(105) NEG POS YES Y
AP26-01/09(102) POS NO SAMPLE N/A Y
BG11-01/09(100) NEG POS NO Y
AP37-01/09(107) NEG NO SAMPLE N/A Y
AP26-01/09(103) N/A POS YES Y
AP26-01/09(104) POS POS NO Y
AP27-01/09(109) NEG POS YES ¥
AP38-01/09(110) NEG POS YES Y
BG11-01/09(108) N/A POS NO Y
AP37-01/09(111) N/A NO SAMPLE N/A Y
RH8MCU-01/09(112) N/A NEG N/A N
AP26-01/09(113) N/A NO SAMPLE N/A Y
RH3A-01/09(115) N/A NO SAMPLE N/A N
RH5B-01/09(117) N/A NEG N/A N
CTA-02/09(120) N/A POS NP Y
CTA-02/09(121) N/A POS YES Y
CTA-02/09(122) N/A POS YES Y
CTA-02/09(123) N/A POS NO Y
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SLT
VLOLVVDVOODDLLLVXLOLVLOOVLODOLVVOLILVDLIO
DYDVLLIDDDDIDVDDLVLOVLVVVDLODVOODLODOVVVDVLOODDOLVLOVIVIOLLDVDVDDLDDLODDODVVOVLOLLLL
VVLVVVDVLLVDDLODDOVDILVVLOLVVVVOVVOODDDODVLOLIDDODDODLLVLIDIDDLODILOLLDIDODVODLLLO
DOLVLLDDVDLVVOVVIOLDDVDVOODLDILOIVVOIDVODODDLDDDLVDLILVIDOVVDODOVOLVVDOLOODDLVOVVOLV
A€7<
VLOLVVDVOODDLLLVOLOLVLOOVLODOLVVDLOLVDLOD
DWDYDVLLIDDDODDDDVDDLVLOVLVVVDLODVOODLODIVVVDVLODOLVLOVOVIOLLDVDVDDLDDLODDODVVOVLOLLLL
VVLVVVDVLLVDDLODDOVDOLVVLOLVVVVOVVOODDDODVLOLIDDIDDODLLVLODIDDLODILOLLDOODODVODLLLO
DOLVLLODVOLVVOVVOLDDVDVODDLDILIODVVIODDVODODDLODDLVDLILVIDIDVVIODOVODLVVDODLOODDLVDVVOLV
AC7<
VLOLVVDVOODDLLLVIOODLLLOOVLODOLVVDLLLIVDLID
DDVLLODDDDDDDVDDLVLOVLIVVVDLDDVDODLODIVVVDVLIDDOLVLOVIVLLLDVDVDDLODLIODODDOVVOVLOLLILL
VVOVVVDVLLVDDLODDOVOLLVVLOLVVVVOVVOODDDODVLOLIDVODDODLLVIODIODLODLLDLLDIDDDVDDLLLO
DOLVLLODVOLVVOVVOLDDVDVODDLDDLIDVVIODVOVODLODDLVDLILVIDOVVOODOVDLOVDIDLDODDLVDVVDLV
A9I<
VLDLVVDVOODDLLLVOLILVLIOVLIDILVVOLOLVDLID
DDVLLOODODIDIDVDDLVLOVLVVVDLDDVODDLODIVVVDVLODDOLVLOVOVOLLDVOVDDLODLODDODVVOVLOLLLL
VVLVVVDVLLVDDLODDOVOLLVVLOLVVVVOVVOODDDODVLOLIDDODDODLLIVLODOODDLODLLOLLDODOODVODLLL
DOLVLLDDVDLVVOVVOLDDVDVODDLDODLIODVVOODVODDOLODDLVDLILVIOOVVODDOVDLVVDODLDODDLVOVVDLV
dII<
VLDLIVVDVOODDLILVOLOLVLIOVLODOLVVDLOLVDLID
IDVLLDDODDIDIDVDDLVLOVLVVVDLDDVODDLIDIVVVDVLODOLVLOVOVOLLSVODVDDLODLIODODODVVOVLOLLLL
VVLVVVDVLLVDDLODDOVDLLVVLOLVVVVOVVOODDDODVLOLIDDOIDDODLLVLODIODLDDLIDLLDDIDODVDDLLL
DDLVLLDOVOLVVOVVOLDDVDVIDOLDIDLIDVVODODVODIOLODOLVDLILVIDODVVODDOVOLVVDIDLDODDLVDVVDLV
J0I<
VLOLVVDVOODDLLLVOLOLVLOOVLODOLVVDLILVDLIIDDDDVLLIDIDID
DDVDDLVLOVLIVVVDLODVODOLODOVVVDVLODODLVLOVOVOLLDVDVDDLODLIDDODVVOVLDLLLLVVLVVVDVLLVD
DLODOVOLLIVVLOLVVVVOVVODDDDODVLIDLIODODDODDLLVLODOLODLLDLLDDDODVDDLLLIDDLVLLDDVOLV
d6<
VLDLVVDVOODDLLLVOLILVLOOVLODOLVVDLOLVDLID
VDDOVLLDDOVOIDODVDDLVLIVLVVVDLODVDDLODOVVVDVLODOLVLOVOVOLLDVDVDDLODLIDDODVVOVLOLLLL
VVLVVVDVLLVDDLODDOVOLLVDLOLVVVVOVVODODDDODVLOLIDDODDIDLLVLOIDIDDLDDILOLLDDDDPVDDLLLD
DOLVLLDDVOLVVOVVOLDDVDVODOLDIDLIDVVODODVODDOLDDDLVDLILVIDOVVOODDOVDLVVDILDODDLVDVVDLV
A9<
VLDIVVDVOODDLILVOLILVLOIOVLODOLVVODLOLVDLOS
IDVLLIDIDIDIDVDDLVLIVLVVVDLDDVODDLOIDIVVVDVLODOLVLOVOVOLLDVDVODLODLIDOODVVOVLOLLLL
VVLVVVDOVLLVODLIDODOVOLLVVLOLVVVVOVVOODDDODVLOLIDDODDODLLVLIDIODLDDLLDLLODOODVDDLLLID
DDLVLLODVOLVVOVVOLDDVDVODODLDDLOIOVVDODVODDOLODOLVDLDLVIDOVVOODDOVOLVVDDLDODDLVDVVDLV
dp<
VLOLVVOVOODDLLLVILILVLOOVLIDOLVVDLOLVDLIO
DDDVLLIDODODIDVDDLVLIVLVVVDLDDVODLODIVVVDVLODDDLVLOVIVILLDVDVODLDDLODOODVVOVLOLLLL
VVLVVVDOVLILVODLOOODOVOLLVVLOLVVVVOVVDODDDODVLOLIDDODDODLLVLIDIDDLODLLDLLDIOODVDDLLLO
DDLVLLDDVOLVVOVVOLDDVDVODODLDODLIDVVODDDVODODODLDDDLVDLILVIDDVVODDOVDLVVDOLDODDLVDVVDLV
dft<
‘gjdures(vAlpes)[v.10=TS‘ajdures[edovj=ysaoquinuApnyjsYIMpaljaqeysaydures
"Y[]‘SNATAO.AOUJOSIsOUSeIp[v.109Y)OFUTApNysoy)WOIEJVpddJUANbasSNATAOION
9LT
VVLVVVDVLLVDDLOODDOVOLLVVLOLVVVVOVVOODDDODVLOLIDDODDODLLVLIDIODDLODOLDLLDDODDVODLLLO
DOLVLLDDVDLVVOVVOLDDVDVIDILDDLOIOWVIODDVODODDLDDDLVDLILVIDIVVIODDOVDLVVDOLDDDDLVDVVOLV
ALb<
VLOLVVDVOODDLLIVIOLILVLOIOVLIDDOVVOLILVDLID
DYDVLLIIDDIDVODLOLOVLIVVVDLODVOODLODIVVVDVLODOLVLOVOVIOLLDVDVDDLODLOODODVVOVLOLLLL
VVLVVVDVLLVDDLOODDOVOLLVVLOLVVVVOVVOODDDODVLOLIDIDDIDLLVLIDIODLODILOLLDODODVOD.LLLO
DOLVLLDDVOLVVOVVOLDDVDVODIDLDOLIOVVIDDVODIDODLDDDLVDLILVIDOVVIDDOVDLVVDDLOODDLVODVVOLV
A9b<
VLOLVVDVOODDALLVILALVLOOVLOODDOVVDLILVOLID
DDVLLIDDDDIDDVODLOLOVLVVVDLDDVODLOIDIVVVDVLODDOLVLOVIVILLDVOVDDLODLODDODVVOVLOLLLL
VVLVVVDVLLVDDLODDOVOLLVVLOLVVVVOVVOODDDODVLOLIODDODDODLLVLIDIODLODILOLLIDOODDDVODLLLO
DOLVLLDDVDLVVOVVOLDDVDVODDLDODLOIODVVIODDVODDOLODDLVDLILVIDOVVIDDOVDLVVDDLDODDLVDVVODLV
dctr<
VLOLVVDVOODDLLLIVOLILVLIDVLIDDOVVDLILVDLID
DPVLLOIDDDODDDVDDLOLOVLVVVDLDDVODLIDIVVVDVLODOLVLOVOVILLDVOVDDLODLODIODVVOVLOLLLL
VVLVVVDVLLVDDLOODODOVODLLVVLOLVVVVOVVOODDDODVLOLIDDODDODLLVLODIODDLODOLOLLDOODODVODLLLO
DDLVLLDDVOLVVOVVOLDDVDVODDLDIDLIODVVIDDVODIOLDDDLVDLILVIDOVVODDOVOLVVDOLDIDDLVOVVDLV
dip<
VLOLVVDOVOODDLLLVOLOLVLIOVLOIDDOVVDLOLVDLID
DDVLLOIDDDODDIDDVDDLOLOVLVVVDLODVOODLODIVVVDVLODOLVLOVIOVIOLLDVOVDDLODLODODODVVOVLOLLLL
VVLVVVDVLLVDDLODODOVOLLVVLOLVVVVOVVOODDDODVLOLIDDODDODLIVLIDIDODLODOLOLLDOODDDVODLLLO
DDLVLLDDVOLVVOVVOLDDVDVODOLDDLOIOVVOODVODIODLODOLVDLOLVIDOVVOODDOVDLVVDILDODDLVOVVDLV
TS8¢<
VLOLVVDVOODDLLLVILILVLIDVLIDODOVVDLOLVDLID
DDVLLIDDDIDIDVDDLOLOVLVVVDLODVOODLODIVVVDVLODOLVLOVOVOLLSVOVDDLODLOIDOODVVOVLOLLLL
VVLVVVDVLLVDDLODODOVOLLVVLOLVVVVOVVOODDDODVLOLIDDODDDODLLIVLIDDODLODOLOLLDOODDDVODLLLS
DDLVLLDDVOLVVOVVOLDDVDVODOLDDLIDVVDDVODIDODLODDLVDLIOLVIODOVVODDDOVOLVVDOLDODDLVOVVOLV
A8E<
VLOLVVDVOODDLLLVOLILVLOOVLIODOLVVDLOLVDLOO
DDVLLOIDDDIDIDVDDLVLOVLVVVDLDDVODLODIVVVDVLODOLVLOVIOVILLDVDVDDLODLIDOIODVVOVLDLLLL
VVOVVVDVLLVDDLODDOVDLLIVVLOLVVVVOVVOODDDODVLOLIDDODDODLLVLODODODLODOLOLLDDOODVODLLLD
DOLVLLDDVOLVVOVVOLDDVDVODODLDOLILVVIODVODODDLODDLVDLOLVIDOVVDODOVOLVVDODLDDDDLVDVVOLV
Afe<
VLOLVVDVOODDLLLIVIOLILVLOOVLODOLVVDLOLVDLOO
DDVLLOIDDDIDIDVODLVLOVLVVVDLDDVODLODIVVVDVLODOLVLOVIVILLDVDVDDLDDLOIDODODVVOVLIDLLLL
VVLVVVDVLLVDDLOOOOVOLLVVLOLVVVVOVVODODDDODVLOLIDDODDODLLVLIDDODDLODOLOLLDOODDVDDLLLD
DDLVLLDDVDLVVOVVOLDDVDVODILDIDLIDVVIDDOVODIDLODOLVDLILVIDIVVIODDOVOLVVDIDLDDDDLVDVVDLV
dle<
VLDLVVDVOODDLLLVOLILVLIOVLODOLVVDLOLVDLID
DPVLLODDDODODVDDLVLOVLVVVDLDDVODLODOVVVDVLODDOLVLOVIVIOLLDVDVDDLODLOODODVVOVLOLLLL
VVOVVVDVLILVDDLODDOVDLLVVLOLVVVVOVVODODDDDODVLOLIDDODDODLLVLIDIDDLODOLODLLDIDODVODLLLD
DOLVLLDDVDLVVOVVOLDDVDVODOLDDLILVVIODDVODDDLDDDLVDLOLVIDOVVIODOVDLVVDOLDODDLVDVVDLV
A0E<
VLOLVVDVOODDDLLLVOLOLVLOOVLOODOLVVDLILVDLOD
DDVLLIDDDDDVDDLVLIVLVVVDLODVODLIDIVVVDVLODDILVLOVOVILLDVDVDDLODLODODDVVOVLOLLLL
VVLVVVDVLLVDDLODDIDVDDLVVLOLVVVVOVVOODDDODVLDLIODDODDDODLLVLIDIDDLODOLOLLDIDODVDDLLLO
DOLVLLDDVOLVVOVVOLDDVDVODIDLDIDLIDVVIDDVODDOLDDDLVDLOLVIDIVVIODDIVDLVVDILDODDDLVDVVDLV
A87<
LLT
VLOLVVDOVOODDLLLVOLOLVLOOVLODOLVVOLILVOLOO
DYVLLIDDDDIDDVDDLVLOVLIVVVDLODVOODLODOVVVDVLODOLVLOVIVOLLDVDVDDLDDLOIDOODVVOVLOLLLL
VVLVVVDVLLVDDLOODDOVDLLVVLOLVVVVOVVOODDDODVLDLIODDIDDODLLVLODIDDLODOLOLLOIDODDVOD.LLLO
DOLVLLDDVOLVVOVVILDDVDVODIDLDDLODVVIODVODIDIDLODDLVDLILVIDIVVIODDIVDLVVDIDLOODDLVODVVOLV
TS09<
VLDOLVVDOVOODDLILVOLILVLIOVLIDOLVVOLILVOLOO
DYDVLLIDDDIDODDVDDLVLOVLVVWVDLODVODLODOVVVDVLODOLVLOVOVOLLSVOVODLODLIDODODVVOVLOLLLL
VVLVVVDVLLVDDLODDOVODLLVVLOLVVVVOVVOODDDODVLOLIODODDODLLVLODIDDLODILOLLDIDIOOVODLLLO
DOLVLLDDVDLVVOVVOLDDVDVODIDLDIDLOIOVVIODDVODIDODLDDDLVDLILVIDOVVDODOVOLVVDDLOODDLVOVVOLV
ALS<
VLOLVVDVOODDLLLVOLOILVLADVLODOLVVOLILVOLID
DYDVLLIDDDIDODVDDLVLOVLVVVDLDDVODLODOVVVDVLODODOLVLOVOVILLSVOVDDLODLIDOODVVOVLOLLLL
VVLVVVDVLLVDDLODODOVOLLVVLOLVVVVOVVOODDDODVLIDLOIODDODDODLLVLODIDDLODILOLLDIIODVODLLLO
DOLVLLDDVDLVVOVVOLDDVOVODDLDOLIOVVIDDVODIOLDDDLVDLILVIDIVVIODDIOVDLVVDIDLDODDLVDVVDLV
d9S<
VLOLVVDVOODDLLLVOLILIMLIOVLODOOVVOLILVDLOO
DWDDVLLIIDODDIDDVODLOLOVLVVVDLODVOOLODIVVVDVLOODDOLVLOVOVOLLDVDVDDLODLIDDOOVVOVLOLLLL
VVLVVVDVLLVDDLOODDOVOLLVVLOLVVVVOVVOODDDODVLOLIDDODDOIDLLVLIDIDDLODOLOLLDOOODVODLLLI
DOLVLLODVDLVVOVVOLDDVDVODDLDIDLODVVIODVODIDLDDDLVDLILVIODODVVIDDOVOLVVDIDLOODDLVODVVOLV
TSSS<
VLOLVVDVOODDLLLVOLOLVLADVLODDOVVDLILVDLID
DDVLLOIIDDDDDDDVDDLOLOVLVVVDLDDVODOLODIVVVDVLODOLVLOVOVILLDVDVDDLODLODODODVVOVLOLLLL
VVLVVVDVLLVDDLODDOVOLLVVLOLVVVVOVVOODDDODVLOLIDDODDODLLIVLIDIODLODOLOLLDOOODVODLLLS
DDLVLLDDVDLVVOVVOLDDVDVODDLDDLOIOVVIODVODIOLDDDLVDLOLVIDODVVIODOVOLVVDDLODDDLVOVVOLV
dss<
VLDLVVDVOODDLLLVOLILVLOOVLODODOVVDLILVDLID
DDVLLIDDDDDDDVDDLOLOVLVVVDLODVOOLOIDOVVVDVLODOLVLOVOVOLLDVOVDDLODLIDODODVVOVLOLLLL
VVLVVVDVLLVDDLODODOVOLLVVLOLVVVVOVVOODDDODVLOLIDDODDODLLVLIDDODLODOLOLLDOOODVODLLLD
DOLVLLDDVDLVVOVVOLDDVDVODODLDIDLOIOVVODODVODIDDLDDDLVDLILVIODOVVIDDOVOLVVDDLDODDLVDVVOLV
dps<
VLIDLIVVDVOODDLLLIVOLOLVLIDVLIDOLVVOLILVDLOO
DDVLLIDDDDDIDVDDLVLOVLVVVDLDDVODDLOIDIVVVDVLODOLVLOVOVOLLSVOVDDLODLIDOODVVOVLIDLLLIL
VVLVVVDVLLVDDLODDOVOLLVVLOLVVVVOVVOODDDODVLOLIDDIDDODLLVLIDIODLODOLOLLDODODVODLLLO
DDLVLLDDVOLVVOVVOLDDVDVDOLDLIODVVODDVODDOLODOLVDLILVIOOVVIDDOVODLVVDODLDODDLVOVVDLV
dgs<
VLDLVVDVOODDLLLVOLOLVLOOVLODOLVVDLOLVDLID
DDVLLIDDDIDIDVDDLVLOVLVVVDLDDVDODLIDIVVVOVLODOLVLOVOVOLLSVOVODLODLODOODVVOVLOLLLL
VVLVVVDVLLVDDLOODOVOLLVVLOLVVVVOVVOODDDODVLDLIDDODDODLLVLODIDDLODOLOLLDIDODVDDLLL
DOLVLLDDVDLVVOVVOLDDVDVODIDLDODLIOVVIODVODODLODDLVDLILVIDOVVIODOVDLVVDIDLDODDLVDVVDLV
ACcS<
VLOLVVDVODDDLLLVOLOLVLODVLODOLVVDLOLVDLID
DDDVLLOODODODODVDDLVLOVLVVVDLODVODLODOVVVDVLODOLVLOVOVILLDVDVDDLODLODODODVVOVLDLLIL
VVOVVVDVLIVODLODDOVDLLVVLOLVVVVOVVDODDDODVLOLIDDODDODLLVLIDDODDLODILDLLDDODODVDDLLLID
DDLVLLDDVOLVVOVVOLDDVDVODOLDODLIODVVOODDVODDOLODOLVDLOLVIDOVVOODDOVDLVVDIDLDODDLVDVVDLV
Jd0s<
VLDLVVDVOODDLLLVIOLOILVLIDVLIDOOVVDLOLVDLOD
DDVLLDOODIDIDVDDLOLIVLVVVDLODVODDLIDIVVVDVLODOLVLOVOVILLDVDVDDLODLODOODVVOVLDOLLLL
>63F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAATAA
TITTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGC
CCTGATCTGAATCCCTACCTATCTCATTTGGCCAGAATGTA
>65F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAACAA
TTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGC
CCTGATCTGAATCCCTACCTATCTCATTTGGCCAGAATGTA
>65SL
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAACAA
TTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGC
CCTGATCTGAATCCCTACCTATCTCATTTGGCCAGAATGTA
>71F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAATAA
TITTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTGTGGAGCGCGCCCTTAGGC
CCTGATCTGAACCCCTACCTATCTCATTTGGCCAGAATGTA
>74F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAATAA
TTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGC
CCTGATCTGAATCCCTACCTATCTCATTTGGCCAGAATGTA
>75F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAACAA
TTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGC
CCTGATCTGAATCCCTACCTATCTCATTTGGCCAGAATGTA
>76F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAACAA
TTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGC
CCTGATCTGAATCCCTACCTATCTCATTTGGCCAGAATGTA
>79F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAATAA
TTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGC
CCTGATCTGAATCCCTACCTATCTCATTTGGCCAGAATGTA
>85F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAACAA
TITTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGC
CCTGATCTGAATCCCTACCTATCTCATTTGGCCAGAATGTA
>87F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAACAA
178
TTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGC
CCTGATCTGAATCCCTACCTATCTCATTTGGCCAGAATGTA
>88F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAACAA
TTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGC
CCTGATCTGAATCCCTACCTATCTCATTTGGCCAGAATGTA
>94F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAATAA
TTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTGTGGAGCGCGCCCTTAGGC
CCTGATCTGAACCCCTACCTATCTCATTTGGCCAGAATGTA
>94SL
GGGAGAATAGGAGGGGTTAGAATAGGGCCTANTGGCGCGCTCCACAGTATTTCACCTGGAGCGTTTCTAGGGGATACTGTGA
ACTCTCCACCAGGGGCTTGTACAAAATTATTTCTAATCCAGGGGTCAATTACATTTTGNNGGCCCGCGTACAGGCGCCGCAAT
AGCGGNACCGACAACGGGCTCCAAAGCCATAACCTTATTGTTGACCNCTGGGACGAGGTTGGNCGCGGACCNANTANANGG
GTTGGCGTCANTGCGACGCCTTCTTCATNCAGAAAATC
>96F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAATAA
TTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTGTGGAGCGCGCCCTTAGGC
CCTGATCTGAACCCCTACCTATCTCATTTGGCCAGAATGTA
>102SL
ATGACGCCNATNNTTCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCANNAATGAGGTTATGGCTTTGGAGCCCGTTGT
CGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTANAAATAATTTTGTACAAGCCCCT
GGNGGAGAGNTCACAGTATCCCCTAGAAACGCTCCAGGCGAAANANTATGGAGCGCGCCC
>103F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAATAA
TTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGC
CCTGATCTGAATCCCTACCTATCTCATTTGGCCAGAATGTA
>105F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAATAA
TTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGC
CCTGATCTGAATCCCTACCTATCTCATTTGGCCAGAATGTA
>106SL
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAATAA
TTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGC
CCTGATCTGAATCCCTACCTATCTCATTTGGCCAGAATGTA
>109F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAATAA
TITTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGC
CCTGATCTGAATCCCTACCTATCTCATTTGGCCAGAATGTA
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>110F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAACAA
TITTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGC
CCTGATCTGAATCCCTACYTATCTCATTTGGCCAGAATGTA
>121F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAATAA
TTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTGTGGAGCGCGCCCTTAGGC
CCTGATCTGAACCCCTACCTATCTCATTTGGCCAGAATGTA
>122F
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAATAA
TTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTGTGGAGCGCGCCCTTAGGC
CCTGATCTGAACCCCTACCTATCTNATTTGGCCWGAATGTA
Reference genotypes
>GI/1_M87661 Norwalk/68/us
ATGATGATGGCGTCTAAGGACGCTACATCAAGCGTGGATGGCGCTAGTGGCGCTGGTCAGTTGGTACCGGAGGTTAATGCTT
CTGACCCTCTTGCAATGGATCCTGTAGCAGGTTCTTCGACAGCAGTCGCGACTGCTGGACAAGTTAATCCTATTGATCCCTGG
ATAATTAATAATTTTGTGCAAGCCCCCCAAGGTGAATTTACTATTTCCCCAAATAATACCCCCGGTGATGTTTTGTTTGATTTG
AGTTTGGGTCCCCATCTTAATCCTTTCTTGCTCCATCTATCACAAA
>GI/2_L07418Southampton/91
ATGATGATGGCGTCTAAGGACGCCCCTCAAAGCGCTGATGGCGCAAGCGGCGCAGGTCAACTGGTGCCGGAGGTTAATACA
GCTGACCCCTTACCCATGGAACCCGTGGCCGGGCCAACAACAGCCGTAGCCACTGCTGGGCAAGTTAATATGATTGATCCCT
GGATTGTTAATAATTTTGTCCAGTCACCACAAGGTGAGTTCACAATTTCCCCTAATAATACCCCCGGTGATATTTTGTTTGATT
TACAATTAGGTCCACATCTAAACCCTTTCTTGTCACATTTGTCCCAAA
>GI/3_U04469DesertShieldDSV/90/US
ATGATGATGGCGTCTAAGGACGCCCCAACAAACATGGATGGCACCAGTGGTGCCGGCCAGCTGGTACCAGAGGCAAACACA
GCTGAGCCTATTTCAATGGAGCCAGTGGCTGGGGCTGCGACAGCAGCCGCAACTGCTGGACAAGTAAATATGATTGACCCCT
GGATAATGAGTAATTATGTACAAGCTCCTCAAGGAGAATTTACCATATCGCCCAACAATACACCCGGTGACATTTTATTTGAC
CTGCAATTGGGCCCACACCTCAATCCTTTCTTGTCCCATTTAGCTCAAA
>GI/4_AB042808Chiba407/87/JP
ATGATGATGGCGTCTAAGGACGCTACACCAAGCGCAGATGGCGCCACTGGCGCCGGCCAGCTGGTACCGGAGGTTAATACA
GCTGACCCCATACCTATTGACCCTGTGGCTGGCTCCTCTACAGCCCTTGCCACAGCAGGCCAGGTTAATTTGATTGATCCCTG
GATAATCAATAATTTTGTGCAAGCCCCCCAGGGCGAGTTCACAATATCCCCAAATAATACCCCCGGTGATGTGCTTTTTGATT
TGCAATTAGGACCCCATTTAAATCCTTTCCTTTCCCACCTTTCTCAGA
>GI/5_AJ277614Musgrove/89/UK
ATGATGATGGCGTCTAAGGACGCTACACCAAGCGCAGATGGCGCGAATGGCGCCGGTCAGCTTGTGCCGGAGGTTAATAAT
GCTRAACCACTGCCACTTGATCCAGTGGCGGGAGCTTCTACCGCTCTAGCCACTGCTGGACAAGTTAATATGATTGACCCATG
GATTTTCAACAACTTTGTTCAGGCCCCCCAGGGTGAATTTACCATATCCCCAAATAATACCCCCGGCGATATTCTTTTTGATTT
GCAATTAGGCCCACRCCTAAACCCTTTCCTAGCACATTTATCCCAGA
>GI/6_AF093797BES/98/GE
ATGATGATGGCGTCTAAGGACGCCCCACCATCGCCTGATGGCGCCAGTGGCGCTGGCCAGCTAGTGCCGGAGGTTAATACAG
CTGACCAAATTTCAATGGATCCTGTTGCGGGTGCTTCTACCGCAGTTGCAACAGCTGGGCAAGTTAATATGATTGATCCATGG
ATATTCAACAATTTTGTCCAGGCCCCCCAGGGTGAATTTACCATTTCTCCAAATAATACCCCCGGTGATATTTTATTTGATTTA
CAATTGGGCCCCCACTTGAATCCTTTCTTAGCTCATTTATCACAGA
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T8T
VVVODVOVLLVDDLLOIOVOVLVVLVLVVVOVVVOLDDOOVILDDIDIODVODDLLIDDIDDIDDDLIDDLODDOVVOLILOLO
DOLVILDDVDLVVLVVLOVVVDVOODDLODLIODDODDVODLODLVDLOVLILVIDLIDIDDOVOLVVDODLOODOLVOVVOLV
MN/68/WeYsHPNGLEI8XZ/IID<
VOVVOLLLOOVOVODVLLOLLVDOLVVVLLIVV9DLID
DYDVLLVVDDLLLVVVLODLLILVVVDLODLOOLILLVVODIDDOLILDLOVIVILLVVDVDDLVVVIDDODVVOOLOLLLOV
VOLVVDOVLLVDDLODIOVDVLVDLOLVVLVVVVOLDDIOVVLOLOODIODIODVLVLILLIDDDDLIDOLODIDOVVDOLODOD
DLVDIVDVDOVVOVVOLDDVDVOOVLDIDLILDDIODVODLODLVDLVVLOLVIDIDDIODDOVOLVVDIDLSDDDLVOVVOLV
SNV/IL/MeMPHTI9LONI/IID<
VOVOIOODDLOIOVOVOLVLODLLIVIODOVVVLLLVOIODODIDOVLLVVOVE
LIVDLLLDLLVLVIVOVDDIDIDOVOVVOVVLOODDOLLLVVOVILLDVDVDDVVOLOIDDODVVOLLDIVLLVVLOVOLVLLVS
DLOIODDOVOLLVDLVLVVLLOVVOLDDVODIDOVVODVODVODVOVOODLIDLIDDLIDDLOLIOVVDDLVVILVLVLOOVVOLO
DVOVLIDVLLDDVDVOOLLDDLODVILDDIDDLODLOVIOVIDDLVDDLVIVVVOVVDODDODDOVDDVVLOLOODDLVDLVOLV
df/10/IDSTLEWRNESOOIZIIAVbI/ID<
VVVODOLVLLLVOLODLIOLLLIODOVVODLILVIDDOODDDLLIVVOLLILVS
LLLOLIVIVLVDLODLIDDOVLVVOVVOODOLILOLVDOVLLLOVDLODDVDDDDDODVVODLOLVLLVVOVVDLVVLVDD.LLO
DILVDLLVDLVLVVDLDDVODDDLIDDOVIDDVODDIDODLOVILDDIDODDDODLLDVIOVVDDLVLVVILVVIOVVDVOLOOV
OIVVLVVLVVDVDVOODLODLOVVOVDDLODVDDODVDOVODDLVDDLVOVVVOLIOVLIDOVODVVLOLODDDDLVODLVDLV
df/lO/IDeSELeweUeSzEIZITAV€1/1D<
VVOLOOVDDVLLVVOVL
LIVOLLIDLLLLIVLVDLODLOIOVOVOVVLVVOODOVOLLLVVOVLLLDVDVODVVODDDOVODVVIOLLDLLLLVVLOVOLVLLVS
DLOODDIOVOLLVDLVLVVVLOVVIOLDDLODLOVOODLLOVODDOVLODLODLODLLDVLOVIDLVDDLVLODLLVLOODVOLID
VOVOVVVODDVDVOOVLODLOIDVIDDDODODDLODLOVIOVODDLVDDLVOVVVIVVODDODOVDDVVLILDDDDLVODLVOLV
df/00/IDe6INweweNessz7sssodVTI/ID<
ODVVIDDVLODLVIDOIDILOOLLIVOODLVVVLLIVVILOOVDDDLLIVVOVLO
IVOLLLVLLLLDLVOVDDLOIOOVOVVLVVVOOVOLILDODOVLLLSVDDDDVVOVOODODODDDVODLDLLLLVVLOVOLVVLVDD
LODDIVOLLVOLVLVVLLVVVOVDDLODLOVVODLLODODVOVVODODODVDDLIDDLOVIDOVDDLVVOLVLVLIOVVD.LOD
VOVLVVVDDVDVOOVLODLODVILDDIODLDDLOVLOVOIDDLVDDLVIVVVIVVIODDODDOVDDVVLOLDDDDLVDLVDLV
df/66/IO8AMewes/pSgsodVL1/ID<
VVDVLOLVLLLVOLODDLIDLLLISDOVVLIDLVILIODDDVLOVVODLL
IVOLLLDLLLLVLVDLODLOOVIVIVVLVVVOODOLLLVLOVLLLDVDDDDVVODDOLIDDVOVLOLLLLVVLVVOLVVLVDD
LODDIVOLLVOLVLVVDLODVIDDDODODLOVLODLLDDDDLOVDODLIDDDDIODDDLOVIOVVVVLVVDOVLLLIOVVDLOD
VOVLVVVODDDDVOOVLODLODVILDDIDDLODLOVIOVODDLVDDLVIVVVOVVOODDODOVDDVVLILDDDDLVOVVDLV
SN/1LO/PXOG6LOBESAVOL/ID<
VVVOVOLDLLIVOOODLIDOLLIDOLVVOLIOVOLIOVODDLLVVO
DLLLVOLLLVLLVLVLVDLODODDDOVLVVLVVLOODOLILVVOVLILIVVDLODDVOLIDODDDVVODLOLLLIVVLVVOLLLLV
DDLLOOLVOLLIVOLVLVVLLOVVOLDDLODLOVLODVLLOODLIVLOLLDDDDDLODOLOLIDLVOLLILIODLIVIOVVDLOD
LVVLVVLLDDVDDOODDLOILIDVILODIODDDDIVVDODODDLVDVODDODVVDOVOVLIDOVDDVVLILDODDLVDLVDLV
df/66/IDNZSeweuespLL6E0dV6/1D<
VVVOVOLILOIOVIDODVLOLLLVIOLVVLLIDVIDIDOVDDVLLVVOV
LLIVOLLLDLLLLVIVDLODODDOOVLVVLVVLOODOLLLVLIVLLLVVDVODVVODDOVODDVDOLDLIDVVLVVILLLLVS
DLVOODOVOLLVDLVLVVLLDVVDDDLODVOVVODOLOVODVOVVOLLDDLODDODLLDLIDOVODLVVILLLVVVODVDLD
DVOVLVVLODDVDDIOVLODLODVDODDLIDODDLOVIODDIDDLVDLIODDIDLVIVVIODODDDOVODVVLILSDDDLVOLVOLV
df/00/IDAMEZLISAV8/1D<
VVVODOLVLLLVOVVOOLOOLIODOLVVLLLVOVODVDDDLLLVODL
JLIVDLLLDLOLLVLVDVDDLOIDOVLVVOVVODOVOLLLVIOVLLLVVDLODDVDLIDDODVVOOLOLLLIVVLVVDLVLLVD
DLODDVOVIVVLLLVVLLOVVOVDDLODLIVIODDDODDODDIDOVVODIDDODDDLOVLODIOVVDLLILIDVLIDDIOVVDLD
DVODLVVLLDDVOVOOLLDDLODVILODODDDLODLDVLIMODDLVDDLVIVVVILIDDOLDVDDVVLILDODDLVDLVDLV
MN/P6/1S2YUIMGOILLTVL/ID<
TTTTGTCCAGGCCCCTAATGGTGAATTTACAGTTTCTCCCCGCAATGCCCCTGGTGAAGTGCTATTGAATCTAGAGTTGGGTC
CAGAATTGAATCCTTATCTGGCACATTTAGCAAGAATGTATAACGGGTATGCC
>GII/3_U22498Mexico/89/MX
ATGAAGATGGCGTCGAATCGCGCTGCTCCATCTAATGATGGTGCCGCCTGCCTCGTCCCAGAGATCAACAATGAGGCAATGG
CGCTAGAGCCAGTGGCGGGTGCAGCGATAGCAGCGCCCCTCACTGGCCAGCAAAATATAATTGATCCCTGGATTATGAATAA
TTTTGTGCAAGCACCTGGTGGTGAGTTTACAGTGTCACCCAGGAATTCCCCTGGTGAAGTGCTTCTTAATTTGGAATTAGGTC
CAGAAATAAATCCTTATTTGGCTCATCTTGCTAGA
>GII/4_X86557Lordsdale/93/UK
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAATAATGAGGTTATGG
CTCTGGAGCCCGTTGTTGGTGCCGCTATTGCGGCACCTGTGGCGGGCCAACAAAACGTAATTGACCCCTGGATTAGAAACAA
TITTGTACAAGCCCCTGGTGGAGAGTTCACAGTGTCCCCTAGAAACGCTCCAGGTGAGATACTGTGGAGCGCGCCCTTGGGC
CCTGATCTGAACCCCTATCTTTCTCATTTGTCCAGA
>GII/5_AJ277607Hillingdon/90/UK
ATGAAGATGGCGTCGAATGACGCTACTCCATCAAATGATGGTGCCGCCGGCCTCGTGCCAGAAAGTAATAATGAGGCAATG
GCTCTGGAACCCGTGGTGGGGGCGTCTTTAGCCGCCCCTGTCACTGGCCAAACTAATATAATAGACCCCTGGATTAGAACTA
ATTTTGTCCAAGCCCCTAATGGTGAATTCACAGTTTCCCCTAAAAATTCCCCTGGAGAGATATTGGTCAATTTGGAGTTGGGT
CCAGAACTGAACCCTTATCTGGCACATTTAGCTAGG
>GII/6_AB039776SaitamaU3/97/JP
ATGAAGATGGCGTCGAATGACGCCGCTCCATCGAATGATGGTGCTGCCAACCTCGTACCAGAGGCCAACAATGAGGTTATGG
CACTTGAACCGGTGGTAGGAGCCTCAATCGCAGCTCCTGTTGTCGGTCAGCAAAATATAATTGACCCCTGGATTAGAGAAAA
TITTGTCCAAGCACCACAGGGCGAGTTTACTGTTTCGCCAAGGAATTCGCCTGGTGAGATGCTTTTAAACCTTGAGTTGGGCC
CAGAACTTAACCCCTATTTGAGTC
>GII/7_AJ277608Leeds/90/UK
ATGAAGATGGCGTCGAATGACGCAGCTCCATCTAATGATGGTGCAGCAGGCCTCGTACCAGARATCAACAATGAGGTCATGC
CCCTTGAGCCCGTGGCTGGTGCATCGCTGGCGACACCAGTTGTTGGGCAACAAAACATAATTGATCCCTGGATAAGAAATAA
TTTTGTGCAAGCCCCTGCAGGTGAGTTTACAGTCTCCCCTAGGAATTCCCCCGGTGAAATCCTGCTTGATTTAGAGTTGGGAC
CAGAATTGAACCCCTACCTTGCTCATTTGGCTCGT
>GII/8_AB067543SaitamaU25/98/JP
ATGAAGATGGCGTCGAATGACGCAGCTCCATCGAATGATGGCGCGGCTGGCCTCGTACCAGAGATCAACCATGAGGTCATG
GCCATAGAACCTGTTGCAGGGGCCTCTTTAGCAGCCCCTGTCGTAGGACAACTCAATATAATTGATCCCTGGATTAGAAATA
ATTTTGTGCAAGCCCCTGCTGGAGAATTTACTGTTTCACCTAGAAATGCTCCAGGTGAATTTTTATTAGATCTAGAGTTAGGC
CCTGAGTTGAACCCCTACCTTGCTCACCTTGCACGC
>GII/9_AY054299I]dahoFalls/378/96/US
ATGAAGATGGCGTCGAATGACGCAGCTCCATCGAGTGATGGCGCAGCCGGCCTCGTCCCAGAGATCAATCATGAGGTTATGG
CAATTGAACCTGTTGCAGGTGCATCAATCGCTGCCCCTGTGGTAGGACAACAAAATATTATTGATCCCTGGATAAGAAATAA
TITTGTACAAGCACCCGCTGGAGAATTCACTGTTTCCCCTAGGAATGCCCCGGGTGAGTTCTTGCTTGATTTAGAATTAGGCC
CTGATCTGAACCCCTATCTGGCACATTTGGCAAGA
>GII/10_AY237415Mc37/99/Thai
ATGAAGATGGCGTCGAATGACGCCGCTCCATCTAGTGATGGTGCAGCCGGCCTCGTGCCAGAAAGTAACAATGAGGTTATGG
CTCTTGAACCTGTTGCTGGGGCATCTTTAGCTGCCCCTGTGACTGGTCAAACTAATATAATTGACCCATGGATCAGAATGAAT
TTTGTTCAAGCCCCAAATGGAGAATTCACTGTTTCCCCAAGAAATTCCCCTGGAGAAGTACTCCTAAATTTGGAATTGGGTCC
TGAATTAAACCCTTATCTGGCACACCTATCTAGG
>GII/11_AB112221SaitamaT29GII/01/JP
ATGAAGATGGCGTCGAATGACGCCGCTCCATCTAACGATGGTGCTACGGGCCTCGTCCCAGAGATCAACAACGAGACCCTCC
CTTTGGAACCAGTTGCGGGTGCAGCAATCGCCGCGCCTGTCACTGGCCAAAATAATATAATTGATCCCTGGATTAGAACAAA
TITTGTACAAGCACCCAATGGAGAGTTCACTGTCTCACCTAGAAACTCCCCTGGAGAAATTCTTTTAAATTTAGAATTGGGTC
CTGACTTAAATCCATATTTGGCACATCTATCTAGA
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€8T
ODDOVOILOLIOVILVDDLOLVLODOVVOLIVVV9I9
IVDDDLLIVVDDLLLVVOLOVLLLLVVVDLODLOOLILLVVVVVLOOVOLILSVOVLLLSVDLODDVODOODODODVVOLLSLLLL
VVVVDVVVLLVDDLOODDOVODLLVVLVOVVVOVOVODDDDLOVLODDOVODDODVLOVIDLIDIDDDDDLLDIDIIDDIDDLIIDD
DDLLVLODVDVVOVVOLOVDVDVODDLDDLOOVVODDDODLODLVDDDDLILVIODLIDLIDIOVOLOVDODLDODDLVOVVOLV
AN/86/UoneydiyLpgs6ldVLI/ID<
VOVVOLLLOLVOLODVLLLVLLIDOVVLLDOVOVOI
ILDDVLLIVVDDLLLVVDLVDLLVLVDVOLODLIDODLLIVVVDVVODDOLLLDVOVILLSVOLODLVVOODOVODDVODLOLLLL
VVLVVVDVLLVDDLODOLVDVLVDLVOVVLOVVVOLDDDOVOLDLIODVIDLODLLVLLSVIDVDDLIDDLOLIDDVDLLIDD
DDLLIOVOVOLOVLVVILVOVDVOODLDOLOILODVOVLODLODLVDLVVLILVIOLIDIDDOVOLVVDILDODDLVODVVDLV
df/ZO/MMDESLEWRNESOOTZITAVII/MID<
VOOVLLLVODODVLLLVLVIDOVVDLLIVVDLDD
VDOOVLLOVDDLLLVVVLLDLLLLVVVDLODLOIODILOVVVDOODODDDOLLIDDOVIOLLSVDLODLIVVIOODDDDVVOVLOLLLLV
VVLLVOVLLVDDLODOOVOVLVVLOLVVOVVVVOLDDIOVVLLIODDODLODOLVVILLDVDDDODLLDVIOVVDLLIVID
DLVVOVOVDOVVOVVOLDDVDVOVLODLDLODIDDVODLODLVDLVVLIDLVIOLODODODOVDLVVDDLDODDLVOVVOLV
df/66/IDPOsnMewesz7ssgsOdVSI/ID<
VOVVOLLLOLVOOODDLLLVLLIOLVVDLILVDVO
IVDOVLLVVDOVLLLIVVVLIVLLLLIVVVDVDDLODDOLLVVVDVVDOVOLDLOVOVLLLSVOVDDLVVDDDDODVVOVLOLLILL
VVVOVVDVVLVDDLODDOVOLLIVVLVIVVOOVVVOVDDDODDLOVODOODLODLIVIDLVIDIDDLIDLLDDDOVVDDLLVD
DDLVLIVOVDLVVLLVOIDDDVDVOOVLODLILDVLIDVODLODLVDLVVVOLVIDOLIDIDODOVOLVVDODLODDDLVODVVOLV
dL/O0/LPPMIYSEMPEESLOAVPI/IID<
DOVOODDLOOVOVODLLILVLOODOLVVDLOVVDLOD
DIDDOLLVVOVLLLVDLIOVLODLIVVDVDDLODLOLOVVVOVLOODDOLLLDVOVOLIVVDLODLODIODODODVVOVLOLLLISD
VVLVVVDVLLVDDLODOLVDLIVVLVLVVDVOVVODDDOLDVLOLOODOODVODLLVIOLIDDDDDLIDILODDIOVVDLLDLS
DDLVLLDDVOLVVOVVOLVDVDVOOVLDILOIODDDODVODLDODLVDLVDLILVIOLOVLIDOVOLVVDOLDODDLVDVVDLV
SN/66/LWIDLOELAV€1/IID<
IVODVLOOVLVIDLVVVLOVVDOO
DDDDVLLVVDDLLOVVVLLVLODLOVVDDDDODODOLIVVODIDDOVOLLLDDOVOLLDVDDDDLVVODODLODDVODLOLLLL
VVVLLVDVLLVDDLOOODOVOVLVLLIVLVVIVVVVOLDDDOVILIVIDODODDDVLVVILLIDDDDLOIDDLODIOVVDLLOVO
DOLVIOVDOVDLVVOVVLODDVDVOOVLDLIDLODDDDVODLDDLVDLVVLOILVIDLIDDODDOVDLOVDDLDODDLVDVVDLV
df/L6/INePweNeSCLL6E0AVTI/ID<
Researchethics approval: Brazilian study into paediatric gastroenteritis.
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ACCEevaluation for immunological based norovirustesting.
Disorder/Assay Background
Is an infectious organism or a specific condition caused by an unknowninfectious organism,
being investigated?
An infectious organism is being studied.
Whatis the infectious organism or condition being studied?
Norovirus
Whatis the history, clinicalfindings andprognoses ofthis disease?
The infection causes acute gastroenteritis characterised by vomiting and diarrhoea. The
prognosisis different in different cohorts. In healthy adults and children it probably has
negligible mortality. In children with poor overall health it is not known how much norovirus
contributes to morbidity, both from acute infection and its contribution to the ongoing heavy
burden of infections faced by this cohort.
Whatis the clinical and molecular epidemiology ofthis disease? Are there public
health/political implications ?
Clinical epidemiology: Norovirus causesinfectionsin all age groupsin all geographical
locations. It is particularly recognised as affecting people in institutions e.g. schools and
hospitals. In these setting norovirus causes outbreaks affecting large numbers of people with
impairmentofthatinstitutions ability to function. This has significant cost implications.
Approximately 20% of the population are resistant to infection with norovirus as they do not
havereceptors in the gastrointestinal tract for the virus to bind to (non-secretors).
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Molecular epidemiology: Norovitusis classified into genogroups of which genogroupI andII
are the main causes of human infection. The genogroupsare separated in genotypes, of which
GII.4 is the cause of the majority of infections worldwide.
Public health implications: Norovirus causes outbreaks of infectionsin institutions with
significant cost implications for these institutions which affects spending in otherareas.
Otherwise, in developed countries there is limited morbidity and mortality caused by
norovirus. The effect on public health in developing countries is not known and may be
greater given the relatively poor health in many countries.
Political Implications:
Norovirusis a political issue given the adverse effect it has on public institutions.
Whattherapy is available? Is empirical therapy available? Whatare the side effects of
therapy?
Nospecific therapy is available. Supportive therapy can be given as for any gastroenteritis.
Whatis theclinical setting in whichthe testis to be performed?
ELISA and ICG norovirustests: Clinical laboratories serving paediatric populations with
significant health resources to coverthe cost of this testing.
What microbiological assays / non microbiological investigations are associated with this
disorder? Which are you evaluating?
Electron Microscopy. This has 30% sensitivity when compared to PCRand is not planned to
be evaluated.
ELISA. A new ELISAassayis available for norovirus testing, the RIDASCREENnorovirus
test. Evaluation of this test is planned.
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ICG testing. A new ICG assayis available for PCR testing, the RIDAQUICKnorovirustest.
Evaluation ofthis test is planned.
PCR. This methodis established as the gold standard test and is planned as the reference
methodin this study.
Howlong does the assay take? Howdoesthis relate to the time course ofthe infection and
other diagnostic assays?
ELISA. This takes a minimum of3 hours andis designed for the testing of multiple samples.
ICG.This takes a minimum of 20 minutes and is designed for the testing of individual
samples
PCR.This takes a minimum of4 hours and is designed for the testing of multiple samples.
Norovirus infection has an incubation period of 24 hours and duration ofinfection of
approximately 48 hours. The tests may therefore relate to the time courseofthe infection in a
numberof different ways depending on the clinical situation and laboratory situation. For
example, in a hospital setting it may be importantto get a rapid diagnosis to improve
infection control.
Whattime periodin relation to anillness is the test relevant to?
ELISA/ICG.Thetest is relevant from the onset of symptomsupto7 days following infection,
but it is recommendedit be used in the first 72 hours ofthe illness.
PCR.Thetest is relevant form the onset of symptomsand will remain positive for on average
1 month.
Are the assays usedfor screening/diagnostic purposes? Are the assays useful to rule in/rule
out a condition?
The tests may be used for diagnostic or screening purposes.
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Is the assay completed within the sameassay as others? Is the assay completed at the same
time as other assays (parallel) or on the basis ofother results (series)? Does the result lead
to further assays/investigations being completed?
Norovirustesting is usually completed independently of other tests, although it may be
commonfor other enteropathogensto be tested for at the same time. The norovirustests
themselves are usually carried out in isolation although onetesting strategy maybeto
complete immunological testing prior to PCRtesting.
Whatis the laboratory setting in which the assay is to be performed?
Immunological tests will be completed at district general hospitals and regional hospitals
where PCRtesting will be more commonly completed in regional hospitals.
Are there developments visible in thefuture (diagnostic, therapeutic or preventative that will
affect the durability ofthe implications ofthe ACCE assessment? Is an ACCEanalysisfor
this test a priority?
Nothing obvious.
Using the information obtained by answering the above define the clinical care pathway this
assayfits into.
Given the absenceof treatment for norovirus and the limited morbidity it causes norovirus
testing will be limited to countries with significant health care resources, and often just to the
investigation of outbreaksof infection.
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Analytic Validity
Is the assay qualitative or quantitative?
Qualitative
Howoften is the test positive/negative when the infectious organism is present (analytic
sensitivity) / absent (analytic specificity)?
In comparison to PCRthesensitivities identified in this study are.
 
      
Test Sensitivity Specificity(%) PPV NPV
RIDASCREENhospital and 64 100 100 95
RIDASCREENhospital 70 100 100 94
RIDASCREEN community 50 100 100 95
RIDAQUICKhospital and 72 100 100 96
RIDAQUICKhospital 80 100 100 96
RIDAQUICK community 47 100 100 95
IDEIA hospital and community 49 100 100 93
IDEIA hospital 62 100 100 93
IDEIA community 20 100 100 93
Is an internal quality control program defined and externally monitored?
This will be location specific
Have repeated measurements been made on specimens(e.g. positive/negative controls)?
Reproducibility has been assessed and foundto be satisfactory for results outside the
equivalent range. Within this range significant (50%) variation in results is seen.
Whatis the within- and between-laboratory precision?
Not known.
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Howsimilarare results obtained in multiple laboratories using the same, or different
technology?
Not known.
Ifappropriate, howis confirmatory testing performed to resolvefalse positive results, how
long does this take?
The tests are highly specific so confirming positive results is not needed.
What range/quality of patient specimenshasbeentested?
Samples collected in the community and hospital were tested form children with modified
Vesikari severity scores of 8 and 10 respectively.
Howoften doesthe test fail to give a useable result?
The RIDASCREENan IDEIA ELISA gave an equivocal result in 5 and 3 of 212 samples
tested respectively.
Clinical Validity
Howoftenis the test positive/negative whenthe infectious disease is present(clinical
sensitivity) / absent(clinical specificity)?
This is difficult to answeras the gold standard detects shedding(identifies the infectious
disease as present whenit is absent). If that the rate if clinical positive infections is assumed
to be 16.8% ( hospital rate) minus the rate of asymptomatic shedding (8%) the level of
clinical positives is 8.8% The ELISAtests detect approximately 70% of hospital PCR
positives, =11.8%. On these assumptions the ELISAtests, given false positives are not seen,
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are likely to detect all clinical positive infections and some asymptomatic shedding (2.0%
(11.8-8.8).
Clinical specificity: the rate of ELISA/ICG positives in those without disease may be
approximately 2%, see section 3.2.2.2 for calculations.
Whatis the prevalence ofthe disorderin this setting? What are the positive and negative
predictive values?
In the hospital setting the PPV of the RIDASCREENis approximately 75%, see discussion.
The negative predictive value will be high as the prevalenceis low.
Are there methodsto resolveclinicalfalse positive results in a timely manner?
Theclinical history and results of other tests offer the only current meansofresolving clinical
false positives.
Hasthe test been adequately validated on all populations to which it may be offered?
This evaluation assesses the RIDASCREEN/RIDAQUICKnorovirustests in paediatric
populations with diarrhoea in the community and presenting to hospital. They have not been
evaluated outside these cohorts.
What are the relationship between presence oforganism and disease (e.g. colonisers/obligate
pathogens)?
Following infection with norovirus there is prolonged shedding of norovirus in children, an
average as detected by PCR of approximately 35 days (Kirkwoodand Streitberg 2008) in one
study and 19 days in another (Murataet al. 2007), up to 100 days. Norovirus shedding as
detectable by ELISA based assayshas only beenassessedin adults, in one human challenge
study antigen was detectable for a median of 7 days (28 by PCR) (Atmaret al. 2008) .
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Infection may though be symptomatic or asymptomatic. In adult challenge studies only half
of infection (detected by PCR) is symptomatic (Lindesmith et al. 2003).
What affects the relationship between organism and disease (e.g. immunosuppression,
prosthetic material)?
Prior infection is believed to offer protection against disease (Lindesmith et al. 2005) for a
period of 6-12 months. Disease duration is prolonged in hospitalised patients. Morbidity and
mortality are influenced by co-morbidities e.g. those with severe cardiac impairment may not
tolerate dehydration well.
Clinical Utility
Whatis the impact ofa positive (or negative) test on patient care?
There is no specific treatment for norovirus so there will only be indirect benefits to a patient
in having this diagnosis made. These indirect benefits may be in making a diagnosis, so
preventing the need for further investigations and alternative therapies e.g. antimicrobial
therapy.
Whatis the impact on the prevention ofspread ofinfection?
Norovirus mayspreadin institutions which children attend causing outbreaks. Making a
diagnosis ofthe aetiological agent of an outbreak may ensure the optimal control strategies
are implemented.
Is there an effective treatment or other measurable benefit? Is there general access to that
treatment or benefit?
No specific therapy.
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Is the test being offered to a socially vulnerable population?
Location specific
What quality assurance measuresare in place?
Location specific
What health risks can be identifiedfor the intervention?
A false positive result may lead to another infection/condition not beingtreated.
What are the economiccosts associated with testing and what are the economic benefits
resultingfrom testing?
Location specific
Whatare the results ofpilot trials?
None
Whatfacilities/personnel are available or easily put in place?
Location specific
Are there informed consent requirements?
No
What methodsexistfor long term monitoring?
N/A
Whatguidelines have been developedfor evaluating clinical care pathway performance?
None
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ELSI
Whatis known about transmission ofinfection, stigmatization, discrimination, confidentiality
andpersonal/family social issues?
Norovirustesting will not lead to any of these problems.
Are there legal issues regarding consent, ownership ofdata and/or samples, patents,
licensing, proprietary testing, obligation to disclose, or reporting requirements?
No
Other
The RIDASCREEN ELISA and RIDAQUICKICG use monoclonalantibodies as opposed to
polyclonal antibodies. This is preferable given the animal involvement in producing
polyclonal antibodies.
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Summaryof the main features of Brazilian studysite.
Table A2: Databaseof results for the evaluation of the IDEIA, RIDASCREENand
RIDAQUICKnorovirus tests on norovirus positive samples (by PCR).
ee Date Hospital/Community Genogroup Genotype IDEIA RIDASCREEN RIDAQUICK
1 10/06 H 2 62.4 N P p2 11/06 H 2 62.4 P P P3 11/06 H 2 62.4 P P P4 11/06 H 2 62.4 N P p5 12/06 H 2 , p P p6 12/06 H 2 62.4 p P p7 12/06 H 2 G2.4 P P p8 12/06 H 2 G2.2 N p P9 12/06 H 2 G2.2 N N N10 12/06 H 2 G2.2 P P P11 12/06 H 3 62.4 p P P12 03/07 H 1 G1.12 N N N13 03/07 H 1 61.3 N N N14 03/07 H 1 G1.7 N N N15 03/07 H 2 , P p P16 03/07 H 2 62.4 p P p17 04/07 H 2 62.4 P P P18 04/07 H 2 G2.4 P N p19 04/07 H 2 G2.4 P P P20 04/07 H 2 G2.4 N N P21 04/07 H 2 G2.4 P P p22 04/07 H 2 G2.4 P p P23 05/07 H 2 G2.4 P P P24 05/07 H 2 G2.4 N P p25 05/07 H 2 G2.4 P P p26 05/07 H 2 G2.4 N P p27 05/07 H 2 G2.4 P P p28 06/07 H 2 62.4 P p Pp29 06/07 H 2 62.4 P P P30 06/07 H 2 62.4 P P P31 06/07 H 2 62.13 N N P32 06/07 H a ; N P P33 06/07 H 2 G2.4 p P P34 06/07 H 1 61.14 N N N35 06/07 H 2 62.4 p P P36 06/07 H 2 62.4 N N P37 06/07 H 2 62.4 P P P38 07/07 H 2 62.4 p P P39 07/07 H 2 62.4 p P P40 07/07 H 2 , N N N41 07/07 H 2 62.4 p P P42 07/07 H 2 62.13 p P P43 07/07 H 2 62.4 p P P44 07/07 H 2 62.4 P P p45 09/07 H 2 p P p46 09/07 H 2 62.4 P p P47 09/07 H 2 62.4 p p N48 09/07 H 2 62.4 p p P49 09/07 H 2 62.4 p P p50 10/07 H 2 62.4 P N p51 10/07 H 2 62.4 N N p52 10/07 H 1 61.14 N p N53 10/07 H 2 62.4 P P p
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Norovirus sequence data from the study on infectious gastroenteritis in Brazil.
>H10/06(1),H03/07(16),H1 1/06(3),H12/06(7), C09/07(90), H11/06(4), H11/06(2), H04/07(19), C06/07(73), C06/07(84), H05/07(23),
H0S5/07(24), HOS07(25), H12/06(11), H12/06(11), H0S/07(25)
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAATAA
TITTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGC
CCTGATCTGAATCCCTACCTATCTCATTTGGCCAGA
>H12/06(6)
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAATAA
CTTTGTACAAGCCCCTGGTGGAGAGTTCACAGTATCCCCTAGAAACGCTCCAGGTGAAATACTATGGAGCGCGCCCTTAGGC
CCTGATCTGAATCCCTACCTATCTCATTTGGCCAGAATGTA
>H12/06(8)
ATGAAGATGGCGTCGAATGACGCCGCTCCATCTACTGATGGTGCAGCCGGCCTCGTGCCAGAAAGTAATAATGAGGTCATGG
CTCTTGAACCCGTGGCTGGTGCCGCCTTGGCAGCCCCGGTCACCGGTCAAACAAATATTATAGATCCTTGGATTAGAGCAAA
TITTGTCCAGGCCCCCAATGGTGAATTTACAGTCTCTCCCCGTAATGCCCCTGGTGAAGTGCTACTGAATCTAGAGTTGGGTC
CAGAATTAAATCCTTATCTGGCACATTTAGCAAGA
>H12/06(9)
ATGAAGATGGCGTCGAATGACGCCGCTCCATCTACTGATGGTGCAGCCGGCCTCGTGCCAGAAAGTAATAATGAGGTCATGG
CTCTTGAACCCGTGGCTGGTGCCGCCTTGGCAGCCCCGGTCACCGGTCAAACAAATATTATAGACCCTTGGATTAGAGCAAA
TTTTGTCCAGGCCCCCAATGGTGAATTTACAGTCTCTCCCCGTAATGCCCCTGGTGAAGTGCTATTGAATCTAGAAGTTGGGT
CCAGAGTTAAATCCTTATCTGGCACATTTAGCAAGAATGTA
>H12/06(10)
ATGAAGATGGCGTTCGAATGACGCCGCTCCATCTACTGATGGTGCAGCCGGCCTCGTGCCAGAAAGTAATAATGAGGTCATG
GCTCTTGAACCCGTGGCTGGTGCCGCCTTGGCAGCCCCGGTCACCGGTCAAACAAATATTATAGACCCTTGGATCAGAGCAA
ATTTTGTCCAGGCCCCCAATGGTGAATTTACAGTCTCTCCCCGTAATGCCCCTGGTGAAGTGCTATTGAATCTAGAGTTGGGT
CCAGAGTTAAATCCTTATCTGGCACATTTAGCAAGAATGTA
>H03/07(12)
ATGATGGCGTCTAAGGACGCCCCAACAAACATGGATGGCACCAGTGGTGCCGGCCAGCTGGTACCAGAGGCAAACACAGCT
GAGCCTATTGCTATGGATCCAGTAGTTGGTGCTGCTACGGCAGTCGCCACTGCTGGTCAAGTAAATATGATTGACCCCTGGAT
TATGAGTAATTTTGTTCAAGCACCTCAAGGAGAGTTTACAATTTCACCCAATAACACACCTGGTGATATTTTGTTTGATTTAC
AATTAGGTCCTCAATTAAACCCCTTTTTGTCTCATTTAGCACAAGACTGGGAGCAAGAATGGTGCAGCCG
>H03/07(13)
ATGGCGTCTAAGGACGCCCCAACAAACATGGATGGCACCAGTGGTGCCGGCCAGCTGGTACCAGAGGCAAACACAGCTGAG
CCTATTTCAATGGAACCAGTAGCTGGGGCTGCGACAGCAGCCGCAACTGCTGGACAAGTAAATATGATTGACCCCTGGATAA
TGAGTAATTATGTGCAAGCCCCTCAAGGAGAGTTCACCATTTCGCCCAACAACACTCCTGGTGACATTTTATTTGACCTACAA
TTGGGCCCACACCTCAACCCTTTCTTATCCCATTTAGCTCAATCATTTGGCCAGA
>H03/07(14)
ATGGCGTCTAAGGACGCCCCCTCAAACATGGATGGCACTAGTGGTGCCGGTCAGCTGGTTCCAGAGGTTAATGCAGCTGAAC
CTTTACCCCTTGAACCGGTAGTGGGCGCCGCAACTGCGGTTGCCACTGCTGGACAAGTTAATTTAATAGACCCCTGGATTATG
AATAATTTTGTTCAGGCCCCTGAGGGCGAGTTCACCATCTCACCTAATAATACCCCTGGAGATATTTTGTTTGATTTGCAATT
AGGACCACATCTTAACCCCTTTCTACAACATTTGTCCCAAA
>H04/07(18),H04/07(20),H04/07(21),H04/07(22),H06/07(28),H06/07(29),H06/07(247),H06/07(35),H05/07(27), H05/07(26), H04/07(17),
H06/07(30),
ATGAAGATGGCGTCGAATGACGCCAACCCATCTGATGGGTCCGCAGCCAACCTCGTCCCAGAGGTCAACAATGAGGTTATGG
CTTTGGAGCCCGTTGTCGGTGCCGCTATTGCGGCGCCTGTAGCGGGCCAACAAAATGTAATTGACCCCTGGATTAGAAATAA
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DVLOLIODVIDDIDDLLVLODODDLODLLDLLDODOVVDDLLLODDLVLLDDVDLVVOVVIOLLDDVDVIDOLDIDLIDVVOIDDVOV
DDLDDOLVXXDLOLVIOLIVVIDDIVDLOVDILDODDLVDVVDLVVODLOLLLLDVODDLIDDLILVVIDIDLVDIDDDDVODD.L
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DDDDILDLLLVVVOOODVLOOVOVOLVLOOLLIVOODLVVVLLLVIDDDODPVLL
VVOVLLLVDLLLDLLVLVOVOVDDODDDOVLVVOVVLODDDLLLVVOVILLSVDVDDVVOLIDLIDVVOLLDLVLLVVLOVOL
VILLVODLODDOVOLLVDLVLVVLLDVVIOLDDVODIOVVODVODVODVOVLODLOIDLODLODOLOLIOVVDDLVVOLVLVLOO
VWVDLODVOVLOVIODDVOVOOLLDDLODVILDDIDDLODLOVOOVIDDLVDDLVIVVVIVVOODDODOVDDVVLOLDDDDLV
(Z6)LO/LIO<
DDIIILOLLLVILOVOLIOVLIODOLVVLLIVVDVO
DIDDDDLLVVOLLOLVVDLOLLDDLVOVDLODODDODILLVVDDVVOOVIOLLLDIDVILLSVDDDDDVOVOOVODVVOODLOLLLO
VVVVDVDVLLVDDLOODOVOLLVVLVLVVVVODVOLDDOLOLIDLIDLIDVODLLVVIOLIDDVODDLODLODOOVVDLLOVO
DOLVLLODVDLOVOVVOODDVDVOOVLDDLIOVVIODDLODLODLVDLVVVILVIODLIDIDDOVDLVVDODLODDDLVOVVOLV
(Z8)L0/800<
VOVIDDDVVVODODVLOOVOVOLVLODLLVIOLVVVLLLVIOODODDDVLLVV)
VILLVOLLLDLLVLVIVOVDDODDIDOVLVVOVVLODODOLLLVVOVOLLSVOVDDVVOLIDLODVVIOLLDLVLLIVVLOVOLVLL
VODLODDOVOLLVDLVLVVLLOVVOLDDVODOOVVDVODVODVOVLODLODLODLODOLOLIOVVDDLVVILVLIVLIOVVD
LODVOVLOVOODDVDVOOLLDDLODVIOLODODDLODLOVOOVODDLVDDLVIVVVOVVODODDDOVDDVVLILDODDLVDLV
(SL)LO/I0D<
VLOLVVOVOOLDLILVOODODDLLLVLVOOLVVIOLVOVOLO
ILOVOLLOOOVLLLVVVLILLDVLOVVDDDDDDDODDDIVVVOVVOOVOLLLDLIVILIVVDLODLODLIODODDVOVLOLLLL
VVOVVVDVLLVDDLOOOLVDVLVVLVOVVVVOVVOVDDLOIDLLDVIDDODLODLLIVLODLIDLODLIDVLOVIOVVDLLIDD
DDLVLLDDVOLVVLOVOLVDVDVODOLDILOOVVDODVOLVDDOVDLOVOOLDDDLVVLIDOVOLVVDODLDODDLVODVVDLV
(€8)L0/609‘(68)L0/01D<
DDOVOODDLLLVOVODLLOLVLODOLVVLLOVVD
LIDLODDLLVVDDLLLVOLLIOVLOLLIVVDVDDLODLILIVVVDVLODDOLLLDVOVLLLVVDLODLODLIDIODVVOVLDOLLL
LIVVLVVVDVLLVDDLODOLVDLLIVVLVLVVDVOVVOODDIOLOVLDDDDDODSVODLLIDOLIDDDDDLIDIOLDDDOVVDLIOLS
DDLVLLDDVOLVVOVVOLVDVDVOODLDOLIDDDODDDVODLODLVDLVDLILVOODLIVLIDIVDLVVDDLDODDLVDVVDLV
(IL)LO/S0O<
VLDLVVDVOODDLLLVIDOLLLDOVLIDOLVVDLLLVDLOD
DDDLADODIDODVDDLVLOVLIVVVDLODVDOLIDIVVVDVLODOLVLOVOVLLLDVOVODLODODDDODPVVOVLOLLLL
VVOVVVDVLLVDDLODDOVODLLVVLOLVVVVOVVODDDDODVLOLIOVODDODLLVLIDIODDLODLLIDLLDIDOVVDDLLLO
DDLVLLDDVOLVVOVVOLDDVDVODDLDOLIDVVOODDVOVOLODDLVDLILVIDOVVOODOVDLOVDIDLDODDDLVDVVDLV
(98)L0/800<
VLDLIVVDVODODDLLIVIDILLLIDOVLODOLVVDLLLVDLID
DDDLLIIIDIDIDVDDLVLIVLVVVDLODVDOLIDIVVVDVLODOLVLOVIVLLLDVDVDDLODLIDODODVVOVLOLLLO
VVLVVVDVLLVDDLODDOVOLLVVLOLVVVVOVVDODDDODVLOLIDVODDODLLVLODIDDLODLLDLLDDODDVDDLLLIO
DOLVLLDDVOLVVOVVOLDDVDVDDDLDLIDVVODDVOVOOLDDDLVDLILVIDOVVODDOVDLOVDILDODDLVDVVDLV
